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A B S T R A C T
Background
Pressure ulcers, also known as bedsores, decubitus ulcers and pressure injuries, are localised areas of injury to the skin or the underlying
tissue, or both. Dressings are widely used to treat pressure ulcers and promote healing, and there are many options to choose from
including alginate, hydrocolloid and protease-modulating dressings. Topical agents have also been used as alternatives to dressings in
order to promote healing.
A clear and current overview of all the evidence is required to facilitate decision-making regarding the use of dressings or topical agents
for the treatment of pressure ulcers. Such a review would ideally help people with pressure ulcers and health professionals assess the best
treatment options. This review is a network meta-analysis (NMA) which assesses the probability of complete ulcer healing associated
with alternative dressings and topical agents.
Objectives
To assess the effects of dressings and topical agents for healing pressure ulcers in any care setting. We aimed to examine this evidence
base as a whole, determining probabilities that each treatment is the best, with full assessment of uncertainty and evidence quality.
Search methods
In July 2016 we searched the Cochrane Wounds Specialised Register; the Cochrane Central Register of Controlled Trials (CENTRAL);
Ovid MEDLINE; Ovid MEDLINE (In-Process & Other Non-Indexed Citations); Ovid Embase and EBSCOCINAHL Plus. We also
searched clinical trials registries for ongoing and unpublished studies, and scanned reference lists of relevant included studies as well as
reviews, meta-analyses, guidelines and health technology reports to identify additional studies. There were no restrictions with respect
to language, date of publication or study setting.
Selection criteria
Published or unpublished randomised controlled trials (RCTs) comparing the effects of at least one of the following interventions with
any other intervention in the treatment of pressure ulcers (Stage 2 or above): any dressing, or any topical agent applied directly to an
open pressure ulcer and left in situ. We excluded from this review dressings attached to external devices such as negative pressure wound
therapies, skin grafts, growth factor treatments, platelet gels and larval therapy.
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Data collection and analysis
Two review authors independently performed study selection, risk of bias assessment and data extraction. We conducted network meta-
analysis using frequentist mega-regression methods for the efﬁcacy outcome, probability of complete healing. We modelled the relative
effectiveness of any two treatments as a function of each treatment relative to the reference treatment (saline gauze). We assumed
that treatment effects were similar within dressings classes (e.g. hydrocolloid, foam). We present estimates of effect with their 95%
conﬁdence intervals for individual treatments compared with every other, and we report ranking probabilities for each intervention
(probability of being the best, second best, etc treatment). We assessed the certainty (quality) of the body of evidence using GRADE
for each network comparison and for the network as whole.
Main results
We included 51 studies (2947 participants) in this review and carried out NMA in a network of linked interventions for the sole
outcome of probability of complete healing. The network included 21 different interventions (13 dressings, 6 topical agents and 2
supplementary linking interventions) and was informed by 39 studies in 2127 participants, of whom 783 had completely healed
wounds.
We judged the network to be sparse: overall, there were relatively few participants, with few events, both for the number of interventions
and the number of mixed treatment contrasts; most studies were small or very small. The consequence of this sparseness is high
imprecision in the evidence, and this, coupled with the (mainly) high risk of bias in the studies informing the network, means that we
judged the vast majority of the evidence to be of low or very low certainty. We have no conﬁdence in the ﬁndings regarding the rank
order of interventions in this review (very low-certainty evidence), but we report here a summary of results for some comparisons of
interventions compared with saline gauze. We present here only the ﬁndings from evidence which we did not consider to be very low
certainty, but these reported results should still be interpreted in the context of the very low certainty of the network as a whole.
It is not clear whether regimens involving protease-modulating dressings increase the probability of pressure ulcer healing compared
with saline gauze (risk ratio (RR) 1.65, 95% conﬁdence interval (CI) 0.92 to 2.94) (moderate-certainty evidence: low risk of bias,
downgraded for imprecision). This risk ratio of 1.65 corresponds to an absolute difference of 102 more people healed with protease
modulating dressings per 1000 people treated than with saline gauze alone (95% CI 13 fewer to 302 more). It is unclear whether the
following interventions increase the probability of healing compared with saline gauze (low-certainty evidence): collagenase ointment
(RR 2.12, 95%CI 1.06 to 4.22); foam dressings (RR 1.52, 95%CI 1.03 to 2.26); basic wound contact dressings (RR 1.30, 95%CI 0.65
to 2.58) and polyvinylpyrrolidone plus zinc oxide (RR 1.31, 95% CI 0.37 to 4.62); the latter two interventions both had conﬁdence
intervals consistent with both a clinically important beneﬁt and a clinically important harm, and the former two interventions each
had high risk of bias as well as imprecision.
Authors’ conclusions
A network meta-analysis (NMA) of data from 39 studies (evaluating 21 dressings and topical agents for pressure ulcers) is sparse and
the evidence is of low or very low certainty (due mainly to risk of bias and imprecision). Consequently we are unable to determine
which dressings or topical agents are the most likely to heal pressure ulcers, and it is generally unclear whether the treatments examined
are more effective than saline gauze.
More research is needed to determine whether particular dressings or topical agents improve the probability of healing of pressure
ulcers. The NMA is uninformative regarding which interventions might best be included in a large trial, and it may be that research is
directed towards prevention, leaving clinicians to decide which treatment to use on the basis of wound symptoms, clinical experience,
patient preference and cost.
P L A I N L A N G U A G E S U M M A R Y
Which dressings or topical agents are the most effective for healing pressure ulcers?
Dressings and topical agents for treating pressure ulcers
Review question
We reviewed the evidence about the effects of dressings and topical agents (such as ointments, creams and gels) on pressure ulcer healing.
There are many different dressings and topical agents available, and we wanted to ﬁnd out which were the most effective.
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Background
Pressure ulcers, also known as bedsores, decubitus ulcers and pressure injuries, are wounds involving the skin and sometimes the tissue
that lies underneath. Pressure ulcers can be painful, may become infected and affect people’s quality of life. People at risk of developing
pressure ulcers include those with limited mobility - such as older people and people with short-term or long-term medical conditions
- and people with spinal cord injuries. In 2004 the total yearly cost of treating pressure ulcers in the UK was estimated as being GBP
1.4 to 2.1 billion, which was equivalent to 4% of the total National Health Service expenditure.
Topical agents such as ointments, creams or gels are applied to unhealed pressure ulcers and left in place to treat the wound; they may
be covered with a dressing. Some of these treatments have been compared with each other in trials, usually comparing two treatments
at a time. We used a method called ’network meta-analysis’ to bring together all the trial results of different treatments in a reliable way.
We hoped that this method, which compares all treatment options, would help us ﬁnd out which was the best treatment for healing
pressure ulcers.
Study characteristics
In July 2016 we searched for randomised controlled trials looking at dressings and topical agents for treating pressure ulcers and that
gave results for complete wound healing. We found 51 studies involving a total of 2947 people. Thirty-nine of these studies, involving
2127 people, gave results we could bring together in a network meta-analysis comparing 21 different treatments. Most participants in
the trials were older people; three of the 39 trials involved participants with spinal cord injuries.
Key results
Generally, the studies we found did not have many participants and results were often inconclusive. This problem carried over into
the network meta-analysis and made the ﬁndings unclear. As a result, it was unclear whether one topical agent or dressing was better
than another. Some ﬁndings for individual comparisons may be slightly more reliable. Protease-modulating dressings, foam dressings
or collagenase ointment may be better at healing than gauze; but even this evidence is not certain enough to be an adequate guide for
treatment choices.
Certainty of the evidence
We judged the certainty of the evidence to be very low or low. The next step might be to do more research of better quality to see which
dressings or topical agents could best heal pressure ulcers.
This plain language summary is up to date as of July 2016.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
NM A evidence for individual network: proportion with complete healing - interventions versus saline gauze
Patient or population: people with pressure ulcers
Intervention: dressing or topical agent
Comparator: saline gauze
Settings: hospital, community or care home, or combinat ions
Contrasts:
interventions versus
saline gauze
Relative effect
(95% CI)
Anticipated absolute effects* (95% CI) -
from median of saline gauze control groups in
direct evidence
Certainty (quality) of
the evidence
(GRADE)
M edian CGR With interventions
Alginate dressings RR 1.09
(0.11 to 10.57)
157 per 1000 171 per 1000 (17 to
1000)
⊕©©©
Very low1
14 more people healed per 1000
(140 fewer to 1000 more)
Sequential hydrocol-
loid alginate dressings
RR 0.50
(0.12 to 1.98)
157 per 1000 78 per 1000 (1.9 to 31.
2)
⊕©©©
Very low1
79 fewer people healed per 1000
(138 fewer to 155 more)
Basic wound contact
dressings
RR 1.30
(0.65 to 2.58)
157 per 1000 204 per 1000 (102 to
407)
⊕⊕©©
Low2
47 more people healed per 1000
(55 fewer to 250 more)
Collagenase ointment RR 2.12
(1.06 to 4.22)
157 per 1000 333 per 1000 (166 to
663)
⊕⊕©©
Low3
176 more people healed per 1000
(9 more to 506 more)
Dextranomer RR 4.76
(0.86 to 26.39)
157 per 1000 747 per 1000 (135 to
1000)
⊕©©©
Very low4
590 more people healed per 1000
(22 fewer to 1000 more)
Foam dressings RR 1.52
(1.03 to 2.26)
157 per 1000 239 per 1,000 (162 to
353)
⊕⊕©©
Low5
82 more people healed per 1,000
(5 more to 196 more)
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Hydrocolloid dressing
with/ without alginate
RR 1.22
(0.06 to 24.74)
157 per 1000 192 per 1,000 (9 to
1000)
⊕©©©
Very low1
35 more people healed per 1,000
(148 fewer to 1000 more)
Hydrocolloid dressings RR 1.43
(1.00 to 2.05)
157 per 1000 225 per 1000 (157 to
322)
⊕©©©
Very low6
68 more people healed per 1000
(f rom 0 fewer to 165 more)
Hydrogel RR 1.55
(1.02 to 2.36)
157 per 1000 243 per 1000 (160 to
371)
⊕©©©
Very low6
86 more people healed per 1000
(f rom 3 more to 214 more)
Iodine-containing
dressings
RR 1.08
(0.58 to 2.03)
157 per 1000 170 per 1000 (91 to
316)
⊕©©©
Very low1
13 more people healed per 1000
(f rom 66 fewer to 159 more)
Phenytoin RR 1.27
(0.58 to 2.80)
157 per 1000 199 per 1000 (91 to
440)
⊕©©©
Very low7
42 more people healed per 1000
(f rom 66 fewer to 283 more)
Protease-modulating
dressings
RR 1.65
(0.92 to 2.94)
157 per 1000 259 per 1,000 (144 to
462)
⊕⊕⊕©
Moderate8
102 more people healed per 1000
(f rom 13 fewer to 305 more)
Polyvinylpyrrolidone +
zinc oxide
RR 1.31
(0.37 to 4.62)
157 per 1000 206 per 1,000 (58 to
732)
⊕⊕©©
Low2
49 more people healed per 1000
(f rom 99 fewer to 575 more)
Combination silicone
foam dressings
RR 1.93
(0.38 to 9.98)
157 per 1000 303 per 1,000 (60 to 1,
000)
⊕©©©
Very low1
146 more people healed per 1000
(f rom 97 fewer to 1,000 more)
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Soft polymer dressings RR 1.35
(0.55 to 3.27)
157 per 1000 212 per 1,000 (86 to
517)
⊕©©©
Very low1
55 more people healed per 1000
(f rom 71 fewer to 360 more)
Sugar + egg white RR 0.70
(0.03 to 15.62)
157 per 1000 110 per 1000 (5 to 1,
000)
⊕©©©
Very low1
47 fewer people healed per 1000
(f rom 152 fewer to 1000 more)
Tripeptide copper gel RR 3.90
(1.04 to 14.63)
157 per 1000 612 per 1000 (163 to
1000)
⊕©©©
Very low9
455 more people healed per 1000
(6 more to 1000 more)
Vapour-permeable
dressings
RR 1.45
(0.74 to 2.81)
157 per 1000 228 per 1000
(118 to 440)
⊕©©©
Very low1
71 more people healed per 1000
(f rom 39 fewer to 283 more)
* The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparator group and the relative
effect of the intervent ion (and its 95% CI).
CGR: control group risk; CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High certainty (quality): we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate certainty (quality): we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the
est imate of the ef fect, but there is a possibility that it is substant ially dif f erent
Low certainty (quality): our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom
the est imate of the ef fect
Very low certainty (quality): we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially
dif f erent f rom the est imate of ef fect
1Majority of evidence at high risk of bias (downgraded once); imprecision: very wide CI (crosses 0.75 and 1.25) (downgraded
twice).
2Imprecision: very wide CI (crosses 0.75 and 1.25) (downgraded twice).
3Majority of evidence at high risk of bias (downgraded once); imprecision: wide CI and direct evidence on collagenase f rom
three studies, 11 events (downgraded once).
4Majority of evidence at high risk of bias (downgraded once): imprecision: wide CI (crosses 1.25) and direct evidence on
dextranomer f rom one study, seven part icipants and four events (downgraded twice).
5Majority of evidence at high risk of bias (downgraded once); imprecision: wide CI (downgraded once).
6Majority of evidence at high risk of bias (downgraded once); inconsistency: heterogeneity in direct evidence (downgraded
once); imprecision: wide CI (downgraded once).
7Majority of evidence at high risk of bias (downgraded once); inconsistency: signif icant dif f erence between direct and indirect
est imates (downgraded once); imprecision: very wide CI (crossed 0.75 and 1.25).
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8Imprecision: wide CI (crosses 1.25); (direct evidence for protease-modulat ing dressing: four studies, 76 part icipants, 31
events) (downgraded once).
9Majority of evidence at high risk of bias (downgraded once): imprecision: wide CI (crosses 1.25) and direct evidence on
tripept ide copper gel f rom one study, six part icipants and f ive events (downgraded twice).
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B A C K G R O U N D
Description of the condition
Pressure ulcers, also known as pressure injuries, bedsores, decu-
bitus ulcers or pressure sores, are localised areas of injury to the
skin, the underlying tissue or both. They often occur over bony
prominences such as the sacrum (base of the spine) and heel
(Vanderwee 2007), and are caused by external forces such as pres-
sure, or shear, or a combination of both (EPUAP-NPUAP-PPPIA
2014; NPUAP 2016; Dumville 2015a; Dumville 2015b; Keogh
2013; Walker 2014).
Risk factors for pressure ulcer development have been summarised
into three main categories: a lack of mobility; poor perfusion (e.g.
diabetes and vascular disease) and low skin status (Coleman 2013);
the latter category includes the presence of stage 1 pressure ulcers
or incontinence or both, which also increases the risk of ulceration
by producing a detrimental environment for the skin (Brandeis
1994).
Pressure ulcers vary in severity. One of the most widely recognised
systems for categorising pressure ulcers is that of theNational Pres-
sure Ulcer Advisory Panel (NPUAP). Their international classiﬁ-
cation recognises four categories or stages of pressure ulcer and two
categories of unclassiﬁable pressure injury. Stage 1 ulcers involve
intact skin, but Stages 2 to 4 describe progressively deeper wounds
with larger degrees of skin and tissue loss: Stage 2 pressure ulcers
have partial-thickness skin loss and exposed dermis; Stage 3 refers
to full-thickness skin loss and exposed fat tissue; and Stage 4 ulcers
have full-thickness skin and tissue loss, with exposed fascia,muscle,
tendon, ligament, cartilage or bone. The two categories of unclas-
siﬁable pressure injury are reserved for wounds for which wound
depth or extent, or both, cannot be accurately determined; unclas-
siﬁable pressure ulcers are generally severe and would be grouped
clinically with Stage 3 or Stage 4 ulcers (EPUAP-NPUAP-PPPIA
2014) (see Appendix 1 for further details of grading).
Prevalence
Pressure ulcers are one of the most common types of complex
wound. Prevalence estimates differ according to the type of pop-
ulation assessed, the data collection methods used and period of
data collection and whether Stage 1 ulcers were included).
One large European study estimated a hospital pressure ulcer
prevalence (Stage 2 and above) of 10.5% (Vanderwee 2007) whilst
a US study estimated a prevalence of 9.0% (Stage 2 and above)
across acute-care, long-term care and rehabilitation settings (the
highest prevalence of 26% was in long-term acute-care settings
(VanGilder 2009)). In the UK, national pressure ulcer data are
collected across community and acute settings (although data col-
lection is not yet universal) as part of the National Health Service
(NHS) Safety Thermometer initiative (Power 2012). About 4.4%
of patients across these settings were estimated to have a pres-
sure ulcer (Stage 2 to Stage 4) in November 2014 (NHS Quality
Observatory 2015).
We note that all the prevalence ﬁgures quoted above are for at-risk
populations currently receivingmedical care. The point prevalence
of pressure ulceration in the total adult population was recently
estimated as 0.31 per 1000 population (including Stage 1) (Hall
2014).
Treatments for pressure ulcers
There are two main strategies in the treatment of pressure ulcers,
namely relief of pressure - commonly using specialist support sur-
faces (McInnes 2011; NICE 2014) - together with management
of the wound environment using wound dressings. Other gen-
eral strategies include patient education, pain management, opti-
mising circulation/perfusion, optimising nutrition and the treat-
ment of clinical infection (EPUAP-NPUAP-PPPIA 2014; NICE
2014). Pressure ulcers are normally expected to show signs of heal-
ing within two weeks, but this may not occur and there can be
deterioration (EPUAP-NPUAP-PPPIA 2014).
Impact of pressure ulcers on patients and financial
costs
Pressure ulcers have a large impact on those affected; the ulcers can
be painful, and may become seriously infected or malodorous. It
has been shown that after adjustment for age, sex and co-morbidi-
ties people with pressure ulcers have a lower health-related quality
of life than those without pressure ulcers (Essex 2009).
The ﬁnancial cost of treating pressure ulcers in the UK has been
estimated to range from GBP 1214 for a Stage 1 ulcer to GBP
14,108 for a Stage 4 ulcer. Costs are mainly dominated by health
professional time, and for more severe ulcers, by the incidence of
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complications including hospital admission/length of stay (Dealey
2012). In 2004, the total annual cost of treating pressure ulcers
in the UK was estimated as GBP 1.4 to 2.1 billion, which was
equivalent to 4% of the total NHS expenditure (Bennett 2004).
Pressure ulcers have been shown to increase length of hospital stay
and associated hospital costs (Allman 1999). Figures from theUSA
suggest that for half a million hospital stays in 2006, ’pressure
ulcer’ was noted as a diagnosis; for adults, the total hospital cost
for these stays was USD 11 billion (Russo 2008). Costs to the
Australian healthcare system for treating pressure ulceration have
been estimated at AUD 285 million annually (Graves 2005).
Description of the intervention
This review includes RCTs of any dressings or topical agents ap-
plied directly onto or into wounds and left in situ, as opposed to
products used to irrigate, wash or cleanse wounds and those that
are only in contact with wounds for a short period.
Dressings
The classiﬁcation of dressings usually depends on the key material
used in their construction, and whether additional substances are
added to the dressing. Several attributes of an ideal wound dressing
have been described (BNF 2016; Bradley 1999), including the
ability of the dressing to:
• absorb and contain exudate without leakage or strike-
through, in order to maintain a wound that is moist but not
macerated;
• achieve freedom from particulate contaminants or toxic
chemicals left in the wound;
• provide thermal insulation, in order to maintain the
optimum temperature for healing;
• allow permeability to water, but not bacteria;
• optimise the pH of the wound;
• minimise wound infection and avoid excessive slough;
• avoid wound trauma on dressing removal;
• accommodate the need for frequent dressing changes;
• provide pain relief; and
• be comfortable.
There are numerous and diverse dressings available for treating
pressure ulcers and their properties are described below.
Absorbent dressings are applied directly to the wound and may
be used as secondary absorbent layers in the management of
heavily exuding wounds. Examples include Primapore (Smith &
Nephew), Mepore (Mölnlycke) and absorbent cotton gauze (BP
1988).
Alginate dressings are highly absorbent fabrics/yarns that come in
the formof calcium alginate or calcium sodium alginate and can be
combined with collagen. The alginate forms a gel when in contact
with the wound surface; this can be lifted off at dressing removal,
or rinsed away with sterile saline. Bonding to a secondary viscose
pad increases absorbency. Examples include: Curasorb (Covidien),
SeaSorb (Coloplast) and Sorbsan (Unomedical).
Capillary-action dressings consist of an absorbent core of hy-
drophilic ﬁbres held between two low-adherent contact layers. Ex-
amples include: Advadraw (Advancis) and Vacutex (Protex).
Films, i.e. permeable film and membrane dressings are perme-
able to water vapour and oxygen, but not to water or micro-or-
ganisms. Examples include Tegaderm (3M) and OpSite (Smith &
Nephew).
Foam dressings contain hydrophilic polyurethane foam and are
designed to absorb wound exudate and maintain a moist wound
surface. There are a variety of versions and some include additional
absorbent materials, such as viscose and acrylate ﬁbres, or particles
of superabsorbent polyacrylate, which are silicone-coated for non-
traumatic removal. Examples include: Allevyn (Smith&Nephew),
Biatain (Coloplast) and Tegaderm (3M).
Honey-impregnated dressings contain medical-grade honey that
is purported to have antimicrobial and anti-inﬂammatory prop-
erties and can be used for acute or chronic wounds. Examples in-
clude: Medihoney (Medihoney) and Activon Tulle (Advancis).
Hydrocolloid dressings are usually composed of an absorbent
hydrocolloid matrix on a vapour-permeable ﬁlm or foam backing.
Examples include: Granuﬂex (ConvaTec) and NU DERM (Sys-
tagenix). Fibrous alternatives that resemble alginates and are not
occlusive have also been developed: Aquacel (ConvaTec).
Iodine-impregnated dressings release free iodine, which is
thought to act as a wound antiseptic when exposed to wound exu-
date. Examples include Iodoﬂex (Smith&Nephew) and Iodozyme
(Insense).
Low-adherence dressings and wound contact materials usually
consist of cotton pads that are placed directly in contact with the
wound. They can be non-medicated (e.g. parafﬁn gauze dress-
ing, saline gauze dressing) or medicated (e.g. containing povidone
iodine or chlorhexidine). Examples include parafﬁn gauze dress-
ing, BP 1993 and Xeroform (Covidien) dressing - a non-adher-
ent petrolatum blend with 3% bismuth tribromophenate on ﬁne
mesh gauze.
Odour-absorbent dressings contain charcoal and are used to ab-
sorb wound odour. Often this type of wound dressing is used in
conjunction with a secondary dressing to improve absorbency. An
example is CarboFLEX (ConvaTec).
Other antimicrobial dressings are composed of a gauze or low-
adherent dressing impregnated with an ointment thought to have
antimicrobial properties. Examples include: chlorhexidine gauze
dressing (Smith&Nephew) andCutimedSorbact (BSNMedical).
Protease-modulating matrix dressings alter the activity of prote-
olytic enzymes in chronic wounds. Examples include: Promogran
(Systagenix).
Silver-impregnated dressings are used to treat infected wounds,
as silver ions are thought to have antimicrobial properties. Sil-
ver versions of most dressing types are available, including silver
8Dressings and topical agents for treating pressure ulcers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
F
r P
re
vie
w 
On
ly
impregnated dressings (e.g. silver hydrocolloid etc). Examples in-
clude: Acticoat (Smith & Nephew) and Urgosorb Silver (Urgo).
Soft polymer dressings are composed of a soft silicone polymer
held in a non-adherent layer; these are moderately absorbent. Ex-
amples include: Mepitel (Mölnlycke) and Urgotul (Urgo).
Topical agents
Topical agents are deﬁned as hydrogels. ointments and creams that
are placed in contact with the wound and left in situ; they may be
covered with a secondary dressing.The following types of topical
agents are considered as interventions in this review:
Cadexomer-iodine paste consists of a water-soluble, modiﬁed
starch polymer containing iodine. It releases free iodine when ex-
posed to wound exudate. The free iodine acts as an antiseptic on
the wound surface, and the cadexomer absorbs wound exudate
and encourages de-sloughing. Examples include: Iodosorb (Smith
& Nephew) ointment and powder.
Collagenase-containing ointment is an enzymatic debriding
ointment. Collagenase is thought to digest collagen in necrotic
tissue and to contribute to granulation and epithelisation.
Hydrogels consist of a starch polymer and up to 96% water. They
can absorb wound exudate or rehydrate a wound depending on
the wound moisture levels. Hydrogels are often considered to be
dressings, but are also topical in nature. They are supplied in either
ﬂat sheets, an amorphous hydrogel or as beads. Examples include:
ActiformCool (Activa and Aquaﬂo (Covidien).
Phenytoin topical is thought to promote wound healing by a
number of mechanisms, including stimulation of ﬁbroblast pro-
liferation, facilitation of collagen deposition and antibacterial ac-
tivity.
Silver sulfadiazine cream is a topical antimicrobial cream that
is used to treat and prevent infection in wounds by damaging
bacterial cell membranes. Examples include Flamazine (Smith &
Nephew) and Silvadene (Pﬁzer).
Products containing growth factors, platelet-rich plasma or
other platelet-derived products and colony-stimulating factors
are outside the scope of this review.
How the intervention might work
Animal experiments conducted over 40 years ago suggested that
acute wounds healmore quickly when their surfaces are keptmoist
rather than left to dry and scab (Winter 1962; Winter 1963a;
Winter 1963b). A moist environment is thought to provide op-
timal conditions for the cells involved in the healing process, as
well as allowing autolytic debridement (removal of dead tissue by
natural processes), which is thought to be an important part of the
healing pathway (Cardinal 2009).
The desire to maintain a moist wound environment is a key driver
for the use of wound dressings and related topical agents. Whilst
a moist environment at the wound site has been shown to aid the
rate of epithelialisation in superﬁcial wounds, excess moisture at
the wound site can cause maceration of the surrounding skin (
Cutting 2002), and it has also been suggested that dressings that
permit ﬂuid to accumulate might predispose wounds to infection
(Hutchinson 1991). Wound treatments vary in their level of ab-
sorbency, so that a very wet wound can be treated with an ab-
sorbent dressing (such as a foam dressing) to draw excess moisture
away and avoid skin damage, whilst a drier wound can be treated
with a more occlusive dressing or a hydrogel to maintain a moist
environment.
Some dressings are now also formulated with an ’active’ ingredient
(e.g. silver, honey or protease modulators).
Why it is important to do this review
The diversity of dressings and related materials available to health
professionals for treating pressure ulcers makes evidence-based
decision-making difﬁcult when determining the optimum treat-
ment regimen for a particular patient (Gillespie 2012; NICE
2014). With increasingly sophisticated technology being applied
to wound care, practitioners need to know the relative effective-
ness and cost-effectiveness of these sometimes expensive dressings.
Even where cost is not an issue, the most effective treatment may
not be available (e.g. in some developing countries) or may be dif-
ﬁcult or to use, so that information on the second and third best
treatments is important too (Salanti 2011).
Current evidence syntheses include four Cochrane Reviews (
Dumville 2015a; Dumville 2015b; Keogh 2013; Walker 2014),
two other systematic reviews (Reddy 2008; Smith 2013), and two
recent clinical guidelines (EPUAP-NPUAP-PPPIA 2014; NICE
2014). Each of these consists of a series of pairwise comparisons.
No review ﬁnds clear evidence of any effect of one dressing com-
pared to another in terms of assessed outcome measures, including
complete wound healing.
In the absence of an overview or network meta-analysis, decision-
makers have to consider the ﬁndings of multiple pairwise ran-
domised controlled trials (RCTs) simultaneously and qualitatively
to judge, in the face of uncertainty, which dressing they might
decide to use. It is extremely difﬁcult to do this effectively, and
this difﬁculty is compounded when the evidence comprises single
small trials, about which decision-makers may have little conﬁ-
dence.
Network meta-analysis (NMA) is the simultaneous comparison
of linked, multiple, competing treatments in a single statistical
model (Caldwell 2005; Chaimani 2013a; Lu 2004; Salanti 2008).
NMA utilises evidence from ’direct’ (head-to-head or ’pairwise’)
comparisons (e.g. trials directly comparing treatments A and B),
’indirect’ comparisons (e.g. the combination of trials comparing
A with C and trials comparing B with C), and a synthesis of both
when available. When pooling relative effect estimates, NMAs
preserve within-trial randomisation (Grant 2013; Thorlund 2012;
Tu 2012).
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Where there are relevant common comparators across trials that
allow treatments to be linked and form a network of evidence,
NMA produces a set of effect estimates for each treatment relative
to every other, whether or not they have been compared in head-
to-head trials. In this way NMA allows us to obtain estimates for
comparisons for which there is no (direct) trial evidence. Even
when direct evidence is available there may not be much of it,
so pooling it with data from indirect comparisons generally gives
more robust evidence and reduces uncertainty in the estimates of
effect (Higgins 1996; Thorlund 2012). From theNMA analysis, it
is possible to evaluate the probability of each treatment being the
best for a speciﬁc outcome: these probabilities reﬂect the precision
surrounding the effect estimates (Caldwell 2014; Salanti 2011).
A glossary of NMA terms is given in Appendix 2.
This review comprised a network meta-analysis (NMA) for the
outcome of pressure ulcer healing, for alternative dressings and
topical agents for the treatment of pressure ulcers of Stage 2 and
above. The NMA enabled us to compare pairs of dressings/topical
agents, taking into account direct and indirect evidence simulta-
neously, and explicitly determining the uncertainty in effect esti-
mates. The ranking process allowed us to examine the evidence
base as a whole, identifying the support of the evidence for each
treatment, having consideration for indirect evidence (where it ex-
isted) and fully reﬂecting evidence uncertainties. We also explored
assumptions made in the analysis.
O B J E C T I V E S
To assess the effects of dressings and topical agents for healing pres-
sure ulcers in any care setting. We aimed to examine this evidence
base as a whole, determining probabilities that each treatment is
the best, with full assessment of uncertainty and evidence quality.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included published and unpublished randomised controlled
trials (RCTs), irrespective of language of report. We did not iden-
tify any cross-over trials, but we would have included them only if
they reported outcome data at the end of the ﬁrst treatment period
and prior to cross-over. We excluded studies using quasi-random
methods of allocation (such as alternation). We highlighted trials
in which three or more interventions were randomised.
Types of participants
We included studies that recruited people with a diagnosis of pres-
sure ulcer, Stage 2 and above (EPUAP-NPUAP-PPPIA 2014),
managed in any care setting. We excluded studies that only re-
cruited people with Stage 1 ulcers as these are not open wounds
requiring dressings.
We accepted study authors’ deﬁnitions of what they classed as
Stage 2 or above, unless it was clear that they included wounds
with unbroken skin.Where authors used grading scales other than
NPUAP, we attempted to map to the NPUAP scale.
We included studies that recruited participantswith pressure ulcers
of Stage 2 severity or higher alongside people with Stage 1 pressure
ulcers or other types of complexwound (e.g. leg and/or foot ulcers),
or both, provided the allocation of participants was stratiﬁed by
type of wound or pressure ulcer severity at randomisation and
provided the results for people with eligible pressure ulcers (that is
Stage 2 or higher) were presented separately (or became available
from the study authors). Where studies included participants with
Stage 1 ulcers or other types of complex wounds, but these made
up 25% or less of the total study population we included all study
data.
Types of interventions
Interventions of direct interest (decision set)
The interventions in this section were all those that can be di-
rectly applied as dressings or topical agents to open pressure ulcers.
We presented results for these interventions and included them in
summary tables. In the context of a network of competing treat-
ments, there are no ’comparators’.
We considered trials for which at least one of the interventions
was (1) any dressing, including impregnated dressings or saline-
moistened dressings or combination dressings or (2) any topical
agent applied directly to an open pressure ulcer and left in situ.
Combination dressings are when two ormore dressings are applied
sequentially over time (e.g., hydrocolloid for four weeks followed
by alginate for four weeks), or a product contains two or more
types of dressing material (e.g., a multilayer product comprising
silicone polymer and hydrocolloid). The treatment of interest had
to be the only systematic difference between treatment groups.We
did not take into account secondary dressings.
Some of the interventions we considered were as follows:
• Basic wound contact dressings (includes low-adherence
(including parafﬁn gauze) or absorbent dressings (of any
absorbency))
• Saline-moistened gauze (all degrees of moistness)
• Hydrogel dressing (includes hydrogel sheet or hydrogel
application (amorphous) or sodium hyaluronate)
• Vapour-permeable ﬁlms and membranes (includes adhesive
ﬁlm (semi-permeable) or adhesive ﬁlm with absorbent pad)
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• Soft polymer dressings (with/without absorbent pad or
cellulose)
• Hydrocolloid dressing (with/without adhesive border or
matrix hydrocolloid)
• Fibrous (spun) hydrocolloid
• Foam dressings (all absorbencies)
• Alginate dressings
• Capillary action dressings
• Alginate dressing with charcoal
• Other charcoal-containing dressing
• Honey sheet dressing or topical honey
• Cadexomer iodine ointments
• Iodine-containing dressings
• Soft polymer dressing (with silver)
• Hydrocolloid (with silver)
• Foam dressings (with silver)
• Alginate dressings (with silver)
• Silver sulfadiazine cream
• Protease-modulating matrix dressings
• Collagenase-containing ointment
• Topical phenytoin
• Topical zinc oxide
• No dressing (wound left exposed)
• Other treatments considered by the review team (with
additional clinical advice where required) to be dressings or
topical agents applied directly to the wound and left in-situ.
The following interventions were not part of the decision set:
treatments in which dressings are attached to external devices such
as negative pressure wound therapies, skin grafts, growth factor
treatments, platelet gels and larval therapy.
We grouped together dressings in the same class (e.g. alginates)
(BNF 2016). This was regardless of a particular brand’s stated ab-
sorbency, size, concentration of active component or the degree of
moistness. Thus, where studies only compared two dressings from
the same class (for example, two alginates or two foam dressings),
we excluded such studies from the review as they contributed no
information about the effectiveness of the class.
We included any RCT in which other concurrent therapies were
given (e.g. antibiotics, debridement), provided that these treat-
ments were delivered in a standardised way across the trial arms
of the individual trial (such that the treatment of interest was the
only systematic difference). We did not treat separately compar-
isons with and without concurrent therapies, that is, we consid-
ered intervention 1 + concurrent therapy versus intervention 2 +
concurrent therapy to be the same as intervention 1 versus inter-
vention 2.
One of the assumptions underpinning NMA is that interven-
tions in the network are exchangeable, that is, participants in the
network could, in principle, be randomised to any of the treat-
ments being compared. For example, a personwith a pressure ulcer
could be equally likely to be randomised to an alginate dressing, a
polyurethane foam dressing, honey or saline gauze. Depending on
the wound requirements for the dressing (e.g. highly absorbent),
this may not always be a good assumption for individual wounds,
but across the population in the trials may be reasonable.
Supplementary intervention set
Some of the trial interventions were not included in the decision
set (see above) but were included in a supplementary intervention
set if they linked two or more decision set interventions: such sup-
plementary interventions were of value solely because they allowed
inferences to be drawn about the treatments of interest. In our
individual network, the supplementary intervention set included
radiant heat and skin substitute.
Terminology
For the rest of this review, we use the term ’comparison’ to mean
two interventions compared in a single study or in a pairwisemeta-
analysis of direct data. We use the term ’contrast’ to mean two
interventions compared across all studies in an NMA. This may
be either direct or indirect evidence or both. We use the follow-
ing terms: ’direct contrast’ for interventions linked directly in the
network; ’indirect contrast’ when the two interventions are linked
solely via indirect NMA evidence; and ’mixed treatment contrast’
when either direct or indirect evidence or both are involved. Direct
evidence may be informed by more than one study comparing the
two interventions. Indirect estimates may be calculated using a
’node-splitting’ approach, in which the NMA is run after exclud-
ing the direct evidence for a particular contrast.
We also use the term ’core intervention’ to mean interventions
that form part of at least one loop and ’peripheral interventions’
to mean interventions that are not part of a loop and are only
connected in a peripheral way.
Types of outcome measures
We reported outcome measures at the last time point available
(assumed to be length of follow-up if not speciﬁed) or the time
point speciﬁed in the methods as being of primary interest (if
this was different from the latest time point available). Initially,
we noted when studies reported results at other time points or
whether they included Kaplan-Meier plots, or both.
Primary outcomes
The primary outcome for this reviewwas completewound healing.
We regarded the following as providing themost relevantmeasures
of outcome for the analyses:
• the proportion of wounds healed (frequency of complete
healing: arm-level data);
• time to complete healing (survival data: study-level data).
We accepted authors’ deﬁnitions of what constituted a healed
wound.
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Secondary outcomes
We did not consider any secondary outcomes, however they are
reported in other relevant reviews (Dumville 2015a; Dumville
2015b; Keogh 2013; Walker 2014).
Search methods for identification of studies
Four existing Cochrane Reviews were relevant to this NMA
(Dumville 2015a; Dumville 2015b; Keogh 2013; Walker 2014),
and the protocol for this NMA complemented the protocols for
these four reviews (an author on these four reviews is also a re-
view author here). We automatically included trials from these
reviews in this NMA if they reported complete healing outcomes;
we planned to use the extracted data from these reviews where
possible, supplementing if necessary which was required as some
reviews had not been completed.
We conducted searches to identify relevant trials not covered by
the four Cochrane Reviews as well as recently published trials. We
cross-checked the identiﬁed trials against those in the 2014 NICE
guideline and the 2013 US Agency for Healthcare Research and
Quality (AHRQ) guideline on treating pressure ulcers to further
locate any additional trials (AHRQ 2013; NICE 2014); we also
checked the references of 24 systematic reviews identiﬁed by our
search.
Electronic searches
We searched the following electronic databases to identify reports
of relevant randomised clinical trials:
• the Cochrane Wounds Specialised Register (searched 12
July 2016);
• the Cochrane Central Register of Controlled Trials
(CENTRAL) (in the Cochrane Library) (2016, Issue 6);
• Ovid MEDILINE (1946 to 12 July 2016);
• Ovid MEDLINE (In-Process & Other Non-Indexed
Citations) (12 July 2016);
• Ovid Embase (1974 to 12 July 2016);
• EBSCO CINAHL Plus (1937 to 12 July 2016).
The search strategies forCENTRAL,OvidMEDLINE,OvidEm-
base and EBSCO CINAHL Plus can be found in Appendix 3.
We combined the Ovid MEDLINE search with the Cochrane
Highly Sensitive Search Strategy for identifying randomised tri-
als in MEDLINE: sensitivity- and precision-maximising version
(2008 revision) (Lefebvre 2011).We combined the Embase search
with the Ovid Embase randomised trials ﬁlter terms developed
by the UK Cochrane Centre (Lefebvre 2011). We combined the
CINAHL search with the randomised trials ﬁlter terms developed
by the Scottish Intercollegiate Guidelines Network (SIGN 2017).
There were no restrictions with respect to language, date of pub-
lication or study setting.
We also searched the following clinical trials registries:
• ClinicalTrials.gov (www.clinicaltrials.gov)
• WHO International Clinical Trials Registry Platform
(ICTRP) (apps.who.int/trialsearch/Default.aspx)
• EU Clinical Trials Register (www.clinicaltrialsregister.eu/).
Searching other resources
We searched for other potentially eligible trials or ancillary publi-
cations in the reference lists of retrieved included studies as well as
relevant systematic reviews, meta-analyses, guidelines and health
technology assessment reports.
Data collection and analysis
Data collection and analysis were carried out according to meth-
ods stated in the published protocol (Westby 2015), which were
based on the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011a).
Selection of studies
Two review authors independently assessed the titles and abstracts
of the citations retrieved by the searches for relevance. After this
initial assessment, we obtained full-text copies of all studies con-
sidered to be potentially relevant. Two review authors indepen-
dently checked the full papers for eligibility; disagreements were
resolved by discussion and, where required, the input of a third
review author. We did not contact study authors. We recorded
all reasons for exclusion of the studies for which we had obtained
full copies. We completed a PRISMA ﬂowchart to summarise this
process (Liberati 2009).
Where studies were reported in multiple publications/reports we
obtained all publications. Such a study was included only once
in the review, but we extracted data from all reports to ensure
maximal relevant data were obtained.
Data extraction and management
We extracted the following information from each included study:
• interventions being compared, including any ineligible
interventions randomised to additional trial groups;
• duration of the intervention;
• details of any co-interventions;
• the unit of randomisation (e.g. participant or ulcer);
• the number of ulcers per person;
• the unit of analysis (including any selection methods for
people with multiple ulcers);
• the number of participants in each arm;
• the hazard ratio and its 95% conﬁdence interval (CI) (or
any data that would allow its calculation (Tierney 2007)) for
comparisons between arms);
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• the number of participants that healed in each arm, both at
the latest time point or (if different) at another time speciﬁed as
of primary interest in the study’s methods section;
• all other follow-up times reported;
• we noted if a Kaplan Meier plot was displayed;
• missing data rates per arm, and reasons for ’missingness’,
including the number of people dying.
Data on potential effect modifiers
We were not aware of any population-speciﬁc effect modiﬁers for
this research question: there was no existing evidence to suggest
that one type of dressing worked better than another for certain
subgroups, for example, people with different depths of tissue
damage.
However, we extracted data that allowed us to determine for each
included study factors that may act as effect modiﬁers (in this
context):
• type of funding (e.g. industry, academic, government); this
was dichotomised into non-for-proﬁt and other;
• risk of bias (see Assessment of risk of bias in included
studies).
Other data
We also extracted the following data regarding patient and study
characteristics at baseline for each intervention arm if possible:
• care setting;
• age of participants;
• duration of pressure ulcer(s);
• severity/grade of pressure ulcer;
• nature of pressure ulcer wounds (e.g. sloughy, necrotic,
infected);
• size of pressure ulcer(s).
Assessment of risk of bias in included studies
Cochrane risk of bias assessment
We assessed risk of bias for each included study for the complete
healing outcome. There is only one outcome in this review (com-
plete wound healing) and so risk of bias assessments at the out-
come level apply to the whole study.
Two review authors independently assessed included studies using
the Cochrane risk of bias tool (Higgins 2011b) with involvement
of a third author where consensus could not be reached. We also
determined an all-domain risk of bias (see below).
Additionally, we reported separately an overall risk of bias for each
direct comparisonmeta-analysis and for each contrast in theNMA
(see next section).
Overall risk of bias and linking to GRADE assessment
In order to link these Cochrane ratings to the GRADE assessment
for risk of bias of the evidence (downgrading 0, 1 or 2 times), we
used a two-stage process. Firstly, we obtained an all-domain risk
of bias for each study and then used this to produce an overall risk
of bias for each comparison.
All-domain risk of bias for each study
We summarised data for each of the key domains of selection bias,
detection bias, attrition bias, reporting bias and other bias, assign-
ing one of four ratings: low, unclear, high and very high. For ex-
ample, selection bias was informed by sequence generation, allo-
cation concealment and comparability of baseline characteristics.
In an adaption of the GRADE approach (Guyatt 2011a), we pro-
duced an all-domain risk of bias, with four ratings deﬁned as:
• ’very high’ - two or more key domains with a high risk of
bias or a single domain with very high levels of uncertainty (e.g.
very high degree of differential missing data);
• ’high’ - high risk of bias for any one domain or we judged
the risk of bias to be ’almost high’ across more than one domain;
• ’low’ - low risk of bias for each of the key domains;
• ’unclear’ - insufﬁcient information for at least one key
domain (with the other domains being at low risk of bias).
Then we grouped together the low and unclear all-domain risk-
of-bias ratings.
We included this all-domain risk of bias in the summary ’Risk of
bias’ ﬁgure, by adding two further columns: red in both of the last
two columns indicated ’very high’ all-domain risk of bias; red in
the penultimate column (but not the last column) indicated ’high’
risk of bias; and the combined low/unclear group was marked
green in the penultimate column, with the last column remaining
blank.
Overall risk of bias for a direct comparison
Wherever more than one study was pooled in a pairwise meta-
analysis, we assigned an overall risk of bias for that comparison,
by calculating a weighted average all-domain risk of bias across
studies; weights were those produced in the meta-analysis (based
on the inverse variance). We assigned numerical values to the all-
domain ratings for each study: low/unclear (1), high (2) and very
high (3) and calculated the weighted average.
We used the weighted average to give a rating of overall risk of bias
for that comparison: low, high and very high, and aligned these
ratings respectively with the GRADE categories of no limitations
(not downgraded on risk of bias), serious limitations (downgraded
once) and very serious limitations (downgraded twice) (Guyatt
2011a; Salanti 2014).
We superimposed the overall risk of bias for each direct comparison
(on the basis of the direct meta-analysis) on the network diagram,
using colours to represent different ratings. We used these overall
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risks of bias to calculate the risk of bias for each mixed treatment
contrast (see below).
Overall risk of bias for each mixed treatment contrast in the
network
An NMA comprises a set of interventions linked via a series of
comparisons (’direct contrasts’). Each direct contrast contributes
data to the evidence for all other contrasts in the network to which
that contrast is linked indirectly (and becomes indirect evidence).
The contribution of each piece of indirect evidence to a mixed
treatment contrast depends on its point estimate, precision and
relative location within the network, and on that of any direct evi-
dence or other indirect evidence (Chaimani 2013b; Salanti 2014).
A recently published tool, Krahn 2013, allows such contributions
to be determined for each contrast in the network informed by
direct and indirect evidence. We summarised the percentage con-
tribution of each direct contrast to each network estimate in a
matrix with columns and rows corresponding to the direct and
mixed treatment contrasts respectively.
The overall risk of bias for each mixed treatment contrast is a
compositemeasure of the risks of bias for all the contributing direct
contrasts (that is, the sum of the all-domain risks of bias for all the
direct contrasts, each weighted by their percentage contributions
to the mixed treatment contrast).
We calculated the overall risk of bias for the entire network using
percentage contributions to the whole network for each direct
contrast.
Measures of treatment effect
Relative treatment effects
For each contrast in the NMA, we presented the risk ratio with
its 95% CI. We used raw data from individual studies, taking the
number of ulcers healed at the latest time point, unless otherwise
stated.
We also recorded separately the time-to-healing outcome for stud-
ies that reported this.
Relative treatment ranking
Wepresented the relative treatment ranking as a cumulative proba-
bility at each rank and as aSurfaceUnder theCumulativeRAnking
(SUCRA) value for each treatment (see Data synthesis - methods
for indirect and mixed comparisons and Appendix 2).
Unit of analysis issues
We expected the main unit of analysis issues to occur when par-
ticipants had more than one wound per person. In these cases, we
treated the participant as the unit of analysis when the number
of wounds assessed appeared to be equal to the number of par-
ticipants (e.g. one wound per person). This included studies in
which participants were randomised to treatments and there was
more than one wound per person, but results were reported for
one selected wound; we considered whether there was risk of bias
in the selection process.
Where studies randomised at the participant level, used the al-
located treatment on multiple wounds per participant, and mea-
sured and analysed outcomes at the wound level (e.g. wound heal-
ing), we expected there to be unit of analysis issues if the data
were not correctly analysed. In practice, there was insufﬁcient in-
formation to approximate the correct analyses (in accordance with
Chapter 16 of the Cochrane Handbook for Systematic Reviews of
Interventions, using information adapted from Higgins 2011c), so
we assessed risk of unit-of-analysis bias, taking into account the
number of people randomly assigned to each intervention; and
the average (mean) number of wounds per person.
Dealing with missing data
It is common to have data missing from trial reports. Excluding
participants post-randomisation, or ignoring those participants
who withdrew from the trial or were lost to follow-up, compro-
mises the randomisation and potentially introduces bias into the
trial. Where data were missing for the primary outcome of pro-
portion of ulcers healed, we assumed participants did not have
the outcome (i.e. they were considered in the denominator but
not the numerator). We examined this assumption in a sensitivity
analysis, using a complete case analysis instead.
Assessment of heterogeneity
Assessment of clinical and methodological heterogeneity
within treatment comparisons
We assessed the presence of clinical heterogeneity within each pair-
wise direct comparison (i.e. the degree to which studies varied in
terms of participant, intervention and outcome characteristics) by
comparing information extracted for included studies.
Assessment of transitivity across treatment contrasts
’Transitivity’ refers to the situation in which an intervention effect
measured using an indirect contrast is valid and equivalent to the
intervention effect measured using a direct contrast. Where there
are differences in (knownor unknown) effectmodiﬁers across con-
trasts, the transitivity assumption may not be met which may gen-
erate statistical inconsistency in the network (Grant 2013; Jansen
2013). We did not identify any potential effect modiﬁers from the
literature, so there was no evidence that the transitivity assump-
tion was not met. There were also limited underlying theoretical
reasons to consider effect modiﬁcation for these treatments.
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If we had had sufﬁcient data we planned to explore the effect of
the funding source and differences in risk of bias as possible ef-
fect modiﬁers across the network. However, there was insufﬁcient
variation in these factors.
Assessment of reporting biases
We assessed for the presence of publication bias using a contour-
enhanced funnel plot, provided there were at least 10 included
studies (Peters 2008; Salanti 2014).
Data synthesis
General methods
We performed analyses in a frequentist framework using the sta-
tistical software STATA (STATA 2013). This is a change from the
protocol, in which we had proposed a Bayesian framework using
the statistical software WinBUGS for most of the analyses (Dias
2016; Lunn 2000; Lunn 2009; Spiegelhalter 2003; WinBUGS
2015), and STATA to calculate contributions of direct contrasts to
theNMA results. Onemajor advantage of the Bayesian framework
would have been to confer ﬂexibility by explicitly considering the
duration of follow-up across studies bymodelling the hazard func-
tion (Dias 2016; Saramago 2014; Soares 2014). However, there
was insufﬁcient variation in follow-up duration and fewer than
20% of the studies reported time-to-event data, in six contrasts
without loops, so we could not justify modelling the outcome data
in this way. We therefore conducted analyses using the proportion
healed, and we pooled risk ratios, ignoring differences in follow-
up, This lack of need to model time, together with recent soft-
ware developments in STATA for NMA (especially the contribu-
tions matrix routine, important for GRADE analysis), led to a
decision to use a frequentist approach in STATA for all analyses
(Chaimani 2013a; Chaimani 2013b; Chaimani 2015; Gasparrini
2015; Salanti 2014).
We have given a brief description of the STATA analytical routines
used in Appendix 4, together with routines that enabled us to
display the output visually (Chaimani 2013b). Where there were
zero events in any one armof a trial, we added 0.5 to the numerator
and 1 to the denominator for each arm in the trial, in accordance
with the general approach taken by STATA.
Methods for standard meta-analysis
We performed pairwise meta-analyses in a frequentist framework,
both within the STATA software and also using ReviewManager 5
(RevMan 5) (RevMan 2014) for convenience in producing forest
plots. For RevMan, we used both inverse variance weighting and a
random-effects model (for consistency with the NMA methods).
Results for the two sets of software were compared and found to be
identical in most cases; where there were differences we reported
both sets of results. Differences were due to how zero cells are dealt
with.
Methods for network meta-analysis
We initially used the STATA software to produce a network dia-
gram based on all included studies in order to inform the analysis
plan (Chaimani 2013b). We then excluded from the analysis two-
arm studies in which one of the interventions could be described
as ’standard care’ or ’mixed care’ involving the choice of more than
one treatment because they crossed intervention categories. We
also excluded from the analysis studies that had one intervention
of direct interest (e.g. hydrocolloid) compared with one ineligible
intervention (e.g. radiant heat), unless we found, after examining
the network diagram, that the ineligible intervention linked two
or more interventions of direct interest.
We performed multivariate network meta-analysis using STATA
routines. This took into account correlations between the effect
sizes frommulti-arm studies (Chaimani 2013a; Chaimani 2013b;
White 2012). We used a consistency model (which assumes that
there is agreement between direct and indirect sources of evidence)
and assumed a random-effects model. The NMA results were re-
ported for ’mixed treatment contrasts’, which means the evidence
synthesis involved both direct evidence and indirect evidence from
across the whole network. The output was reported as pooled risk
ratios, with their 95% CIs.
We evaluated the surface under the cumulative ranking curve (SU-
CRA) and obtained mean ranks (Salanti 2011) for each treatment.
Both these measures are based on an assessment of the probabil-
ity of each treatment being best, second best, etc. In general, the
probability that a particular treatment ranks best represents the
likelihood of it being considered the most effective (within the
pool of treatments analysed) reﬂecting the evidence of effective-
ness and the precision surrounding the estimates. It is expressed
as a proportion, where a value of 1 means that the evidence deter-
mines that a particular treatment is the best with certainty and 0
is the certainty that it is not the best. The SUCRA is a numerical
summary of the distribution of ranks for each treatment (proba-
bility of being best, second best, etc) and provides a hierarchy of
the treatments that accounts both for the location and the variance
of all relative treatment effects. The larger the SUCRA value, the
better the rank of the treatment.
We conducted two NMAs: one for individual treatments and
one in which dressings interventions were grouped in broader
categories, with clinical guidance. We had planned the second
(grouped) network as a sensitivity analysis at the protocol stage,
but later decided to conduct this analysis in parallel with the in-
dividual treatment NMA, because we expected the group analysis
to provide valuable and complementary clinical information. The
results of the group analysis are presented in Appendix 5.
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Assessment of statistical heterogeneity
We assessed statistically the presence of heterogeneity within each
pairwise comparison using the I² (Higgins 2003) and tau² statis-
tics from the RevMan 5 analyses; I² measures the percentage of
variability that cannot be attributed to random error and tau²mea-
sures the extent of heterogeneity among the intervention effects
observed in different studies. We also took into account the over-
lap of CIs and the variability in the point estimates.
Assessment of statistical inconsistency
We assessed inconsistency in two main ways: determining local
inconsistencies (around particular contrasts in the network) and
assessing inconsistency for the network as a whole. These tests are
often underpowered so we assessed at the 90% signiﬁcance level.
Local approaches to evaluating inconsistency
To evaluate the presence of inconsistency locally we considered
two main approaches.
Firstly, we used a loop-speciﬁc approach. This method evaluated
the consistency assumption in each closed loop of the network
separately as the difference between direct and indirect estimates
for a speciﬁc contrast in the loop (inconsistency factor: IF). We
assumed a common heterogeneity estimate within each loop. We
report results as the ratio of risk ratios (RoRR) with its 90% CI -
the natural logarithm of the RoRR is the same as IF (Appendix 2).
The magnitude and 90% CIs were used to draw inferences about
the presence of inconsistency in each loop. If the CI excluded 1,
statistically there was signiﬁcant inconsistency. We also considered
whether the CI included 2 or more (or 0.5 or less). This means
that the direct estimate could be twice as large (half as big) as the
indirect estimate, which is an indication of potential inconsistency
(Chaimani 2013b). We also report the IF assuming a common
heterogeneity estimate for the whole network (Veroniki 2013).
Secondly, we considered a “node splitting” approach (Dias 2010;
Salanti 2014) This method was applied, singly, to each direct con-
trast (called a “node” by Dias 2010). The STATA routine calcu-
lated an indirect estimate using the rest of the network, by running
theNMA after excluding the direct evidence for that contrast. The
indirect estimates were then compared with the respective direct
estimates, again calculating a RoRR with its 90% CI for each con-
trast.
Finally, we comparedNMA results using inconsistency versus con-
sistency assumptions for each contrast.
Global approaches to evaluating inconsistency
We evaluated consistency in the entire network simultaneously,
by extending the analysis to include an inconsistency model that
omitted consistency equations (Dias 2013). The latter used a de-
sign-by-treatment interaction model, which allowed for different
designs (2-arm trials (A-X); 2-arm trials without A, and 3-arm tri-
als, where A is the base treatment). This approach produced a set
of inconsistency parameters. After ﬁtting the inconsistency model,
the null hypothesis of consistency is tested for the set of incon-
sistency parameters using a global Wald test. This test may lack
power and we considered a signiﬁcance level of P < 0.1 (Higgins
2012; White 2012).
Investigation of heterogeneity and inconsistency
If there had been sufﬁcient studies available, we would have per-
formed networkmeta-regression or subgroup analyses using fund-
ing source and risk of bias as possible sources of inconsistency or
heterogeneity, or both. This was not possible.
Sensitivity analysis
We had intended to re-analyse the network with studies removed
that were considered to be at high risk of bias for any one ormore of
selection, attrition or detection bias, however, due to the sparseness
of the data available and the generally poor methodological quality
of the studies, this analysis had to be restricted to removing studies
with two or more domains at high risk of bias (“very high risk of
bias”) (Appendix 6).
We conducted a sensitivity analysis to assess the impact of imput-
ing missing outcome data on the network estimates, via assess-
ment of risk of attrition bias (as deﬁned in Appendix 6), testing
the assumption of imputation of no event for missing data by con-
ducting a complete case analysis.
Quality assessment of evidence (GRADE) generated
from the NMA and ’Summary of findings’ table
We summarise the ﬁndings according to GRADE principles
(Schünemann 2011a; Schünemann 2011b).
The quality of the data included in any synthesis model is key
to determining the validity of the results and of inferences made.
We explored the application of GRADE methodology to network
meta-analysis, focusing on the approach of Salanti 2014. We as-
sessed evidence quality (certainty) in two main ways, ﬁrstly, for
each contrast and secondly, for the network as a whole, in order
to assess the quality of the ranking order. We assessed GRADE
factors as follows:
• Risk of bias: we considered contributions for each particular
contrast, and used them to assess the overall risk of bias for that
contrast (see Assessment of risk of bias in included studies
section, Risk of bias for each contrast in the network). We
assessed overall risk of bias per contrast and also for the network
as a whole.
• Indirectness: we deﬁned this as without limitations in
GRADE because we had not identiﬁed any effect modiﬁers.
• Inconsistency:
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◦ At the level of the contrast, inconsistency could only
be assessed where there was both direct and indirect evidence.
We took into consideration heterogeneity in the direct evidence
for that contrast (see Data synthesis, Assessment of statistical
heterogeneity) and inconsistency, as described above (see Data
synthesis, Local approaches to evaluating inconsistency). We
assessed GRADE inconsistency as ’serious limitations’ if there
was heterogeneity in the direct estimate or inconsistency in the
network with respect to that contrast. We attributed ’very serious
limitations’ to the contrast if there was severe heterogeneity or
severe inconsistency or limitations with both heterogeneity and
inconsistency, as agreed by two review authors.
◦ At the level of the network, we considered the global
Wald test for inconsistency (see Data synthesis, Assessment of
statistical inconsistency). Tests of this nature are typically
underpowered, so a P value less than 0.1 was considered
signiﬁcant. Additionally, if several contrasts showed direct and
indirect results that would have led to different clinical decisions,
we assigned inconsistency.
• Imprecision: currently, NMA GRADE methods do not
consider the optimal information size (OIS) approaches used for
systematic reviews of pairwise interventions (Guyatt 2011b) and
imprecision is based solely on the CI in relation to minimum
important difference (MID) values or the null (Salanti 2014), or
both. However, in the type of sparse networks typically found in
wounds research, the small sample size and ensuing Type I and
Type II errors are potentially more of an issue (Dumville 2012;
Soares 2014). We ﬁrstly considered whether the network was
sparse, taking into account the total number of participants, the
total number of events and the number of interventions and
contrasts in the NMA. If we considered the network not to be
sparse, we applied the methods of Salanti 2014. If we considered
the network to be sparse, we used the following approach
adapted from the Salanti 2014 guidance:
◦ At the level of the contrast - we considered the CI for
the individual contrast in relation to the GRADE ’default’
minimum important difference (MID) values of RR = 1.25 and
0.75. If the CI crossed both of these MIDs, we downgraded
twice for imprecision. If the CI crossed one MID, we
downgraded once, regardless of whether the null was crossed. For
contrasts involving peripheral interventions, for which large
effects were found, we additionally took into account the amount
of direct evidence involving this intervention, considering (in an
analogous way to simple meta-analysis) whether the evidence was
’fragile’ because of small numbers of events (Guyatt 2011b).
◦ At the level of the network, we took into
consideration the overlap of the rankograms/the magnitude of
the SUCRA estimates and the sparseness of the network.
• We assessed publication bias by plotting a contour-
enhanced funnel plot, which allowed visual assessment of
asymmetry for either a particular contrast (all one colour) or for
the network as a whole. We did this for the former only if there
were 10 studies or more.
We have presented the main results of the review in a ’Summary
of ﬁndings’ table, reporting the results for a representative set of
contrasts, with one row for each intervention versus saline gauze.
Such tables present key information concerning the certainty (for-
merly, quality) of the evidence, the magnitude of the effects of
the interventions examined, and the sum of the available data
(Schünemann 2011a). ’Summary of ﬁndings’ tables also include
an overall grading of the evidence using the GRADE approach.
The GRADE approach deﬁnes the certainty of a body of evidence
as the extent to which one can be conﬁdent that an estimate of
effect or association is close to the true quantity of speciﬁc interest.
For calculating absolute risk differences for the probability of heal-
ing we used a ’control group risk’, calculated as the median of the
probability of healing for saline gauze across all studies with these
interventions.
R E S U L T S
Description of studies
Results of the search
The search generated 1038 records: we obtained 381 full papers
Figure 1); 305 studies were excluded with reasons (Characteristics
of excluded studies). We included 51 studies described in
74 reports. Two protocols of studies were also identiﬁed (
ISRCTN57842461; ChiCTR-TRC-13003959), which appear to
be ongoing (see Characteristics of ongoing studies).
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Figure 1. Study flow diagram
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We also searched reference lists from identiﬁed systematic reviews
and for two recent guidelines, but found no extra studies outside
the electronic searching.
Included studies
This review distinguishes three sets of included studies: (i) all
studies that meet the inclusion criteria (’all included studies’); (ii)
the subset of (i) for which all studies have interventions that are
joined into the network (’the individual network’) (see Effects of
interventions) and (iii) the subset of (i) for which all studies are
joined in a network in which interventions are grouped (’the group
network’) (see Appendix 5). In this section we have given a brief
summary for the individual network. Further details of each set of
included studies are given in Table 1.
Fifty-one studies, involving 2947 participants, met the inclusion
criteria for the whole review. Most of these studies could be
linked to form a network of interventions, but 12 were not linked
into the network; further details, and the results for the compar-
isons reported in these 12 studies are given in Appendix 7. The
joined network (Figure 2) included 39 studies (Aguilo Sanchez
2002; Alm 1989; Bale 1997a; Banks 1994b; Banks 1994a; Banks
1994c; Barrois 1992; Belmin2002; Brod 1990; Brown-Etris 1996;
Brown-Etris 1997; Brown-Etris 2008; Burgos 2000b; Colwell
1993; Darkovich 1990; Graumlich 2003; Hollisaz 2004; Hondé
1994; Kaya 2005; Kraft 1993; Matzen 1999; Meaume 2003;
Motta 1999;Muller 2001;Neill 1989a;Oleske 1986; Parish 1979;
Payne 2009; Piatkowski 2012; Price 2000; Romanelli 2001; Seeley
1999; Serena 2010; Sopata 2002; Thomas 1997a; Thomas 1998;
Thomas 2005; Xakellis 1992; Zeron 2007). The median (range)
study size was 41 (10 to 168).
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Figure 2. Network diagram - individual interventions, by risk of bias (3 categories)Key: green = low/unclear;
yellow = high; red = very high overall risk of bias for the contrast. The number of studies for each contrast is
given in .
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Themajority of the 39 studies had only two randomised interven-
tions (37), randomised people rather than ulcers or clusters (34),
included at least some of the participants from a hospital setting
(20), and were not funded by industry (7) or funding was not
stated (17). The median follow-up time was eight weeks; range
10 days to 6 months. Most studies included participants with a
mean age more than 65 years (33) and had ulcers that were mainly
Stage 2 (15), Stage 3 (10) or Stages 2 and 3 (7). Sixteen studies
included participants with ulcers of less than three months’ du-
ration; two had more than three months’ duration and the rest
(21) were unclear on duration. Further details are given in Table 1.
We considered the clinical characteristics to be sufﬁciently similar
across the studies to combine in the analysis, particularly since we
had not deﬁned clinical effect modiﬁers.
Excluded studies
We excluded 305 studies from this review (see Characteristics of
excluded studies) Themost common reasons for exclusionwere 67
with a non-RCT study design; ineligible outcomes in 120 studies
(including 64 with healing outcomes that were not reported as the
time to complete healing or the probability of complete healing)
and 57 had an ineligible patient population. Eleven studies were
excluded because they had two interventions in the same class and
36 other studies had ineligible interventions in both randomised
arms, or had treatments that could not be classiﬁed as a single
intervention.
Risk of bias in included studies
Risk of bias for all included studies is summarised in Figure 3.
In order to represent ’very high’ risk of bias, we have used two
columns - so very high risk of bias occurs when the cell is red in the
ﬁnal column (see Assessment of risk of bias in included studies).
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
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We judged only one of the 51 studies (2%) to be at low risk
of bias (Graumlich 2003) and ten (20%) to have unclear risk of
bias (Aguilo Sanchez 2002; Banks 1994b; Barrois 1992; Hollisaz
2004;Nisi 2005*; Parish 1979; Piatkowski 2012; Romanelli 2001;
Thomas 1998; Zeron 2007). We judged 14 (27%) studies to be
at very high risk of bias, that is, to have high risk of bias for
two or more domains (Bale 1997a; Banks 1994a; Brown-Etris
1996; Burgos 2000b;Gorse 1987*;Hondé 1994; Imamura 1989*;
Nussbaum 1994*; Oleske 1986; Payne 2004*; Ramos-Torrecillas
2015*; Sebern 1986*; Thomas 2005; Yapucu Güne 2007*). We
assessed the rest of the studies at high risk of bias. We grouped the
low and unclear categories together.
*Studies marked with an asterisk were not included in the indi-
vidual network.
Effects of interventions
See: Summary of findings for the main comparison NMA
evidence for individual network: proportion with complete
healing - interventions versus saline gauze
In this section, we present the results for the individual NMA.
Results for the group network are given in Appendix 5.
We report the results in two ways. Firstly, we give risk ratios (RR)
with their 95% CIs for each intervention compared with every
other intervention in the network (NMA effect estimates); all re-
sults are presented in a forest plot, but we focus on a representative
set of comparisons versus a reference intervention (saline gauze for
the individual network). Secondly, we summarise ﬁndings for the
network as a whole, giving the rank order for all the interventions
in the network and the probability that a particular intervention
is the best, second best, etc treatment.
We report the results alongside the assessment of evidence quality.
To do this we applied various statistical techniques and tests, in-
cludingmethods for determining risk of bias in the whole network,
examining whether the results for each comparison in the network
were consistent with one another, and considering the uncertainty
in various measures (e.g. the CI around the RR). For the latter, we
downgraded evidence twice if the 95% CI crossed both of the two
GRADE ’default’ values (RR = 1.25 and RR = 0.75) and once if
the 95% CI crossed one of these values. Additionally, if there was
a large effect and there were very few events in the direct evidence
for a particular intervention, we downgraded the evidence further
(’fragility’; see Data synthesis, Quality assessment). We also con-
ducted some sensitivity analyses to test assumptions made in the
analysis. Much of the assessment of evidence quality is reported
in Appendices, but is summarised in ’Summary of ﬁndings’ tables
for the comparisons with the reference intervention.
Interventions and comparisons
The individual network comprised 21 interventions: 13 eligible
dressings (foam, hydrocolloid, alginate, protease-modulating, io-
dine-containing, soft polymer, vapour-permeable, silicone-foam
combination, two alginate-hydrocolloid combination or sequen-
tial dressings, saline gauze, polyvinylpyrrolidone plus zinc oxide
and basic wound contact); six topical agents (hydrogel, dextra-
nomer, collagenase ointment, phenytoin, tripeptide copper gel,
and sugar plus egg white) and two supplementary linking inter-
ventions (skin substitute and radiant heat dressing).
Two studies were three-arm trials:Hollisaz 2004 (hydrogel, pheny-
toin and saline gauze); and Parish 1979 (dextranomer, collagenase
ointment, and sugar plus egg white). The total number of com-
parisons was 43, encompassing a total of 2127 participants, who
experienced a total of 783 events (complete healing) - this is 72%
of the participants included in all studies in the review before we
excluded studies for not ﬁtting into the network. There were 27
different direct contrasts and eight triangular loops, including one
that was exclusive to one of the three-arm trials (Parish 1979).
In the network diagram (Figure 2), node (circle) size reﬂects
weighting according to the number of studies reporting each in-
tervention and the thickness of the edge lines reﬂects weighting
according to the inverse variance of the direct treatment effect es-
timates for the particular contrast (Chaimani 2013b). We identi-
ﬁed seven interventions as ’core interventions’ (i.e. part of at least
one loop: foam dressing, hydrocolloid dressing, hydrogel, iodine-
containing dressing, phenytoin, protease-modulating dressing and
saline gauze). The other interventions were only connected in a
peripheral way.
Risk of bias for the individual network
We report risk of bias in three ways (see Methods: Assessment of
risk of bias in included studies):
1. For each study, as the all-domain risk of bias - taking into
account selection bias, detection bias, attrition bias, reporting
bias and other bias
2. For each direct comparison of two interventions, as an
overall risk of bias - taking into account the all-domain risk of
bias for the studies (1 above) and the weighting in the meta-
analysis for that comparison
3. For each contrast in the network (any pair of interventions
in the network) as the overall risk of bias - taking into account
the risk of bias for each direct comparison (2 above) and their
percentage contributions to the network estimate. We also
calculated the overall risk of bias in the network as a whole.
All-domain risk of bias for each study is shown in Figure 3. We
judged one study to be at low risk of bias (Graumlich 2003)
and nine at unclear risk of bias (Aguilo Sanchez 2002; Banks
1994b; Barrois 1992; Hollisaz 2004; Parish 1979; Piatkowski
2012; Romanelli 2001; Thomas 1998; Zeron 2007). Seven were
at very high risk of bias (Bale 1997a; Banks 1994a; Brown-Etris
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1996; Burgos 2000b; Hondé 1994; Oleske 1986; Thomas 2005)
and the rest we assessed to be at high risk of bias. We grouped the
low and unclear categories together.
We have indicated the overall risk of bias for each direct compar-
ison in Figure 2, using colour for three risk of bias ratings: low/
unclear (green), high (yellow), very high (red). There is a relatively
large amount of direct evidence at high or very high risk of bias.
For each contrast in the network, we calculated the overall risk of
bias as described in Appendix 8, and the ’Risk of bias’ ratings are
shown beside the results in Figure 4.
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Figure 4. NMA results: individual intervention 1 versus individual intervention 2Key for overall risk of bias
for the contrast: green = low/unclear; one red = high; two reds = very high
25Dressings and topical agents for treating pressure ulcers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fo
r P
re
vie
w 
On
ly
Network meta-analysis results
The NMA generated results for 210 mixed treatment contrasts
(i.e. all possible pairwise combinations of the interventions). The
data were sparse and there was much uncertainty.
Figure 4 shows all NMA results, with the all-domain risk of bias
shown alongside the forest plot contrasts.
As a consequence of the sparseness in the network, no contrast had
precise estimates, all CIs were wide or very wide and we down-
graded all evidence at least once for imprecision, some because of
’fragility’ (Figure 4). The majority of the evidence for each con-
trast was informed by studies at high or very high risk of bias.
Across all themixed treatment contrasts, therewas only one thatwe
assessed to have moderate-certainty evidence (downgraded once
only): protease-modulating dressing versus saline gauze. Evidence
for all other contrasts was of low or very low certainty, and the
moderate-certainty evidence should also be interpreted in the light
of the very low-certainty evidence for the network from which it
was derived.
As a summary, we presented the evidence for the individual mixed
treatment contrasts using a representative set of each intervention
versus saline gauze (Summary of ﬁndings for themain comparison)
and Figure 4, ﬁrst subgroup of results); we did not include the
ineligible interventions (radiant heat and skin substitute) in the
’Summary of ﬁndings’ table. Further details of information used
forGRADE assessment can be found in Appendix 8 andAppendix
9).
It is not clear whether protease-modulating dressings increase the
probability of pressure ulcer healing, compared with saline gauze
dressings (RR 1.65; 95% CI 0.92 to 2.94, moderate certainty
evidence). This corresponds to an absolute risk difference of 102
more people healed per 1000 (95% CI 13 fewer to 305 more), for
a saline gauze median probability of healing of 157 per 1000. We
downgraded the evidence once for imprecision (low risk of bias).
For each of four contrasts, it is unclear whether the intervention in-
creases the probability of healing comparedwith saline gauze dress-
ings: collagenase ointment (RR 2.12; 95% CI 1.06 to 4.22); foam
dressing (RR 1.52; 95% CI 1.03 to 2.26); basic wound contact
dressing (RR1.30; 95%CI0.65 to 2.58) andpolyvinylpyrrolidone
(PVP) plus zinc oxide (RR 1.31; 95% CI 0.37 to 4.62) (Figure
4). In each of these four contrasts, the evidence was graded as low
certainty; downgraded either once for imprecision and once for
risk of bias (collagenase ointment and foam dressing) or twice for
imprecision and not for risk of bias (basic wound contact dressing
and PVP plus zinc oxide).
It is unclear whether there is a difference in the probability of
healing associated with the following interventions compared with
saline gauze for the remaining 13 contrasts because the evidence
is of very low certainty (downgraded mainly for risk of bias (once)
and imprecision (twice)): alginate dressings, sequential hydrocol-
loid alginate dressings, dextranomer, hydrocolloid dressing with/
without alginate ﬁller (given if the wound was highly exuda-
tive), hydrocolloid dressings, hydrogel, iodine-containing dress-
ings, phenytoin, silicone-foam dressings, soft polymer dressings,
sugar plus egg white, tripeptide copper gel and vapour-permeable
dressings. Two contrasts were informed by very few participants
in the direct evidence, with seven participants (4 events) receiving
dextranomer and six participants (5 events) receiving tripeptide
copper gel; we therefore downgraded imprecision twice to allow
for the fragility this invoked. There was also heterogeneity or in-
consistency, or both, for some contrasts.
Ranking of treatments
The NMA produced a large number of estimates. An alternative
way of presenting and interpreting data from the whole NMA was
to summarise using rankograms: data for each intervention were
shown as the probability that each intervention is the best, second
best, third best treatment, etc. These probabilities are based on
uncertainty, reﬂecting the effectiveness from the network contrasts
and the precision around the estimates. The closer the probabil-
ity of a rank to 100% (or 0%) and the narrower the distribution
across different ranks, the greater the conﬁdence in the ranking.
Results are given in Figure 5 and Appendix 10 and summarised
here, but must be interpreted in the light of the considerable un-
certainty and sparseness in the network and the individual esti-
mates, giving potentially misleading results (see quality assessment
below). Numerically, dextranomer and tripeptide copper gel had
the highest probabilities of being the best treatments (41% and
25%, respectively), and the sequential hydrocolloid alginate dress-
ings and sugar plus egg white were most likely to be the worst
treatments (35% and 32%, respectively). No intervention had
more than 50% probability of being the best treatment and the
rankograms for each treatment show considerable overlap. How-
ever, these rankings are likely to be artiﬁcially high: the direct ev-
idence for dextranomer and tripeptide copper involves one study
each with, respectively, seven participants (4 events) and six par-
ticipants (5 events). The NMA results for these peripheral inter-
ventions have wide CIs and large point estimates. Consequently,
these interventions have a ﬁnite probability of having a very large
effect estimate (at their upper conﬁdence limit), in turn leading
to an artiﬁcially high probability of being the best treatment.
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Figure 5. Rankograms for each intervention - individual network
Comparison of results from standard meta-analysis with
NMA findings
We compared the NMA results with the direct comparison (pair-
wise) results for the proportion completely healed for the 27 dif-
ferent comparisons informing the individual network (Table 2).
Six of these comparisons had two or more direct comparison stud-
ies (Analysis 1.1; Analysis 1.2). The direct comparison evidence
shows heterogeneity for the comparisons of hydrocolloid dressing
versus saline gauze dressing; hydrogel versus saline gauze dress-
ing and hydrogel versus hydrocolloid dressing. Direct comparison
evidence results for the time-to-healing outcome are reported in
Appendix 11 for six comparisons in seven studies. The results for
the direct comparison evidence and the NMA are shown in Table
2: there is too much uncertainty (wide CIs) to determine whether
there are differences.
Certainty/quality assessment of the evidence across the whole
network
The weighted average risk of bias across the network was high (
Appendix 8). There did not appear to bemuch inconsistency in the
network (see Appendix 9) and there were relatively few contrasts
with conﬂicting results for direct and indirect or NMA estimates,
so across the network we did not downgrade for inconsistency.
We downgraded the evidence twice for imprecision: in addition
to the sparseness (and probably as a consequence of it), there is
substantial overlap of the individual rankograms (see Appendix
10); themean rankwas no smaller than 3.6 and no larger than 18.6
(out of 21) for any intervention, with no SUCRA value being zero
or 1 (indicating uncertainty). A contour-enhanced funnel plot is
shown in Figure 6. There may be a small studies effect, but this
was too unclear for downgrading. Overall, we classed the evidence
for the whole network as being of very low certainty (downgraded
once on risk of bias and twice on imprecision).
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Figure 6. Funnel plot - individual networkKey to interventions: 1: saline gauze; 2: alginate dressing; 3:
sequential hydrocolloid alginate dressings; 4: basic wound contact dressing; 5: collagenase ointment; 6:
dextranomer; 7: foam dressing; 8: hydrocolloid dressing; 9: hydrocolloid +/- alginate (hydrocolloid dressing
with/without alginate filler); 10: hydrogel dressing; 11: ineligible radiant heat; 12: ineligible skin substitute; 13:
iodine-containing dressing; 14: phenytoin; 15: protease-modulating dressing; 16: PVP + zinc oxide 17: silicone +
foam dressing; 18: soft polymer dressing; 19: sugar + egg white; 20: tripeptide copper gel; 21: vapour-
permeable dressing
Overall, we have little conﬁdence in the ﬁndings in this network,
either in terms of the effect estimates or in the ranking of inter-
ventions.
Sensitivity analyses
We carried out the following pre-speciﬁed sensitivity analyses to
examine the above inconsistencies: excluding studies at very high
risk of bias; and assuming an available case analysis rather than
imputing no event for missing values. The sensitivity analyses are
discussed in Appendix 12. Neither sensitivity analysis had much
impact on the effect estimates or the rankograms. There appeared
to be less inconsistency in the sensitivity analysis that excluded
studies at very high risk of bias, but this possible improvement
was at the expense of precision and resulted a smaller network,
and so the original analysis was preserved. An additional post-hoc
sensitivity analysis (Appendix 12) examined the original assump-
tion of combining topical agents and dressings in the same NMA,
by restricting the network to studies comparing any two eligible
dressings - similar results were found for the contrasts versus saline
gauze, and the imprecision in the overall network continued to
give uncertainty.
Group network findings
We mapped individual interventions onto the group categories
(Appendix 5), grouping together dressings into the following pre-
speciﬁed categories: basicwounddressings, advanceddressings and
antimicrobial dressings (as described in the BNF 2016), and keep-
ing specialist dressings (e.g. protease-modulating matrix dressings)
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and the different topical agents as separate categories. The group
network included 22 studies (of 51 included) in 946 participants,
encompassing 10 different interventions in 12 direct contrasts and
these informed 45 mixed treatment contrasts. The median (range)
study size was 38.5 (10 to 100). We had hoped that grouping
interventions might increase the power in the network, but fewer
than half of the included studies formed the group network (see
Appendix 5) and only 32% of the participants were involved; only
three contrasts were informed by more than one study.
The group NMA generated results for 45 mixed treatment con-
trasts. The network was dominated by the advanced dressing ver-
sus basic dressing contrast and the rest of the data were sparse.
Figure 7 shows all group NMA results, with the all-domain risk
of bias shown alongside the forest plot contrasts. The results and
the certainty of the evidence are summarised for a representative
set of contrasts (each intervention versus basic dressing) in Table
3. Evidence was of low or very low certainty, with the exception of
one contrast, for which we assessed the evidence to be of moderate
certainty. As for the individual network, this moderate-certainty
evidence should be interpreted in the light of the very low-cer-
tainty evidence for the network as a whole.
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Figure 7. Intervention 1 versus intervention 2 - group networkKey for overall risk of bias for the contrast:
green = low/unclear; one red = high; two reds = very high
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Rankograms for the group network are shown in Figure 8. There
wasmore of a distinction between interventions, but still overlap of
rankograms and the improvement in precision came at the expense
of increased inconsistency and possible publication bias (Figure
9). Overall we downgraded the evidence certainty three times for
the network as a whole, because of risk of bias (once), imprecision
(once) and inconsistency and publication bias (once). As in the
individual network, dextranomer and tripeptide copper had high
ranks and this was again likely to be an artiﬁcial result. Further
details of the group network are given in Appendix 5.
Figure 8. Rankograms combined - group network
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Figure 9. Funnel plot - group networkKey to interventions: 1: basic dressing; 2: advanced dressing; 3:
advanced or antimicrobial dressing; 4: antimicrobial dressing;5: collagenase ointment; 6: dextranomer; 7:
phenytoin; 8: protease-modulating dressing; 9: sugar + egg white; 10: tripeptide copper gel
D I S C U S S I O N
Summary of main results
We have successfully conducted a network meta-analysis of dress-
ings and topical agents for healing pressure ulcers. Alongside the
analysis we have applied a new method of GRADE assessment
(Salanti 2014), which allows us to view the results in the light of
our certainty in their ﬁndings. Using this approach, we found the
majority of the evidence to be of low or very low certainty, and was
mainly downgraded for risk of bias and imprecision (see Quality
of the evidence). This level of uncertainty within the totality of
the dataset impacts on all subsequent interpretation of its outputs.
This review includes 51 RCTs involving a total of 2964 partici-
pants, comparing 39 different dressings or topical agents for the
healing of pressure ulcers.Most of the studies were in older partici-
pants, but four included participants with spinal cord injuries and
one was in younger people said to be chronically ill or physically
disabled. Seventeen (33%) studies included participants mainly
with Stage 2 pressure ulcers and 15 (29%) mainly had Stage 3
pressure ulcers; 13 studies investigated treatment of ulcers with a
mean duration of less than three months.
We treated each topical agent as a separate intervention, but ini-
tially grouped dressings by class as described in the BNF 2016
(e.g. alginates, hydrocolloids). The network involved 39 studies
in 2116 participants, encompassing 21 different interventions in
27 direct contrasts and these informed 210 mixed treatment con-
trasts.
We reported the evidence in two ways, ﬁrstly, as effect estimates
for each of 210 NMA mixed treatment contrasts , and secondly
as rank order of interventions. We summarised the set of effect
estimates using contrasts versus saline gauze.
Overall ﬁndings reﬂect the uncertainty of the component evi-
dence and the sparseness of the network, and even moderate rat-
ings should be interpreted in the context of the network uncer-
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tainty. For network contrasts involving saline gauze, it is not clear
whether protease-modulating dressings result in more healing (RR
1.65, 95% CI 0.92 to 2.94; moderate certainty evidence). It is un-
clear whether four interventions increase the probability of healing
compared with saline gauze dressings: collagenase ointment RR
2.12 (95%CI 1.06 to 4.22); foam dressing RR 1.52 (95%CI 1.03
to 2.26); basic wound contact dressing RR 1.30 (95% CI 0.65 to
2.58) and PVP plus zinc oxide RR 1.31 (95%CI 0.37 to 4.62) (all
low certainty evidence). It is worth noting that the contrasts for the
latter two interventions had CIs consistent with both a clinically
important beneﬁt and a clinically important harm, and the other
two contrasts had both high risk of bias and some imprecision.
The remaining contrasts were all very low-certainty evidence, with
all being imprecise, often with CIs consistent with both a clini-
cally important increase and a clinically important decrease in the
probability of healing.
Relative to the median control group risk (probability) (CGR) of
healing for saline gauze of 157 per 1000, the absolute risk differ-
ences for the above comparisons in the individual network were:
protease-modulating dressings: 102 more people healed per 1000
(13 fewer to 305 more); foam dressings: 82 more per 1000 (5
more to 196 more); collagenase ointment 176 more per 1000 (9
more to 506 more); basic wound contact dressing: 47 more per
1000 (55 fewer to 250 more); polyvinylpyrrolidone plus zinc ox-
ide: 49 more per 1000 (99 fewer to 575 more). Thus, uncertainty
notwithstanding, the effect is relatively small and fairly large num-
bers of wounds remain unhealed.
For the network as a whole, the evidence was of very low cer-
tainty, reﬂecting the general uncertainty surrounding the mixed
treatment contrasts, as described above. There was considerable
uncertainty in the ranking of interventions and no intervention
had more than 50% probability of being the best treatment.
Overall completeness and applicability of
evidence
The network is sparse, in terms of the total number of partici-
pants, the total number of wounds healed, the number of studies
per contrast, the size of the constituent studies and the duration
of follow-up: 21 of 27 direct contrasts were informed by only one
study and the average number of events per mixed treatment con-
trast was around four. The median (range) study size was 41 (10 to
168) and several studies had zero events. The duration of follow-
up was relatively short for most studies (median 8 weeks): only 3/
39 studies in the network had a follow-up duration of 16 weeks
or more.
In parallel we conducted a second NMA, grouping together some
classes of dressings. We had hoped that the group network would
provide more power in the analysis, but in practice too many data
were excluded from the network, and the network was also un-
balanced, being dominated by the advanced dressing versus basic
dressing contrast, which involved about 55% of the participants
in the group network. The group network provided equally un-
certain evidence and the ﬁndings are not discussed further here,
but are reported in Appendix 5 for the interested reader.
There may have been small-study effects, and the contour-en-
hanced funnel plot appeared to show some asymmetry. The
Chaimani 2013b methodological paper demonstrated that small-
study effects can materially affect the rank order of effectiveness.
STATA code is available to adjust for small-study effects in rank-
ing, however, we did not investigate this approach because the ev-
idence was of such low certainty for reasons of risk of bias, impre-
cision and inconsistency. Additionally, Kibret 2014 suggested in a
simulation study in a Bayesian setting that an unequal number of
studies per comparison may result in biased estimates of treatment
rank probabilities.
In the absence of evidence for effect modiﬁers, we can make ob-
servations about the population covered and the trial duration,
only approximating the applicability of the evidence. In particu-
lar, there were eight studies with a follow-up time of less than six
weeks, which may be too short to properly investigate healing, and
the reporting of time-to-event data was insufﬁcient to understand
how the hazard of healing changes over time. Whilst treatments
may have impacted on the speed of wound healing as well as the
number of healing events per se, this requires further exploration,
which would be better supported by increased collection and anal-
ysis of time-to-healing data in wound care trials. We note that the
two small three-arm trials, which may have shown some incon-
gruent results, were in younger people with spinal cord injuries or
chronic illnesses/physical disabilities. Overall, our view is that the
results can probably be applied more generally, within the con-
straints of the uncertainty of the evidence and also the compar-
isons for which trial data exist. There are many different dressing
and topical treatment choices and, whilst several key treatments
are represented by trial data, others are addressed only in pilot
studies and there may be treatments that are yet to be evaluated
in a trial or for which data remain unpublished. We could only
assess publication bias in a limited way.
TheNMA focused on complete wound healing as the key outcome
- this has repeatedly been found to be themost important outcome
to patients and health professionals (Cullum 2016; Kelly 2015).
Dressings and topical agents are generally low risk treatments sowe
did not consider adverse events. Other outcomes that might have
been useful include those related to the management properties
of dressings such as ease of use, exudate management and pain
on removal. We did not consider these in the NMA for practical
reasons: such outcomes are reported inconsistently with data that
rarely allow meta-analysis. Given that the quality assessment of
healing data was based on study-level issues like small samples and
ﬂawed methodology, we can suppose the quality of other outcome
data would have been equally sparse and likely uncertain.
Quality of the evidence
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We have explored the application of a new approach to GRADE
analysis, alongside NMA in STATA (Chaimani 2013b; Salanti
2014). We applied the GRADE approach separately to effect esti-
mates for different contrasts and to the ranking of interventions,
but the two aspects are closely inter-related and, in this review,
are a consequence of the sparse network and the high risk of bias
through much of the network. The effect estimates were exempli-
ﬁed by contrasts of interventions versus saline gauze.
For the effect estimates’ assessment, most of the evidence was of
very low certainty (very low quality). The GRADE meaning of
’low-certainty evidence’ is that “our conﬁdence in the effect esti-
mate is limited: the true effect may be substantially different from
the estimate of the effect”. ’Very low-certainty evidence’ means
“We have very little conﬁdence in the effect estimate: the true
effect is likely to be substantially different from the estimate of
effect”. ’Moderate-certainty evidence’ means “We are moderately
conﬁdent in the effect estimate: the true effect is likely to be close
to the estimate of the effect, but there is a possibility that it is
substantially different” (Balshem 2011). Exceptions to an assign-
ment of very low certainty were found for contrasts with protease-
modulating dressings (moderate certainty); collagenase ointment,
basic wound contact dressing, foam dressing and PVP plus zinc
oxide (low-certainty evidence),We downgraded evidence certainty
mainly because of risk of bias and imprecision, although there was
inconsistency for the contrasts hydrogel and hydrocolloid versus
saline gauze and phenytoin versus saline gauze. Having said this,
we are uncertain about the inconsistency assessment because of
wide CIs around the test parameters. The majority of the compar-
isons with saline gauze had high risk of bias. However, a few con-
trasts had evidence solely downgraded on the basis of wide conﬁ-
dence intervals, that is, random error (protease-modulating dress-
ings, basic wound contact dressing and PVP plus zinc oxide, each
in comparisons with saline gauze). The sparseness of the network
led to widespread imprecision in the effect estimates. Although
we rated the evidence for one contrast as moderate-certainty, this
result should be interpreted in the context of the network as a
whole and not taken as an implication for practice.
Across the network as a whole, the evidence was of very low cer-
tainty. There was overall high risk of bias and overlap of the rank-
ing probability distributions, and no clearcut results. The evidence
was of such poor quality that we consider it inappropriate to focus
on which treatments had the highest probabilities of healing (see
also Potential biases in the review process).
Potential biases in the review process
This was a sparse network and there may have been small-study
effects which impacted on the network (see Overall completeness
and applicability of evidence). The STATA routines have largely
beendeveloped for and tested on larger networks, and ourworkhas
contributed to modiﬁcations for sparse networks in the netweight
routine. Other STATA routines can be modiﬁed by the user to
take into account small-study effects, but we did not explore these
approaches because there was toomuch uncertainty in the network
for us to be conﬁdent of interpreting the results. Instead, we used
the standard routines for NMA and adapted the recent approach
to GRADE (Salanti 2014) to bring in sparseness when assessing
evidence certainty.
The recentGRADE approach has not been applied inmanyNMA
reviews so far, and so could give potential for bias. We judge that
it is a useful approach for many of the GRADE factors, however,
there is one area in which we consider imprecision is underesti-
mated: the GRADE method does not currently have a way of as-
sessing optimum information size and ’fragility’ of the conﬁdence
intervals when there are large effect estimates with wide CIs; such
effects can result when the direct evidence for a particular inter-
vention derives from very small studies peripheral to the network.
Wide CIs can lead some interventions to have a ﬁnite probabil-
ity of having a very large effect estimate, in turn leading to an
artiﬁcially high probability of being the best treatment. For ex-
ample, there were only seven participants who actually received
dextranomer, yet this intervention was the most highly ranked,
and effect estimates versus other treatments were largest for dex-
tranomer. Numerically, when we consider the direct evidence for
dextranomer versus collagenase ointment, for example, a missed
healing diagnosis for just one person treatedwith collagenase could
change the risk ratio by 50%. This, in turn, could affect the rank-
ing and effect estimates of other contrasts with dextranomer. It
was important to capture this potential bias in the review process,
and we therefore produced a modiﬁcation to the GRADE process
to enable the ’sample size’ of the direct evidence to be considered
in a way analogous to the GRADE ’fragility’ effects in pairwise
meta-analysis (Guyatt 2011b). Our approach does not change the
magnitude of the effect estimate or ranking order, rather it allows
us to represent our uncertainty around these values.
A further effect of the sparseness of the network may have been to
hide any inconsistencies. The various statistical tests for inconsis-
tency were generally not signiﬁcant, but this may have been due
to a lack of sensitivity of the tests and the wide CIs around the
measures. Despite this, we found inconsistencies in the network
for contrasts involving phenytoin. We cannot be sure that there
are no other inconsistencies, but this may not matter given the
already identiﬁed large uncertainties.
We have made some assumptions: ﬁrstly, to include dressings and
topical agents of various types in the sameNMA. This implies that
dressings and topical agents fulﬁl the same role and are exchange-
able (i.e. that the participants/wounds receiving topical agents are
similar to those receiving dressings). We did a post-hoc sensitivity
analysis, which included only trials comparing two dressings, to
investigate this assumption. It gave similar effect estimates and CIs
for individual contrasts.
Finally, application of the GRADE approach to this NMA has
given a rating of moderate-certainty evidence for only one contrast
in the whole NMA, and we recognise that by using a representa-
34Dressings and topical agents for treating pressure ulcers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fo
r P
re
vie
w 
On
ly
tive set of comparisons and by applying GRADE rules of thumb,
however carefully, we may have inadvertently emphasised the im-
portance of one intervention. This is a limitation of the approach.
Instead the evidence on protease-modulating dressings should be
set in the context of the uncertainty in the network as a whole.
Agreements and disagreements with other
studies or reviews
We have been unable to identify any network meta-analyses di-
rected at healing pressure ulcers and incorporating both dressings
and topical agents. The AHRQ guideline reviewed the evidence
for dressings in a series of pairwise comparisons and stated that
overall, they did not ﬁnd substantial evidence to support certain
local wound applications over others (AHRQ 2013). Themost re-
cent NICE guideline on the prevention and management of pres-
sure ulcers (NICE 2014) considered all RCT evidence on dressings
and separately all RCT evidence on topical agents. NICE recom-
mendations are to not use saline gauze dressings and for the health
professional and adult to discuss the type of dressing to use, taking
into account pain and tolerance, position of the ulcer, amount of
exudate and frequency of dressing change. These recommenda-
tions rely heavily on consensus decisions, weakly supported by the
evidence, and as such, agree with the ﬁndings of this review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is currently insufﬁcient evidence to judge whether any one
dressing or topical treatment increases the probability of pressure
ulcer healing compared with others (and neither is there sufﬁcient
evidence to judge whether there is a negative relative impact on
wound healing or no relative impact). None of the interventions
withmoderate- or low-quality evidence appear to result in a higher
proportion of wounds healed. It is important to note that many
trials in this review were small and at high risk of bias. Based on
current evidence, decision-makersmaywish tomakewound dress-
ing choices on the basis of wound symptoms, clinical experience,
patient preference and cost.
Implications for research
There is a lack of high-quality research evidence regarding whether
particular wound dressings or topical treatments have a beneﬁcial
impact on wound healing, even compared with basic dressings.
This lack of evidence is disturbing in view of the high personal
and health service burden of pressure ulcers (and indeed several
other types of wounds), and also in view of the many potential
participants who could be invited to take part in trials. The net-
work meta-analysis (NMA) exposes the generally poor quality of
randomised controlled trials of pressure ulcer dressings, suggesting
a need for radical improvements in the planning and conduct of
trials in this ﬁeld.
Given the high uncertainty across several competing interventions,
any investment in future research must maximise its value to de-
cision-makers. Any future evaluation of interventions for healing
pressure ulcers could focus on the dressings or topical agents that
health professionals use most widely, with consideration given to
protease-modulating dressings. Any future research should con-
sider time to healing: quicker healing may be as important to peo-
ple with pressure ulcers as whether healing occurs.
There may be value in asking decision-makers (including people
with pressure ulcers) what they feel are the most important issues,
for example, type of dressing, purpose of the dressing/topical agent
(including possible evaluation of broader groups of dressings e.g.
advanced or basic), or duration that a dressing remains in situ,
as well as which outcomes are most important. At a more funda-
mental level, decision-makers and funders should decide where re-
search resources are best invested, for example, pressure ulcer treat-
ment or prevention. Such planning means that research resources
can be focused to address priorities. Where trials are conducted,
good practice guidelines must be followed in their design, imple-
mentation and reporting, in particular outcome assessors should
be blinded. Studies should be adequately powered and have sufﬁ-
cient follow-up time to allow healing to occur.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aguilo Sanchez 2002
Methods RCT; unit of randomisation unclear (unclear if > 1 wound per person)
Funding: not stated. Setting: not stated
Duration of follow-up about 7 weeks
Unit of analysis: unclear
Participants ~24 participants with pressure ulcers. PU Stage: not stated (PU classiﬁcation: not stated)
Age: not stated. Duration of ulcer: not stated. Ulcer size: not stated
Wound characteristics at baseline: infection not reported; slough not reported; necrosis
not reported; exudate not reported
Comment: PU grade not stated
Interventions Group 1: hydrocolloid dressing - Comfeel Plus: hydrocolloid-alginate, combination of
2 groups randomised to treatment in the debridement and granulation phases; n = 12
(probably). Grouped intervention category: advanced dressing
Group 2: foam dressing - Biatain Adhesive (combination of 2 groups randomised to
treatment in the debridement and granulation phases); n = 12 (probably). Grouped
intervention category: advanced dressing
Outcomes Primary outcomes: proportion completely healed at about 7 weeks; time to complete
healing not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability unclear - no
information. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: unclear who the outcome asses-
sor was
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data: Group 1 - none. Group 2 -
none - i.e. no missing data
Selective reporting (reporting bias) Unclear risk Unclear reporting
Other bias
unit of analysis
Unclear risk Unit of randomisation unclear and unit of
analysis unclear - assumed the participant
58Dressings and topical agents for treating pressure ulcers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fo
r P
re
vie
w 
On
ly
Aguilo Sanchez 2002 (Continued)
was analysed (“cases”); no details on the ra-
tio of ulcers:participants
Other bias
additional
Unclear risk Insufﬁcient information to assess whether
an important risk of bias exists
ALL-DOMAIN RISK OF BIAS Unclear risk Rating: unclear
Reasons: unclear selection bias; unclear
blinding; unclear unit of analysis; unclear
subgroup
Comments: unclear risk of bias on unit of
analysis; time to event may have been re-
ported - unclear
Alm 1989
Methods RCT; ulcers randomised (> 1 wound per person, all followed)
Funding: not stated. Setting: hospital inpatients
Duration of follow-up 6 weeks (also reported at 12 for time to event weeks)
Unit of analysis: ulcer
Participants 50 participants with pressure ulcers. PU Stage: not stated and no indication apart from
mean depth (PU classiﬁcation: not stated)
Age: mean 83.6 (SD 9.2) and 83.4 (SD 9.4). Duration of ulcer: 4.6 (SD10.9) and 4.8
(SD 6.5). Ulcer size: median (range?) 2.02 (0.95, 3.10) and 2.44 (0.97, 3 .24)
Wound characteristics at baseline: no wounds infected; slough not reported; necrosis not
reported; exudate not reported
Comment: “considerable amount of debris”
Interventions Group 1: hydrocolloid dressing - Comfeel Ulcus (not in BNF): 1 week washout with
saline gauze; then hydrocolloid sheet and, if appropriate, hydrocolloid paste (7) and
powder (1 ulcer); dressings changed when necessary; n = total 50 (number per group not
reported). Grouped intervention category: advanced dressing
Group 2: gauze saline dressing - saline wet (1 week washout with saline gauze; then
saline gauze changed twice/day); n = total 50 (number per group not reported). Grouped
intervention category: basic dressing
Outcomes Primary outcomes: complete healing not reported; time to complete healing reported
(Kaplan Meier plot included)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
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Alm 1989 (Continued)
- no information on allocation conceal-
ment. Baseline comparability unclear -
baseline difference but of unclear impor-
tance. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded to interventions (clear description)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Missing data: not reported by group and
very unclear overall - possibly 9/50 (18%)
missing (1 died, 2 protocol violations, 2
results missing, 3 discontinued for surgery,
1 adverse event)
Selective reporting (reporting bias) High risk Inadequate - reported incompletely (e.g. P
value > 0.05)
Other bias
unit of analysis
Low risk Unit of randomisation ulcer and unit of
analysis ulcer - 6/50participants had2pres-
sure ulcers (2 participants had 1 ulcer as-
signed to each group); ulcer:person = 60/
56 overall = 1.12
Other bias
additional
Unclear risk Insufﬁcient information to assess whether
an important risk of bias exists
ALL-DOMAIN RISK OF BIAS High risk Rating: high
Reasons: unclear selection bias; unclear
missing data; unclear if PU grade sufﬁcient;
main outcome results estimated
Comments: very poorly reported study; PU
stage not stated; main outcomes estimated;
ulcers randomised and analysed, so no unit
of analysis errors; stated to be some base-
line differences in ulcer duration, but de-
gree and importance unclear
Ashby 2012
Methods RCT; participants randomised (> 1 wound per person, other selection of wound)
Funding: non-industry funding - MRC grant. NPWT units supplied by Kinetic Con-
cepts Inc, but they had no input to the trial. Setting: hospital and community
Duration of follow = up to 26 weeks (6 months)
Unit of analysis: person (1 ulcer/person)
Participants 12 participants with pressure ulcers. PU Stage: 3 (n = 7); 4 (n = 5) overall; data per group
not stated (PU classiﬁcation: NPUAP)
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Ashby 2012 (Continued)
Age: median (IQR) 67.5 (54.5 to 82.0) years. Duration of ulcer: median (IQR): overall
- 4.0 months (2.2 to 28.5). Ulcer size: median: 3.0 cm wide x 5.0 cm long x 4 cm deep
(overall)
Wound characteristics at baseline: no wounds infected; slough not reported; necrosis not
reported; exudate not reported
Comment: deepest wound selected if more than 1 per person (but not stated if this
occurred)
Interventions Group 1: standard care (all advanced dressings): hydrocolloid (ﬁbrous hydrocolloid)
dressing, a foam dressing or an alginate dressing (all non-silver); n = 6. Grouped inter-
vention category: advanced dressing
Group 2: ineligible intervention - negative pressure wound therapy (PU was ﬁlled with
either VACWhiteFoamW or Granufoam dressings and VAC applied); n = 6). Grouped
intervention category: ineligible - NPWT
Outcomes Primary outcomes: proportion completely healed at 26 (6 months) weeks; time to com-
plete healing not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Low risk Sequence generation adequate - computer-
generated. Allocation concealment ade-
quate - central randomisation with contact
details or list held independently. Baseline
comparability unclear - baseline difference
but unclear of importance. Rating: low
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded to interventions (clear description)
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing data: Group 1 - 1/6 (17%) with-
drew from treatment and received other
treatment; 0/6 died (PU slow to heal).
Group2 - 6/6 (100%)withdrew from treat-
ment and received other treatment. 2/6
(33%) died during the trial (1 recurrence of
black slough, 1 ulcer too small to continue
treatment, 1 foam embedded in granula-
tion tissue, 1 deterioration, 1participant re-
fusal, 1 difﬁculty with applying treatment)
i.e. differential missing data rates; high dif-
ferential rate - likely to change effect esti-
mate
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Ashby 2012 (Continued)
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (1 ulcer/person)
Other bias
additional
Low risk The study appears to be free of other
sources of bias
ALL-DOMAIN RISK OF BIAS High risk Rating: high
Reasons: differential missing data due to
death; also differential switching to other
treatments
Comments: attrition bias (death); small
trial, but more comorbidities in NPWT
group
Bale 1997a
Methods RCT; participants randomised (only 1 wound per person)
Funding: not stated. Setting: hospital inpatients
Duration of follow-up 4 (30 days) weeks
Unit of analysis: person (1 ulcer/person)
Participants 60 participants with pressure ulcers. PU Stage: II/III (acceptable); 71% and 79% Stage
II (PU classiﬁcation: Stirling)
Age: median 74 years and 73 years. Duration of ulcer: not stated. Ulcer size: < 5 cm²
(32% and 48%), 5 to < 10 (19% and 21%), 10 to < 20 (29% and 14%), > 20 (19%
and 17%)
Wound characteristics at baseline: no wounds infected; slough not reported; necrosis not
reported; exudate low-moderate levels
Comment: same number of ulcers as participants in table; exudate: none (32% and 28%)
, slight (58% and 31%), moderate (10% and 41%); 5-centre trial
Interventions Group 1: hydrocolloid dressing - Granuﬂex; n = 31. Grouped intervention category:
advanced dressing
Group 2: foam dressing - Allevyn Adhesive; n = 29. Grouped intervention category:
advanced dressing
Outcomes Primary outcomes: proportion completely healed at 4 (30 days) weeks; time to complete
healing not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Bale 1997a (Continued)
Selection bias High risk Sequence generation unclear - not stated.
Allocation concealment inadequate - evi-
dence that researchers knew the sequence.
Baseline comparability inadequate - base-
line characteristics different between arms.
Rating: high
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Other evidence for no blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing data: Group 1 - 22/31 (71%) with-
drew (8 discharged, 2 died, 2 adverse inci-
dent, 2 participant request, 2 dressing un-
suitable, 2 wound deteriorated, 1 lack of
progress, 2 dressing rolling). Group 2 - 18/
29 withdrew (62%) (5 discharged, 6 died,
3 adverse incident, 2 participant request, 1
dressing unsuitable, 1 wound deteriorated)
i.e. similar ratemissing in both groups; high
rate - more than control event rate
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (1 ulcer/person)
Other bias
additional
Low risk The study appears to be free of other
sources of bias
ALL-DOMAIN RISK OF BIAS High risk Rating: very high
Comments: allocation concealment inad-
equate - “allocated sequentially using an
open randomisation list”; ulcer size larger
for hydrocolloid group. Not blinded: per-
formance assessed at dressing change; attri-
tion bias
ALL-DOMAIN RISK OF BIAS 2 High risk
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Banks 1994a
Methods RCT; participants randomised (only 1 wound per person)
Funding: industry funded -CVLaboratories Ltd (foammanufacturer) andCalgonVestal
Laboratories (HC manufacturer). Setting: community
Duration of follow-up 6 weeks
Unit of analysis: person (1 ulcer/person)
Participants 40 participants with pressure ulcers. PU Stage: II and III (Stages I, IV, V excluded);
proportions not stated (PU classiﬁcation: not stated)
Age: median (range): 73 (46-93) years and 71 (40-100) years. Duration of ulcer: median
(range): 21 (5-252) days and 56 (3-365) days; P < 0.08. Ulcer size: median (range): 0.
74 (0.16-8.19) cm² and 0.67 (0.03-9.7) cm²; mean 1.51 (SD1.86) cm² and 1.47 (SD
2.26) cm²
Wound characteristics at baseline: no wounds infected; slough not reported; no wounds
necrotic; exudate unclear
Comment: exuding wounds but level not stated. Inclusion criteria: shallow/moist pres-
sure sore involving loss of skin tissue
Interventions Group 1: hydrocolloid dressing - Granuﬂex: concurrent standard pressure-relieving de-
vices and cushions in community as appropriate; n = 20. Grouped intervention category:
advanced dressing
Group 2: foam dressing - Spyrosorb (not in BNF) (necessary by the treating health
professional); n = 20). Grouped intervention category: advanced dressing
Outcomes Primary outcomes: proportion completely healed at 6 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation adequate - computer-
generated. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability unclear -
baseline difference but of unclear impor-
tance. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded (’open label’) and no evidence
that outcome assessor was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing data: Group 1 - 10/20 (50%) with-
drawn (2wound deteriorated, 2 overgranu-
lation, 2 discomfort, 4 unrelated to wound
(2 died, 2 had respite care)). Group 2 - 2/20
(10%) (2 for reasons unrelated to wound
(1 died, 1 admitted to hospital))
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Banks 1994a (Continued)
i.e. differential missing data rates; high dif-
ferential rate - likely to change effect esti-
mate
Selective reporting (reporting bias) High risk Inadequate - outcome included inmethods
section but not results
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (1 ulcer/person)
Other bias
additional
Unclear risk Insufﬁcient information to assess whether
an important risk of bias exists
ALL-DOMAIN RISK OF BIAS High risk Rating: very high
Reasons: unclear selection bias, not
blinded, attrition bias
Comments: some difference in duration of
ulcers; time-to-event data reported only as
not signiﬁcant; Grade II assumed to be ac-
ceptable (loss of skin tissue)
ALL-DOMAIN RISK OF BIAS 2 High risk
Banks 1994b
Methods RCT; participants randomised (> 1 wound per person, unclear how assessed)
Funding: unclear - authors at wound healing research unit. Setting: hospital and com-
munity
Duration of follow-up 12 weeks (also reported at 1, 2, 6 weeks)
Unit of analysis: person (unclear if > 1 ulcer analysed)
Participants 50 participants with pressure ulcers. PUStage: II (non-blanching erythema +/- superﬁcial
damage) and III (PU classiﬁcation: Torrance)
Age: 68% over 75 years. Duration of ulcer: ascertained but not reported. Not available
for 28%. Ulcer size: 16 and 19 ≤ 1 cm², 3 and 3 > 1 cm² and ≤ 2.5 cm²; 7 and 2 > 2.5
cm²
Wound characteristics at baseline: nowounds infected; not reported; nowounds necrotic;
exudate not reported
Comment: number ulcers/person not stated, but some had > 1 ulcer
Interventions Group 1: foam dressing - Lyofoam; n = 26. Grouped intervention category: advanced
dressing
Group 2: basic wound contact dressing - N-A Dressing; n = 24). Grouped intervention
category: basic dressing
Outcomes Primary outcomes: proportion completely healed at 12 weeks; time to complete healing
not reported
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Banks 1994b (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - “ran-
domised”. Allocation concealment ade-
quate - independent 3rd party allocates
and retains schedule. Baseline comparabil-
ity unclear - baseline difference but unclear
of importance. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear - vague
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data: Group 1 - 7/26 (27%) (2
died, 5 withdrew; 2 reasons NS, 2 im-
proved, 1 deteriorated). Group 2 - 9/24
(38%) (2 died, 7 withdrew, 2 reason NS, 1
improved, 4 deteriorated)
i.e. similar rate missing in both groups; low
rate - less than control event rate
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (unclear if > 1 ulcer anal-
ysed) - stated that protocol allowed > 1 per
wound person, but no evidence that this
happened
Other bias
additional
Unclear risk Insufﬁcient information to assess whether
an important risk of bias exists
ALL-DOMAIN RISK OF BIAS Unclear risk Rating: unclear
Comments: trial co-ordinatorwas outcome
assessor, unclear if blinded; imbalance at
baseline - not clear if problem. More large
ulcers for intervention 1
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Methods RCT; participants randomised (only 1 wound per person)
Funding: industry funded -CVLaboratories Ltd (foammanufacturer) andCalgonVestal
Laboratories (HC manufacturer). Setting: hospital inpatients
Duration of follow-up 6 weeks
Unit of analysis: person (1 ulcer/person)
Participants 29 participants with pressure ulcers. PU Stage: II and III (involving loss of skin) propor-
tions not stated (PU classiﬁcation: not stated)
Age: median (range): 74 (40-95) years and 73 (40-88) years. Duration of ulcer: median
(range): 5.5 (2-365) days and 7 (2-14) days. Ulcer size: median (range): 2.4 (0.1-25.8)
and 1.4 (0.5-14.3) cm²
Wound characteristics at baseline: no wounds infected; slough not reported; no wounds
necrotic; exudate moderate levels
Interventions Group 1: hydrocolloid dressing - Granuﬂex: Granuﬂex E; additional support therapy for
immobile participants; n = 16. Grouped intervention category: advanced dressing
Group 2: foam dressing - Spyrosorb (not in BNF) (additional support therapy for im-
mobile participants); n = 13). Grouped intervention category: advanced dressing
Outcomes Primary outcomes: proportion completely healed at 6 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability unclear -
baseline difference but unclear of impor-
tance. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded (’open label’) and no evidence
that outcome assessor was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data: Group 1 - 4/16 (25%) (3
wound deterioration, 1 wound/dressing-
related problems). Group 2 - 3/13 (23%)
(1wounddeterioration, 1wound/dressing-
related problems, 1 discharged from hospi-
tal)
i.e. similar rate missing in both groups; low
rate - less than control event rate
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Banks 1994c (Continued)
Selective reporting (reporting bias) High risk Inadequate - outcome included inmethods
section but not results
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (1 ulcer/person)
Other bias
additional
Unclear risk Insufﬁcient information to assess whether
an important risk of bias exists
ALL-DOMAIN RISK OF BIAS High risk Rating: high
Reasons: unclear selection bias, not
blinded, baseline differences
Comments: wound area showed no signif-
icant difference, but median 2.4 versus 1.
4; Grade II assumed to be acceptable (loss
of skin tissue)
Barrois 1992
Methods RCT (abstract); participants randomised (unclear if > 1 wound per person)
Funding: not stated. Setting: not stated
Duration of follow-up 8 weeks
Unit of analysis: person (unclear if > 1 ulcer analysed)
Participants 76 participants with pressure ulcers. PU Stage: not stated (PU classiﬁcation: not stated)
Age: not stated. Duration of ulcer: not stated. Ulcer size: mean 15 cm² overall
Wound characteristics at baseline: infectionnot reported; slough not reported; all wounds
necrotic; exudate not reported
Comment: implies 1 ulcer per person; “multicentre good practice trial”
Interventions Group 1: hydrocolloid dressing - Granuﬂex; n = 38. Grouped intervention category:
advanced dressing
Group 2: iodine containing dressing - povidone iodine soaked gauze (tulle impregnated
with PI); n = 38. Grouped intervention category: antimicrobial dressing
Outcomes Primary outcomes: proportion completely healed at 8 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability unclear - no
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Barrois 1992 (Continued)
information. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who outcome assessor was
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data: Group 1 - 2/38 (5%) (2
dropped out due to deterioration). Group
2 - 5/38 (13%) (5 dropped out due to de-
terioration in the wound)
i.e. similar rate missing in both groups; low
rate - less than control event rate
Selective reporting (reporting bias) Unclear risk Unclear reporting
Other bias
unit of analysis
Unclear risk Unit of randomisation person and unit of
analysis person (unclear if > 1 ulcer anal-
ysed) - probably 1 ulcer per person
Other bias
additional
Unclear risk PU classiﬁcation unclear
ALL-DOMAIN RISK OF BIAS Unclear risk Rating: unclear
Comments: unclear selection bias, unclear
whether ulcer or person is unit of analysis.
Grade of PU not stated (but open necrotic
pressure sores/ulceration)
Belmin 2002
Methods RCT; participants randomised (> 1 wound per person, other selection of wound)
Funding: industry funded - Urgo (manufacturers of intervention 2). Setting: hospital
inpatients
Duration of follow-up 8 weeks
Unit of analysis: person (selected ulcer)
Participants 110 participants with pressure ulcers. PU Stage: III and IV; stage III proportions = group
1: 82.7% and group 2: 71.4% (PU classiﬁcation: Yarkony)
Age: 82.2 (SD 7.9) years and 84.8 (SD 7.1) years . Duration of ulcer: 7.7 weeks and 7.
2 weeks. Ulcer size: mean 12.6 (SD 8.0) cm² and 14.7 (SD 10.4) cm² (NS)
Wound characteristics at baseline: no wounds infected; slough not reported; necrosis not
reported; exudate not reported
Interventions Group 1: hydrocolloid dressing - DuoDERM Extra Thin: note different HC; hydrocol-
loid paste for deep ulcers. Prior treatment withmainlyHC; n = 53. Grouped intervention
category: advanced dressing
Group 2: sequential dressing - hydrocolloid-alginate (Urgosorb (4 weeks) then Algo-
plaque (4 weeks); hydrocolloid paste for deep ulcers in ﬁrst 4 weeks only. Prior treatment
mainly HC); n = 57. Grouped intervention category: advanced dressing
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Belmin 2002 (Continued)
Outcomes Primary outcomes: proportion completely healed at 8 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- other. Baseline comparability unclear -
baseline difference but unclear of impor-
tance. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who outcome assessor was
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing data: Group 1 - all analysed,
though 16/53 (30%) did not complete
treatment (8 died and 8 withdrew (2 trans-
fer to another unit, 3 local infection, 3
PU impairment)). Group 2 - all analysed,
though 17/57 (30%) did not complete
treatment (11 died and 6 withdrew (1
transfer to another unit, 1worsening health
status, 1 local infection, 3 PU impairment)
)
i.e. all analysed but non-completers - simi-
lar rate in each group; high rate - more than
control event rate
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (selected ulcer) - one ulcer
selected
Other bias
additional
Unclear risk Insufﬁcient information to assess whether
an important risk of bias exists
ALL-DOMAIN RISK OF BIAS High risk Rating: high
Comments: unclear selection bias (block
randomised), different hydrocolloids and
pastes used; unclear who assessed healing
- nurses not blinded, assessor of wound
area was blinded; baseline differences: dia-
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Belmin 2002 (Continued)
betes, hypertension signiﬁcantly higher for
sequential; proportion of grade IV ulcers
higher in sequential
Brod 1990
Methods RCT (letter to journal); participants randomised (unclear if > 1 wound per person)
Funding: industry funded - Acme/Chaston division,National PatentDevelopmentCorp
(manufacturer poly HEMA). Setting: care home
Duration of follow-up 8 weeks
Unit of analysis: person (unclear if > 1 ulcer analysed)
Participants 43 participants with pressure ulcers. PU Stage: II and III (description available); stratiﬁed
then randomised; proportions not stated (PU classiﬁcation: not stated)
Age: median 86 years and 82 years. Duration of ulcer: not stated, but comparable. Ulcer
size: median 2.5 cm² and 1.9 cm² (P = 0.09)
Wound characteristics at baseline: infection not reported; slough not reported; some
wounds necrotic; exudate not reported
Comment: if necrosis, wounds were debrided ﬁrst
Interventions Group 1: hydrogel dressing - poly HEMA: Hydron dressing; n = 27. Grouped interven-
tion category: advanced dressing
Group 2: hydrocolloid dressing - DuoDERM; n = 16. Grouped intervention category:
advanced dressing
Outcomes Primary outcomes: proportion completely healed at 8 weeks; time to complete healing
reported (Kaplan Meier plot included)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability adequate - no
suggestion of problems. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded to interventions - clear de-
scription
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data: Group 1 - 2/27 (7%) (both
died). Group 2 - 3/16 (19%) (1 died, 2 did
not complete treatment (1 poor response,
1 adverse event))
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Brod 1990 (Continued)
i.e. differential missing data rates; low dif-
ferential rate - unlikely to change effect es-
timate
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (unclear if > 1 ulcer anal-
ysed) - one ulcer implied (e.g. “52% of
group 1 had complete healing of the study
ulcer”)
Other bias
additional
Low risk Adequate - no suggestion of problems
ALL-DOMAIN RISK OF BIAS High risk Rating: high
Reasons: unclear selection bias, not blinded
Comments: unblinded research nurse who
had no clinical responsibilities
Brown-Etris 1996
Methods RCT; ulcers randomised (> 1 wound per person, other selection of wound)
Funding: not stated. Setting: care home and hospital and community
Duration of follow-up 10 weeks
Unit of analysis: person (1 ulcer/person)
Participants
Interventions Group 1: hydrogel dressing - Transorbent dressing; n = 77. Grouped intervention cate-
gory: advanced dressing
Group 2: hydrocolloid dressing - DuoDERM CGF (not BNF); n = 63. Grouped inter-
vention category: advanced dressing
Outcomes Primary outcomes: proportion completely healed at 10 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias High risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability inadequate
- baseline characteristics different between
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Brown-Etris 1996 (Continued)
arms. Rating: high
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded (’open label’) and no evidence
that outcome assessor was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data: Group 1 - 19/77 (25%) (11
unable to follow, 5 died, 3 other; overall 19
participants did not complete ﬁrst 3 weeks
of trial ormissed 2 sequential visits ).Group
2 - 12/63 (19%) (4 unable to follow, 5
died, 3 other; overall 19 participants did
not complete ﬁrst 3 weeks of trial or missed
2 sequential visits)
i.e. similar rate missing in both groups; low
rate - less than control event rate
Selective reporting (reporting bias) Unclear risk Unclear reporting
Other bias
unit of analysis
High risk Unit of randomisation ulcer and unit of
analysis person (1 ulcer/person) - ulcers
randomised (stratiﬁed), but one II, III or
IV ulcer was selected (implied at the begin-
ning), at the discretion of the (unblinded)
investigator at each centre
Other bias
additional
Unclear risk Some discrepancy between text and table
in the number of participants
ALL-DOMAIN RISK OF BIAS High risk Rating: very high
Reasons: selection bias (baseline differ-
ences), not blinded, ulcer selected by inves-
tigator
Comments: allocation concealment - each
centre randomised independently. Says
wounds randomised and stratiﬁed by sur-
face area and stage, but later says one ulcer
was selected (implied at the beginning), at
the discretion of the investigator. Baseline
differences in the proportion with Grade
III/IV ulcers (more in foam group) and
duration of ulcer shorter in hydrocolloid
group. Some discrepancy between text and
table in the number of participants
ALL-DOMAIN RISK OF BIAS 2 High risk
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Brown-Etris 1997
Methods RCT (abstract); participants randomised (unclear if > 1 wound per person)
Funding: non-industry funding - authors worked for health care agency. Setting: unclear
Duration of follow-up 8 weeks
Unit of analysis: person (unclear if > 1 ulcer analysed)
Participants 36 participants with pressure ulcers. PU Stage: II, III and IV (proportions not stated)
(PU classiﬁcation: not stated)
Age: not stated. Duration of ulcer: not stated. Ulcer size: not stated
Wound characteristics at baseline: infection not reported; slough not reported; necrosis
not reported; exudate not reported
Comment: few details (abstract)
Interventions Group 1: protease-modulating dressing - Fibracol (90% collagen, 10% alginate (from
suppliers’ website)); n = 24. Grouped intervention category: protease-modulating dress-
ing
Group 2: alginate dressing - Kaltostat; n = 12. Grouped intervention category: advanced
dressing
Outcomes Primary outcomes: proportion completely healed at 8 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability unclear - no
information. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded (’open label’) and no evidence
that outcome assessor was blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Missing data: Group 1 - 116 total enrolled,
80 evaluable and interim analysis on 36
(not stated). Group 2 - 116 total enrolled,
80 evaluable and interim analysis on 36
(not stated)
i.e. missing data, but unclear
Selective reporting (reporting bias) High risk Inadequate - outcome included inmethods
section but not results
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (unclear if > 1 ulcer anal-
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Brown-Etris 1997 (Continued)
ysed) - one ulcer implied (e.g. “participants
stratiﬁed before randomisation according
to pressure ulcer location and size”)
ALL-DOMAIN RISK OF BIAS High risk Rating: high
Reasons: unclear selection bias, not blinded
Comments: interim analysis - but planned,
so acceptable
Brown-Etris 2008
Methods RCT; participants randomised (> 1 wound per person, other selection of wound)
Funding: industry funded - 3M grant (manufacturers of Tegaderm). Setting: care home
and community
Duration of follow-up 8 weeks
Unit of analysis: person (1 ulcer/person)
Participants 72 participants with pressure ulcers. PU Stage: II (59.5% and 65%; P = 0.59), and
shallow III (PU classiﬁcation: not stated)
Age: mean 72.7 (SD 18.61) years and 78.3 (SD 14.70) years. Duration of ulcer: median
(range): 32.0 days (2-635) and 21.0 days (1-291); P = 0.169. Ulcer size: mean (SD): 2.
5 (4.86) and 1.5 (1.69) cm²
Wound characteristics at baseline: no wounds infected; slough not reported; some
wounds necrotic; exudate low-moderate levels
Comment: < 25% necrotic
Interventions Group 1: hydrocolloid dressing - DuoDERM CGF; n = 37. Grouped intervention
category: advanced dressing
Group 2: vapour-permeable dressing - Tegaderm Absorbent Clear; n = 35). Grouped
intervention category: advanced dressing
Outcomes Primary outcomes: proportion completely healed at 8 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability adequate - no
suggestion of problems. Rating: unclear
Blinding of outcome assessment (detection
bias)
High risk Not blinded (’open label’) and no evidence
that outcome assessor was blinded
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Brown-Etris 2008 (Continued)
All outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data: Group 1 - none. Group 2 -
none
i.e. no missing data (no details)
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (1 ulcer/person) - if > 1, au-
thors selected highest grade PU then largest
ulcer
Other bias
additional
Low risk Adequate - no suggestion of problems
ALL-DOMAIN RISK OF BIAS High risk Rating: high
Reasons: unclear selection bias, not blinded
Burgos 2000b
Methods RCT; participants randomised (only 1 wound per person)
Funding: industry funded - supported by Laboratorios Knoll (manufacturer of collage-
nase ointment). Setting: hospital inpatients
Duration of follow-up 12 weeks
Unit of analysis: person (1 ulcer/person)
Participants 37 participants with pressure ulcers. PU Stage: III only (PU classiﬁcation: not stated)
Age: mean 78.6 (SD 10.4) years and 81.9 (SD 12.7) years. Duration of ulcer: 2.6 (SD 1.
9) months and 3.2 (SD 2.0) months P = 0.44; 89% and 83% previously treated. Ulcer
size: approx 22 and 20.5 cm² (estimated from graph)
Wound characteristics at baseline: no wounds infected; slough not reported; necrosis not
reported; exudate not reported
Comment: same number of ulcers as participants in table
Interventions Group 1: hydrocolloid dressing - Varihesive (not in BNF): ulcers cleaned with saline;
Varihesive paste used for deep ulcers/high exudate for HC group only; n = 19. Grouped
intervention category: advanced dressing
Group 2: collagenase-containing ointment - Iruxol (not BNF) (ulcers cleanedwith saline)
; n = 18. Grouped intervention category: collagenase ointment
Outcomes Primary outcomes: proportion completely healed at 12 weeks; time to complete healing
not reported
Notes
Risk of bias
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Burgos 2000b (Continued)
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation adequate - computer-
generated. Allocation concealment unclear
- other. Baseline comparability adequate -
no suggestion of problems. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Other evidence for no blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing data: 6 participants excluded over-
all (4 protocol violations) - not given
by group. Additionally, discontinuations:
Group 1: 6 (32%) (because of death due
to unrelated cause, deterioration in general
condition, discharge from hospital, proto-
col violations, lack of efﬁcacy). Group 2: 8
(44%) (because of deaths due to unrelated
cause, discharge from hospital, transfer to
another centre), i.e. similar rate missing in
both groups; high rate - more than control
event rate
“Eight (44.4%) and six (31.6%) patients
in the collagenase and hydrocolloid groups,
respectively, discontinued the study prema-
turely. Reasons for discontinuation in the
collagenase group were: death due to unre-
lated cause (n = 3), discharge from the hos-
pital (n = 3) and transfer to another cen-
tre (n = 3). Reasons for discontinuation in
the hydrocolloid group included death due
to unrelated cause (n = 1), deterioration of
the patient’s general condition (n = 1), dis-
charge from the hospital (n = 1), protocol
violation (n = 2) and lack of efﬁcacy (n =
1)”, i.e. discrepancy between total number
missing and sum of reasons for group 2 -
but 44% corresponds to 8 participants
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
Low risk Unit of randomisation person and unit
of analysis person (1 ulcer/person) - same
number of ulcers as participants in table
Other bias
additional
Unclear risk Paste used for hydrocolloid group only
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Burgos 2000b (Continued)
ALL-DOMAIN RISK OF BIAS High risk Rating: very high
Comments: randomisation conducted by
department of biometry of sponsor; said to
be not blinded; paste used for hydrocolloid
group only; difference between interven-
tions for people leaving study prematurely
ALL-DOMAIN RISK OF BIAS 2 High risk
Colwell 1993
Methods RCT; ulcers randomised (> 1 wound per person, all followed)
Funding: industry funded - Convatec (manufacturer of hydrocolloid). Setting: hospital
inpatients
Duration of follow-up 12 weeks
Unit of analysis: ulcer
Participants 70 participants with pressure ulcers. PU stage: II (69% and 44%) and III (PU classiﬁca-
tion: NS).
Age: mean (range): 68 (18-100) years and 68 (29-92) years. Duration of ulcer: 55% and
59% < 1 month; 45% and 41% 1-3 months. Ulcer size: surface area: 2.29 cm² and 2.
37 cm²
Wound characteristics at baseline: no wounds infected; slough not reported; necrosis not
reported; exudate not reported
Comment: tertiary care centre; “each patient’s ulcers were randomised to 1 of 2 treat-
ments” and discussion states ulcers randomised. 94 participants enrolled, but analysis on
70 participants with 97 ulcers
Interventions Group 1: hydrocolloid dressing - DuoDERM CGF (not BNF); n = 33. Grouped inter-
vention category: advanced dressing
Group 2: gauze saline dressing - saline moist; n = 37. Grouped intervention category:
basic dressing
Outcomes Primary outcomes: proportion completely healed at 12 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias High risk Sequence generation unclear - not stated.
Allocation concealment unclear - no infor-
mation on allocation concealment. Base-
line comparability inadequate - baseline
characteristics different between arms. Rat-
ing: high
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Colwell 1993 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who outcome assessor was
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data: Group 1 - Overall 24/94
(26%) (12 died from causes unrelated to
PU, 5 discharged from hospital, 5 lost
to follow-up, 1 colonised with MRSA,
1 participant’s ulcer progressed to Stage
4. Equivalent number dropped from each
group). Group 2 -Overall 24/94 (26%) (12
died from causes unrelated to PU, 5 dis-
charged from hospital, 5 lost to follow-up,
1 colonised with MRSA, 1 participant’s ul-
cer progressed to Stage 4. Equivalent num-
ber dropped from each group)
i.e. overall rate only; low rate - less than
control event rate
Selective reporting (reporting bias) Unclear risk Unclear reporting
Other bias
unit of analysis
Low risk Unit of randomisation ulcer and unit of
analysis ulcer - approx 1.5 ulcer:person ra-
tio = 48/33 and 49/37
Other bias
additional
Unclear risk Insufﬁcient information to assess whether
an important risk of bias exists
ALL-DOMAIN RISK OF BIAS High risk Rating: high
Reasons: selection bias (baseline imbal-
ance), available case only, baseline imbal-
ance
Comments: results and number of ulcers
not reported for those that dropped out of
the study, so available case analysis only.
Signiﬁcantly more grade III ulcers for the
saline gauze dressing vs hydrocolloid (56%
vs 31%). Ulcers randomised and analysed
so no unit of analysis issues
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Darkovich 1990
Methods RCT; unit of randomisation unclear (> 1 wound per person, all followed)
Funding: not stated. Setting: hospital and care home
Duration of follow-up 8.5 (60 days) weeks
Unit of analysis: ulcer
Participants 90 participants with pressure ulcers. PU Stage: I and II (54% and 56%) (results separate)
; stage I is ulceration or skin breakdown limited to superﬁcial epidermal and dermal layer
- probably corresponds to grade II? (PU classiﬁcation: Enis and Sarmiento).
Age: overall mean: 75 years (range 30-98); mean in acute care 69 years, in care homes
83 years. Duration of ulcer: not stated. Ulcer size: hydrogel: mean 11.0 (range 0.2-100)
cm²; hydrocolloid: mean 9.2 (0.4-63.75) cm²
Wound characteristics at baseline: no wounds infected; slough not reported; necrosis not
reported; exudate not reported
Comment: it says wounds randomised, but also says people with multiple wounds had
same treatments; 67/49 (1.4) and 62/41 (1.5) wounds per person
Interventions Group 1: hydrocolloid dressing - DuoDERM; n = 49 overall. Grouped intervention
category: advanced dressing
Group 2: hydrogel dressing - Bioﬁlm (not in BNF); n = 41 overall. Grouped intervention
category: advanced dressing
Outcomes Primary outcomes: proportion completely healed at 8.5 (60days)weeks; time to complete
healing not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability unclear -
baseline difference but unclear of impor-
tance. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear - no information
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data: Group 1 - 4/67 (6%)
excluded from the authors’ analysis (3
wounds’ size increased by more than 10%
per day and 1 decreased by more than 25%
per day). Group 2 - 2/62 (3%) excluded
from the authors’ analysis (1 wound’s size
increased by more than 10% per day and 1
decreased by more than 25% per day).
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Darkovich 1990 (Continued)
i.e. similar rate missing in both groups; low
rate - less than control event rate
Selective reporting (reporting bias) High risk Inadequate - reported incompletely
Other bias
unit of analysis
High risk Unit of randomisation unclear and unit of
analysis ulcer - Overall ulcer:person ratio =
67/49 and 62/41 (1.52)
Other bias
additional
Unclear risk Extraction from a graph
ALL-DOMAIN RISK OF BIAS High risk Rating: high/very high
Reasons: unclear selection bias, unit of
analysis issues; extraction from a graph
Comments: baseline difference: 11.0 ver-
sus 9.2 cm² mean wound area; number of
ulcers reported for grade II only on graph.
May be best to report overall (see deﬁni-
tion of stage I). Unit of analysis issues; 6/
90 participants excluded as outliers
Gorse 1987
Methods RCT; wards randomised (> 1 wound per person, all followed)
Funding: not stated. Setting: hospital inpatients
Duration of follow-up approx 11 (assumed from mean + SD) weeks
Unit of analysis: ulcer
Participants 52 participants with pressure ulcers. PUStage: II (87%and 79%) and III (with acceptable
deﬁnition) (PU classiﬁcation: not stated)
Age: mean (SD): 72.0 (12.8) years and 68.4 (13.5) years; proportion ≥ 65 years: 75%
and 56%. Duration of ulcer: not stated. Ulcer size: not stated
Wound characteristics at baseline: some wounds infected; slough not reported; some
wounds necrotic; exudate not reported
Comment: infection at baseline: 9% and 23%; proportion with necrotic wounds not
stated
Interventions Group 1: hydrocolloid dressing - DuoDERM; n = 27. Grouped intervention category:
advanced dressing
Group2: ineligible intervention -whirlpool + chloramine dressing (gauze dampenedwith
Dakin’s solution + whirlpool hydrotherapy 3 times/week); n = 25. Grouped intervention
category: ineligible - whirlpool
Outcomes Primary outcomes: proportion completely healed at approx 11 (assumed from mean +
SD) weeks; time to complete healing not reported
Notes
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Gorse 1987 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias High risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability inadequate
- baseline characteristics different between
arms. Rating: high
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who outcome assessor was
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data: Group 1 - none. Group 2 -
none
i.e. no missing data (clearly stated)
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
High risk Unit of randomisation ward and unit of
analysis ulcer - each ward assigned one or
other treatment regimen
ALL-DOMAIN RISK OF BIAS High risk Rating: very high
Reasons: selection bias (large baseline dif-
ferences); unit of analysis issues - ward ran-
domised, ulcer analysed; unclear blinding
Comments: baseline differences for: pro-
portion of ulcers in over 65 age group
(greater for hydrocolloid), proportion of
grade II ulcers (87% and 79%), proportion
infected ulcers (9% and 23%)
ALL-DOMAIN RISK OF BIAS 2 High risk
Graumlich 2003
Methods RCT; participants randomised (only 1 wound per person)
Funding: mixed industry and non-industry - Biocore Medical Technologies supplied the
collagen + grant from Retirement Research Foundation. Setting: care home
Duration of follow-up 8 weeks (also reported at 1 and 4 weeks)
Unit of analysis: person (1 ulcer/person)
Participants 65 participants with pressure ulcers. PUStage: 2 (77%and 83%) and 3 (PU classiﬁcation:
NPUAP)
Age: 80.6 (SD 12.2) years and 82.0 (SD 9.9) years. Duration of ulcer: median (IQR):
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Graumlich 2003 (Continued)
6.5 (2.0, 12.0) weeks and 3.0 (1.6, 8.0) weeks (not statistically signiﬁcant). Ulcer size:
median (IQR) 1.74 (0.5, 4.36) and 1.21 (0.63, 3.38); not statistically signiﬁcant
Wound characteristics at baseline: infectionnot reported; nowounds sloughy; nowounds
necrotic; exudate not reported
Comment: wounds with eschar (not slough) or necrosis excluded (but re-included after
debridement)
Interventions Group 1: hydrocolloid dressing - DuoDERM: twice-weekly. Standard nursing care. No
ancillary non-protocol treatments; n = 30. Grouped intervention category: advanced
dressing
Group2: protease-modulatingdressing (cleansedwith saline then sprinkledwith collagen
particles in thin continuous layer; covered with dry gauze. Standard nursing care. No
ancillary non-protocol treatments); n = 35. Grouped intervention category: protease-
modulating dressing
Outcomes Primary outcomes: proportion completely healed at 8 weeks; time to complete healing
reported (Kaplan Meier plot included)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Low risk Sequence generation adequate - computer-
generated. Allocation concealment ade-
quate - central randomisation with contact
details or list held independently. Baseline
comparability adequate - no suggestion of
problems. Rating: low
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded to interventions (clear description)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data: Group 1 - 5/30 (17%) (1
withdrew consent, 3 died, 2 hospitalised)
. Group 2 - 6/35 (17%) (2 died, 1 hospi-
talised, 2loss to follow-up).
i.e. similar rate missing in both groups; low
rate - less than control event rate
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (1 ulcer/person)
Other bias
additional
Low risk Adequate - well-conducted study
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Graumlich 2003 (Continued)
ALL-DOMAIN RISK OF BIAS Low risk Rating: low
Comments: some differences at baseline
(size and duration) but not statistically sig-
niﬁcant
Hollisaz 2004
Methods RCT; participants randomised (> 1 wound per person, all followed)
Funding: non-industry funding - Jaonbazan Medical and Engineering Research Center
(Iranian government body for spinal chord injury war victims). Setting: care home and
community with spinal injury
Duration of follow-up 8 weeks
Unit of analysis: ulcer
Participants 52 participants with pressure ulcers. PU Stage: I (33%; 36%) and II (58%, 64%) (strat-
iﬁed and results separate). Shea I deﬁned as “Limited to epidermis, exposing dermis;
includes a red area” (PU classiﬁcation: Shea).
Age: for all participants (mixed wounds): mean 36.6 (SD 6.0) years - no difference
between groups. Duration of ulcer: for all participants (mixed wounds): 7.6 (SD 5.6)
weeks, 5.8 (SD 8.0) weeks, 5.3 (SD 5.4) weeks; P > 0.10. Ulcer size: for all participants
(mixed wounds): mean 7.26 cm² (SD 15.4), 5.12 cm² (SD 3.63), 10.27 cm² (SD 15.
32); P > 0.10.
Wound characteristics at baseline: infection not reported; slough not reported; no
wounds necrotic; exudate not reported
Comment: spinal chord injury; all male and young war victims; wounds debrided ﬁrst
if necessary
Interventions Group 1: hydrogel dressing - hydrocolloid adhesive dressing (description “hydrocolloid
adhesive dressings absorb water and low molecular weight components from ulcer se-
cretions, so they swell to produce a jelly”). No concomitant antibiotic, steroid or an-
tisuppressant treatments allowed. No debridement needed during treatment. All other
concomitant treatments the same; n = 16. Grouped intervention category: advanced
dressing
Group 2: phenytoin topical - phenytoin topical (no concomitant antibiotic, steroid or
antisuppressant treatments allowed. No debridement needed during treatment. All other
concomitant treatments the same); n = 19. Grouped intervention category: phenytoin
topical
Group 3: saline wet - no concomitant antibiotic, steroid or antisuppressant treatments
allowed. No debridement needed during treatment. All other concomitant treatments
the same (no concomitant antibiotic, steroid or antisuppressant treatments allowed. No
debridement needed during treatment. All other concomitant treatments the same; n =
17. Grouped intervention category: basic dressing
Outcomes Primary outcomes: proportion completely healed at 8 weeks; time to complete healing
not reported
Notes
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Hollisaz 2004 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Low risk Sequence generation adequate - random
number tables. Allocation concealment ad-
equate - central randomisation with con-
tact details or list held independently. Base-
line comparability adequate - no suggestion
of problems. Rating: low
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded to interventions (clear description)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data: Group 1 - none. Group 2 -
none. Group 3 - none
i.e. no missing data (clearly stated)
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
Unclear risk Unit of randomisation person and unit of
analysis ulcer - probably participants ran-
domised; if > 1 ulcer then same treatment
within participant; < 1.2 ulcer:person = 18/
16, 21/19 and 19/17
Other bias
additional
Low risk Adequate - no suggestion of problems
ALL-DOMAIN RISK OF BIAS Unclear risk Rating: unclear/low
Reasons: unit of analysis issues (small)
Comments: slight unit of analysis issues
(but number of ulcers very close to number
of participants)
Hondé 1994
Methods RCT; participants randomised (> 1 wound per person, other selection of wound)
Funding: industry funded - funded by Synthelabo Recherche (manufacturers of Inerpan)
. Setting: hospital inpatients
Duration of follow-up 8 weeks
Unit of analysis: person (1 ulcer/person)
Participants 168 participants with pressure ulcers. PU Stage: 1 grade I (excluded from analysis), 187
II to IV (II: 54% and 64%; III: 40% and 30%; IV: 5.7% and 6.2%) (PU classiﬁcation:
Shea)
Age: mean 83.5 (SD 7.8; range 64-101) years and mean 80.4 (SD 8.2, range 63-98)
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Hondé 1994 (Continued)
years. Duration of ulcer: not stated. Ulcer size: mean surface area: 6.85 cm² and 8.99
cm²
Wound characteristics at baseline: infection not reported; slough not reported; unclear
necrotic; exudate unclear
Comment: study says, “in cases of multiple ulcers, only one sore per patient was evalu-
ated”
Interventions Group 1: hydrocolloid dressing - Comfeel (unspeciﬁed); n = 88. Grouped intervention
category: advanced dressing
Group 2: ineligible intervention - skin substitute (amino acid copolymer (leucine and
methyl glutamate) - Interpam); n = 80. Grouped intervention category: ineligible inter-
vention - skin substitute
Outcomes Primary outcomes: proportion completely healed at 8 weeks; time to complete healing
not reported (Kaplan Meier plot included)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation adequate - computer-
generated. Allocation concealment unclear
- vague statement about central randomisa-
tion. Baseline comparability unclear - base-
line difference but unclear of importance.
Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded (’open label’) and no evidence
that outcome assessor was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing data: Group 1 - 24/88 (27%) (6
withdrew because of local complications
(mainly necrosis), 18 withdrew for rea-
sons unconnected with treatment (mainly
death, transfer to another ward, discharge
from hospital)). Group 2 - 14/80 (17.5%)
(4 withdrew because of local complications
(mainly necrosis), 10 withdrew for rea-
sons unconnected with treatment (mainly
death, transfer to another ward, discharge
from hospital))
i.e. differential missing data rates; high dif-
ferential rate - likely to change effect esti-
mate
Selective reporting (reporting bias) High risk Inadequate - analysis methods differed
from those of other trials
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Hondé 1994 (Continued)
Other bias
unit of analysis
Unclear risk Unit of randomisation person and unit of
analysis person (1 ulcer/person) - study
says, “in cases of multiple ulcers, only one
sore per patient was evaluated”. Not stated
how many this applied to
ALL-DOMAIN RISK OF BIAS High risk Rating: very high
Reasons: not blinded, attrition bias, un-
clear selection bias
Comments: allocation concealment: ac-
cording to a randomisation list prepared by
Biometry group (does not say what hap-
pened to list). Open label trial, “investiga-
tors asked to give an assessment of treat-
ment performance (healed)”. Time to event
analysis using Wilcoxon. Age and grade of
PU differences at baseline
ALL-DOMAIN RISK OF BIAS 2 High risk
Imamura 1989
Methods RCT (translation); participants randomised (only 1 wound per person)
Funding: unclear. Setting: hospital inpatients
Duration of follow-up 8 weeks (also reported at 1, 2, 4, 6 weeks)
Unit of analysis: person (1 ulcer/person)
Participants 141 participants with pressure ulcers. PU Stage: I (23% and 21%), II and III (44% and
38%) and IV (34% and 41%) (PU classiﬁcation: not stated)
Age: not stated/translated. Duration of ulcer: not stated/translated. Ulcer size: not stated
Wound characteristics at baseline: unclear infection; slough not reported; necrosis not
reported; exudate not reported
Comment: number with change in infection status reported, but unclear what sort of
change
Interventions Group 1: topical - sugar plus povidone iodine: sugar 70 g/100 g and povidone iodine
3 g/100 g; ointment applied directly on the wound or applied on a sheet of gauze and
then applied on the wound once or twice a day; n = 72. Grouped intervention category:
sugar plus povidone iodine
Group 2: other topical - lysozyme ointment (5 g/100 g ointment applied directly on
the wound or on a sheet of gauze and then on the wound once or twice a day); n = 69.
Grouped intervention category: lysosyme ointment
Outcomes Primary outcomes: complete healing not reported; time to complete healing not reported
Notes
Risk of bias
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Imamura 1989 (Continued)
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation adequate - random
number tables. Allocation concealment ad-
equate - central randomisation with con-
tact details or list held independently. Base-
line comparability unclear - baseline dif-
ference but unclear of importance. Rating:
unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Other evidence for no blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing data: Group 1 - 27/72 (38%)
(withdrew (1 because of adverse effects)).
Group 2 - 29/69 (42%) (withdrew (1 be-
cause of adverse effects)).
i.e. similar ratemissing in both groups; high
rate - more than control event rate
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (1 ulcer/person)
Other bias
additional
Unclear risk Insufﬁcient information to assess whether
an important risk of bias exists
ALL-DOMAIN RISK OF BIAS High risk Rating: very high
Comments: unclear selection bias: baseline
differences for proportion of Stage 4 ulcers
(34% vs 41%); translated as ’not blinded’;
attrition bias
ALL-DOMAIN RISK OF BIAS 2 High risk
Kaya 2005
Methods RCT; participants randomised (> 1 wound per person, all followed)
Funding: non-industry funding - declaration of interest: none. Setting: hospital with
spinal chord injury
Duration of follow-up unclear weeks
Unit of analysis: ulcer
Participants 27 participants with pressure ulcers. PU Stage: 1 (24% and 25% of ulcers), 2 (68% and
71%) and 3 (results separate, but best to combine) (PU classiﬁcation: NPUAP)
Age: mean (SD): 35.3 (14.6), range 16-56 years and 29.7 (6.4), range 17-39 years.
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Kaya 2005 (Continued)
Duration of ulcer: not stated. Ulcer size: mean (SD): 4.13 (2.73; range: 2-13) cm²;
reporting of control group unclear: range 2-35 cm²
Wound characteristics at baseline: no wounds infected; slough not reported; necrosis not
reported; exudate not reported
Comment: spinal chord injury (78% complete, 22% incomplete SCI); 15 participants/
25 ulcers and 12 participants/24 ulcers
Interventions Group 1: hydrogel dressing - Elastogel (not in BNF); n = 15. Grouped intervention
category: advanced dressing
Group 2: iodine containing dressing - povidone iodine soaked gauze; n = 12. Grouped
intervention category: antimicrobial dressing
Outcomes Primary outcomes: complete healing not reported; time to complete healing not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability adequate - no
suggestion of problems. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear - no information
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data: Group 1 - 0. Group 2 - 0; i.
e. no missing data (no details)
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
High risk Unit of randomisation person and unit of
analysis ulcer - for combination of stages I
and II and III, ulcer:person ratio = 25/15
(1.7) and 24/12 (2.0)
Other bias
additional
Unclear risk Adequate - no suggestion of problems
ALL-DOMAIN RISK OF BIAS High risk Rating: high
Comments: unclear selection bias, unclear
blinding; unit of analysis issues
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Kraft 1993
Methods RCT; participants randomised (only 1 wound per person)
Funding: industry funded - Calgon Vestal Laboratories, manufacturer of foam dressing.
Setting: hospital and care home with spinal injury
Duration of follow-up 24 weeks (also reported at 3, 6, 12 (graph) weeks)
Unit of analysis: person (1 ulcer/person)
Participants 38 participants with pressure ulcers. PU Stage: II (58% overall) and III (PU classiﬁcation:
Enterstomal Therapy)
Age: overall mean: 76, range 28-78 years. Duration of ulcer: 58% for 2 months or less;
range 0-5 years. Ulcer size: not stated
Wound characteristics at baseline: no wounds infected; slough not reported; necrosis not
reported; exudate not reported
Comment: 33/38 were people with spinal chord injury
Interventions Group 1: foam dressing - Epi-Lock (not in BNF); n = 24. Grouped intervention category:
advanced dressing
Group 2: gauze saline dressing - saline moist; n = 14. Grouped intervention category:
basic dressing
Outcomes Primary outcomes: proportion completely healed at 24 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - not stated.
Allocation concealment unclear - no infor-
mation on allocation concealment. Base-
line comparability unclear - no informa-
tion. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who outcome assessor was
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing data: Group 1 - 11/24 (45%) and
(5 staff-requested removal, 1 participant-
requested removal, 1 special bed treatment,
4 reactions to treatment). Group 2 - 6/14
(43%) (2 died, 1 staff-requested removal, 1
participant-requested removal, 1 surgery, 1
reaction to treatment).
i.e. similar ratemissing in both groups; high
rate - more than control event rate
Selective reporting (reporting bias) Low risk Adequate - full results reported
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Kraft 1993 (Continued)
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (1 ulcer/person)
Other bias
additional
Unclear risk Insufﬁcient information to assess whether
an important risk of bias exists
ALL-DOMAIN RISK OF BIAS High risk Rating: high
Reasons: unclear selection bias, attrition
bias
Comments: all assessed by same rater (a reg-
istered nurse), but no information on what
she knew
Matzen 1999
Methods RCT; participants randomised (only 1 wound per person)
Funding: not stated. Setting: community
Duration of follow-up 12 weeks
Unit of analysis: person (1 ulcer/person)
Participants 32 participants with pressure ulcers. PU Stage: III and IV: median for both groups was
IV (PU classiﬁcation: not stated)
Age: median (range): 82 (32-97) years and 84 (46-89) years. Duration of ulcer: not
stated. Ulcer size: not stated
Wound characteristics at baseline: no wounds infected; slough not reported; unclear
necrotic; exudate not reported
Interventions Group 1: hydrogel dressing - amorphous hydrocolloid (hydrogel, Coloplast) - in
Cochrane Review as hydrogel; n = 17. Grouped intervention category: advanced dressing
Group 2: gauze saline dressing - saline gauze; n = 15. Grouped intervention category:
basic dressing
Outcomes Primary outcomes: proportion completely healed at 12 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability adequate - no
suggestion of problems. Rating: unclear
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Matzen 1999 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who outcome assessor was
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing data: Group 1 - 9/17 (53%) (5
other illness, 2 deaths, 1 missing schedule,
1 wish to cease participation). Group 2 -
11/15 (73%) (6 insufﬁcient effect of treat-
ment, 3 other illness, 1 death, 1 wish to
cease participation)
i.e. differential missing data rates; high dif-
ferential rate - likely to change effect esti-
mate
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (1 ulcer/person)
Other bias
additional
Low risk Adequate - no suggestion of problems
ALL-DOMAIN RISK OF BIAS High risk Rating: high
Comments: unclear selection bias, attri-
tion bias; unlikely that outcome assessor
blinded, but not clear who it was
Meaume 2003
Methods RCT; participants randomised (unclear if > 1 wound per person)
Funding: not stated. Setting: care home
Duration of follow-up 8 weeks
Unit of analysis: person (unclear if > 1 ulcer analysed)
Participants 38 participants with pressure ulcers. PU Stage: 2 (PU classiﬁcation: EPUAP)
Age: mean age 83.8 years, range 74.9-95.1 and 82.5 years, range 66.4-91.9 . Duration
of ulcer: at least 4 weeks; NICE guideline: mean (range) 8.3 (1-24) weeks and 13.0 (1-
52) weeks. Ulcer size: not reported (table 2 missing); NICE guideline: mean 4.9 (0.7-
25.3) cm² and 5.4 (0.2-26.0)
Wound characteristics at baseline: nowounds infected; somewounds sloughy; nowounds
necrotic; exudate not reported
Comment: red-yellow wounds in the red-yellow-black system (no necrosis, but some
slough)
Interventions Group 1: soft polymer dressing -Mepilex Border; n = 18. Grouped intervention category:
advanced dressing
Group 2: foam dressing - Tielle; n = 20. Grouped intervention category: advanced
dressing
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Meaume 2003 (Continued)
Outcomes Primary outcomes: proportion completely healed at 8 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation adequate - computer-
generated. Allocation concealment unclear
- envelopes not said to be opaque. Base-
line comparability unclear - no informa-
tion. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded to interventions - clear de-
scription
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data: Group 1 - 1/18 ? (6%) (un-
clear if other withdrawals) (1 died during
the study (so missing), 1 had hip fracture).
Group 2 - 1/20? (5%) (unclear about with-
drawals) (1 died (but unclear when and not
listed by authors as missing); 1 developed
symptoms of heart disorder).
i.e. similar rate missing in both groups; low
rate - less than control event rate
Selective reporting (reporting bias) Unclear risk Unclear reporting
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (unclear if > 1 ulcer anal-
ysed) - implies 1 per person
Other bias
additional
Unclear risk Insufﬁcient information to assess whether
an important risk of bias exists
ALL-DOMAIN RISK OF BIAS High risk Rating: high
Comments: unclear selection bias - allo-
cation concealment: envelopes not said to
be opaque; also says block size unknown
to investigators and predetermined list; not
blinded; unclear re missing data and appro-
priate tables not available
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Motta 1999
Methods RCT; participants randomised (only 1 wound per person)
Funding: industry funded - educational grant from Acryl Med (manufacturer of hydro-
gel). Setting: community
Duration of follow-up 8 weeks
Unit of analysis: person (1 ulcer/person)
Participants 10 participants with pressure ulcers. PU Stage: II (30%) and III (PU classiﬁcation: not
stated)
Age: ’average’ 60 (range 34-76) years. Duration of ulcer: ’average’ 49.8 days. Ulcer size:
Group 1 IPD: mean (SD) area 10.2 cm² (SD 10.6), median 6.67 cm² (range 0.75-24);
Group 2: mean(SD) 1.94 cm² (SD 1.48), median 2 cm²
Wound characteristics at baseline: infection not reported; slough not reported; necrosis
not reported; exudate low-moderate levels
Comment: exudate levels assumed from text
Interventions Group1: hydrogel dressing - Flexigel (not inBNF); n =5.Grouped intervention category:
advanced dressing
Group 2: hydrocolloid dressing - DuoDERM CGF (not BNF); n = 5. Grouped inter-
vention category: advanced dressing
Outcomes Primary outcomes: proportion completely healed at 8 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability unclear -
baseline difference but unclear of impor-
tance. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Other evidence for no blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data: Group 1 - 0. Group 2 - 0. i.
e. no missing data (no details)
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (1 ulcer/person)
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Motta 1999 (Continued)
Other bias
additional
Unclear risk Insufﬁcient information to assess whether
an important risk of bias exists
ALL-DOMAIN RISK OF BIAS High risk Rating: high
Comments: circumstantial evidence for
lack of blinding (e.g. parameters relating
to dressing performance scored at each
dressing change, and participants receiving
wound care treatment in a home health-
care environment); hydrogel group had 4/
5 grade III ulcers and hydrocolloid had 2/
5; ulcer area: mean 10.2 cm² and 1.9 cm²
Muller 2001
Methods RCT; participants randomised (> 1 wound per person, all followed)
Funding: non-industry funding - cost effectiveness study stated to have an unrestricted
grant fromKnoll AG (manufacturers of collagenase); original trial states no support from
either manufacturer. Setting: hospital inpatients
Duration of follow-up probably 16 weeks
Unit of analysis: person (all ulcers analysed as a whole)
Participants 24 participants with pressure ulcers. PU Stage: IV (PU classiﬁcation: not stated)
Age: mean (range) 72.4 (65-78) years and 74.6 (68-79) years. Duration of ulcer: not
stated. Ulcer size: not stated
Wound characteristics at baseline: infection not reported; slough not reported; no
wounds necrotic; exudate not reported
Comment: debridement to remove all necrotic tissue; 2/24 participants had 2 ulcers i.e.
approx 1 ulcer/person. All participants were female. Heel ulcers only
Interventions Group 1: hydrocolloid dressing - DuoDERM: complete debridement ﬁrst. New necrosis
led to a change to alginate or collagenase (4/12; 33%); n = 12. Grouped intervention
category: advanced dressing
Group 2: collagenase-containing ointment - Novuxol (not BNF) (Novuxol + parafﬁn
gauze secondary dressing. Complete debridement ﬁrst. New necrosis led to a change to
alginate or collagenase (1/12; 8%)); n = 12. Grouped intervention category: collagenase
ointment
Outcomes Primary outcomes: proportion completely healed at probably 16 weeks; time to complete
healing reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Muller 2001 (Continued)
Selection bias Unclear risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability adequate - no
suggestion of problems. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded to interventions - clear de-
scription
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data: Group 1 - 1/12 (8%); 4/
12 (33%) changed treatment (1 failed
to comply with weekly inspection, so
dropped; changed treatment for newnecro-
sis). Group 2 - 1/12 (8%) changed treat-
ment (changed treatment for new necrosis)
i.e. differential switching data rates; switch-
ing rate low - less than control event rate
Selective reporting (reporting bias) Low risk Adequate - reported incompletely as ‘sig-
niﬁcant’ or P value < 0.05
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (all ulcers analysed as a
whole) - 2/24 (8%) participants had 2 ul-
cers - but participants analysed; ratio ulcers:
participants = 13/12 (1.08) in each group
Other bias
additional
Low risk Adequate - no suggestion of problems
ALL-DOMAIN RISK OF BIAS High risk Rating: high/very high
Comments: not blinded; outcome asses-
sor was ’physician each week’, who also
oversaw the changing of dressings (so not
blinded)
Neill 1989a
Methods RCT; ulcers randomised (> 1 wound per person, all followed)
Funding: industry funded - 3M Company. Setting: hospital and care home
Duration of follow-up 8 weeks
Unit of analysis: ulcer
Participants 87 participants with pressure ulcers. PU Stage: II (60% and 76%) and III (% of available
cases) (PU classiﬁcation: Shea)
Age: not stated. Duration of ulcer: not stated. Ulcer size: mean (SD): 8.3 (9.9), range 0.
4-43.9 cm² and 7.6 (8.6), range 0.2-35.2 cm²
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Neill 1989a (Continued)
Wound characteristics at baseline: some wounds infected; some wounds sloughy; some
wounds necrotic; exudate not reported
Comment: 32/42 (76%) and 32/45 (71%) had infected wounds at baseline. Initially
81% and 62% wounds necrotic but treated before randomised treatments given
Interventions Group 1: hydrocolloid dressing - Tegasorb (not in BNF): dressing scheduled to be
changed every 7 days; if there was necrotic tissue it was debrided; n = 100 ulcers ran-
domised (total), number of participants not stated, but available cases 87 total. Grouped
intervention category: advanced dressing
Group 2: gauze saline dressing - saline wet-to-damp (dressing scheduled to be changed
every 8 h; if there was necrotic tissue it was debrided); n = 100 ulcers randomised (total)
, number of participants not stated, but available cases 87 total. Grouped intervention
category: basic dressing
Outcomes Primary outcomes: proportion completely healed at 8 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias High risk Sequence generation unclear - “ran-
domised”. Allocation concealment inade-
quate - alternation. Baseline comparability
inadequate - baseline characteristics differ-
ent between arms. Rating: high
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who outcome assessor was
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data: Group 1 - overall 13/100
(13%) ulcers excluded from the analysis
(intercurrent medical events (n = 11) and
2 had protocol violations). Group 2 - over-
all 13/100 (13%) ulcers excluded from the
analysis (intercurrent medical events (n =
11) and 2 had protocol violations)
i.e. overall rate only; low rate - less than
control event rate
Selective reporting (reporting bias) Unclear risk Unclear reporting
Other bias
unit of analysis
Low risk Unit of randomisation ulcer and unit of
analysis ulcer - 22/87 (25%) participants
had 2 ulcers
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Neill 1989a (Continued)
Other bias
additional
Unclear risk 25% had 2 ulcers - not treated as paired
data
ALL-DOMAIN RISK OF BIAS High risk Rating: high/very high
Reasons: high selection bias; unclear blind-
ing, some unit of analysis issues
Comments: some baseline differences in
grade of ulcer 60% and 76% grade II and
HC size was larger, with more necrotic tis-
sue; if participants had 2 ulcers, then alter-
nation; blinding not stated, overall 13/100
missing data; number of ulcers per group
not stated, so available case used; 25% had
2 ulcers - not treated as paired data
Nisi 2005
Methods RCT; participants randomised (only 1 wound per person)
Funding: not stated. Setting: hospital inpatients
Duration of follow-up 8 weeks
Unit of analysis: person (1 ulcer/person)
Participants 80 participants with pressure ulcers. PU Stage: 2-4 (proportion not stated) (PU classiﬁ-
cation: NPUAP)
Age: mean 45 (range 35-85) years, overall. Duration of ulcer: not stated. Ulcer size: not
stated
Wound characteristics at baseline: no wounds infected; slough not reported; no wounds
necrotic; exudate unclear
Comment: debridement to remove infection and necrosis; some exudate but level not
stated
Interventions Group 1: protease-modulating dressing - Promogran: hydropolymer secondary dressing;
preparation phase included hydrogel; n = 40. Grouped intervention category: protease
modulating dressing
Group 2: ineligible intervention - povidone iodine + parafﬁn-soaked gauze (50% povi-
done iodine wash then viscose-rayon gauze soaked in white Vaseline + hydropolymer
secondary dressing; phase 1 included hydrogel); n = 40. Grouped intervention category:
ineligible - basic dressing + antiseptic
Outcomes Primary outcomes: proportion completely healed at 8 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Nisi 2005 (Continued)
Selection bias Unclear risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability unclear - no
information. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who outcome assessor was
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data: Group 1 - 0 (all appear to be
covered). Group 2 - 0
i.e. no missing data (no details)
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (1 ulcer/person)
Other bias
additional
Unclear risk Insufﬁcient information to assess whether
an important risk of bias exists
ALL-DOMAIN RISK OF BIAS Unclear risk Rating: unclear
Reasons: unclear selection bias, unclear
blinding
Comments: times of healing given, so po-
tential for time to event, but not reported
Nussbaum 1994
Methods RCT; participants randomised (> 1 wound per person, all followed)
Funding: non-industry funding - study was funded by the John Labatt Seed Fund Award.
Setting: hospital with spinal chord injury
Duration of follow-up could choose (IPD) e.g. Results given at 8 (reviewer choice) weeks
(also reported at various times from IPD graph weeks).
Unit of analysis: ulcer
Participants 20 participants with pressure ulcers. PU Stage: not stated (PU classiﬁcation: not stated)
Age: mean (range): 36 (15-46) years; 42.2 (26-59) years; 42 (30-61) years. Duration of
ulcer: > 6 weeks 67%, 100%, 100%, < 1 week 33%, 0%, 0%. Ulcer size: not stated
Wound characteristics at baseline: infection not reported; slough not reported; necrosis
not reported; exudate not reported
Comment: people with spinal chord injury (younger people)
Interventions Group 1: basic wound contact dressing - parafﬁn gauze (Jelonet); n = 9. Grouped inter-
vention category: basic dressing
Group 2: ineligible intervention - ultrasound + UV (US/UV + Jelonet); n = 5. Grouped
intervention category: ineligible - ultrasound + UV
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Nussbaum 1994 (Continued)
Group 3: laser - laser + Jelonet (laser + Jelonet; n = 6). Grouped intervention category:
ineligible - laser
Outcomes Primary outcomes: proportion completely healed at could choose (IPD) e.g. Results
given at 8 (reviewer choice) weeks; time to complete healing reported (Kaplan Meier
plot included)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability unclear -
baseline difference but unclear of impor-
tance. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded to interventions (clear description)
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing data: Group 1 - 3/9 (33%) (2
elected to have wounds surgically repaired
and withdrew; 1 transferred to acute hos-
pital). Group 2 - 0. Group 3 - 1/6 (17%)
(1 transferred to acute hospital).
i.e. differential missing data rates; high dif-
ferential rate - likely to change effect esti-
mate
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
High risk Unit of randomisation person and unit of
analysis ulcer - IPD reported per ulcer (but
only 2/16 (12.5%) participants had 2 ul-
cers); ≤ 1.2 ulcer:person = 9/9, 6/5 and 7/
6
Other bias
additional
Unclear risk Insufﬁcient information to assess whether
an important risk of bias exists
ALL-DOMAIN RISK OF BIAS High risk Rating: very high
Reasons: unclear selection bias, attrition
bias, unit of analysis issues
Comments: PU grade not reported. Base-
line characteristics: laser group had 2/6
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Nussbaum 1994 (Continued)
deeper ulcers (6-10 mm), other ulcers all
shallower; control group had 2/6 acute ul-
cers
ALL-DOMAIN RISK OF BIAS 2 High risk
Oleske 1986
Methods RCT; nursing module (cluster)s randomised (> 1 wound per person, all followed)
Funding: non-industry funding - supported by Rush-Presbyterian-St Lukes Medical
Center and Chicago Community Trust. Setting: hospital inpatients
Duration of follow-up 1.5 (12 days) weeks
Unit of analysis: ulcer
Participants 15 participants with pressure ulcers. PU Stage: I (22% and 50%) and II, results separately
for II. Inclusion criteria state all should have break in skin (PU classiﬁcation: Enis and
Sarmiento)
Age: overall mean (SD): 69 (6), range 52-93 years. Duration of ulcer: not stated. Ulcer
size: mean 3.5 (SD 1.2), range 1.7-5.0 cm²; mean 7.9 (SD 7.3), range 1.2-22.7cm²
Wound characteristics at baseline: no wounds infected; slough not reported; necrosis not
reported; exudate not reported
Comment: nursingmodules on 4 participating units were randomised (no info on cluster
size)
Interventions Group 1: foam dressing - self adhesive PU dressing; n = 7 (5 grade II). Grouped inter-
vention category: advanced dressing
Group 2: gauze saline dressing - other (normal saline dressing); n = 8 (5 grade II).
Grouped intervention category: basic dressing
Outcomes Primary outcomes: proportion completely healed at 1.5 (12days)weeks; time to complete
healing not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias High risk Sequence generation unclear - other. Allo-
cation concealment unclear - no informa-
tion on allocation concealment. Baseline
comparability inadequate - baseline char-
acteristics different between arms. Rating:
high
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded to interventions (clear description)
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Oleske 1986 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Missingdata:Group1 - 1/16 dropped from
analysis but group unclear (1 unanticipated
transfer to nursing home). Group 2 - 1/16
dropped from analysis but group unclear (1
unanticipated transfer to nursing home).
i.e. overall rate only; high rate - comparable
with control event rate
Selective reporting (reporting bias) Low risk Inadequate - reported incompletely (e.g. P
value > 0.05)
Other bias
unit of analysis
High risk Unit of randomisation nursing module
(cluster) and unit of analysis ulcer - 4/15
(27%)participants had2ulcers each (2par-
ticipants had different treatments for their
2 ulcers); < 1.3 ulcer:person ratio = 9/7 and
10/8
Other bias
additional
Unclear risk Results not adjusted for clustering. Unclear
if grades I and II are subgroups in this clas-
siﬁcation
ALL-DOMAIN RISK OF BIAS High risk Rating: very high
Reasons: inadequate selection bias (base-
line characteristics), attrition bias, unit of
analysis issues
Comments: results not adjusted for clus-
tering. Unclear if grades I and II are sub-
groups in this classiﬁcation. Differences at
baseline in proportion grade II (7/9 and 5/
10 ulcers) and size of PU (mean 3.5 and 7.
9 cm²)
ALL-DOMAIN RISK OF BIAS 2 High risk
Parish 1979
Methods RCT; participants randomised (> 1 wound per person, all followed)
Funding: not stated. Setting: care home
Duration of follow-up 4 weeks
Unit of analysis: results for both people and ulcers
Participants 17 participants with pressure ulcers. PU Stage: not stated (PU classiﬁcation: not stated)
Age: range 28-59 years, 29-57 years and 32-70 years. Duration of ulcer: not stated. Ulcer
size: collagenase: 10.24 cm²; dextranomer: 20.25 cm² and sugar + egg white 5.76 cm²
Wound characteristics at baseline: infection not reported; slough not reported; necrosis
not reported; exudate not reported
Comment: assumed that all ulcers in a participant had to heal before a participant was
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Parish 1979 (Continued)
healed
Interventions Group 1: collagenase-containing ointment - collaganese: ointment applied with wooden
applicator and covered with a dry dressing; n = 5. Grouped intervention category: col-
lagenase ointment
Group 2: dextranomer - dextranomer (dextranomer beads poured into the ulcer and
covered with dry dressing); n = 7. Grouped intervention category: dextranomer
Group 3: sugar + egg white - sugar + egg white applied to the area 4 times/d (sugar + egg
white applied to the area 4 times/d; n = 5. Grouped intervention category: sugar + egg
white
Outcomes Primary outcomes: proportion completely healed at 4 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability unclear -
baseline difference but unclear of impor-
tance. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who outcome assessor was
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data: Group 1 - none. Group 2 -
none. Group 3 - none
i.e. no missing data (no details)
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
Unclear risk Unit of randomisation person and unit of
analysis results for both people and ulcers
- we used the results for the participants,
but unclear what was meant by healing =>
unclear risk of bias
Other bias
additional
Unclear risk Insufﬁcient information to assess whether
an important risk of bias exists
ALL-DOMAIN RISK OF BIAS Unclear risk Rating: unclear
Reasons: unclear selection bias, unclear
unit of analysis issues
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Parish 1979 (Continued)
Comments: says participants and investi-
gators were blinded and nurses looked after
participants => implies outcome assessors
were investigators. Baseline differences said
to be not statistically signiﬁcant in area of
ulcer
Payne 2004
Methods RCT; participants randomised (> 1 wound per person, largest selected)
Funding: industry funded - sponsored by Smith & Nephew Inc, makers of Dermagraft.
Setting: community outpatients
Duration of follow-up 26 weeks (also reported at 12 weeks)
Unit of analysis: person (1 ulcer/person)
Participants 34 participants with pressure ulcers. PU Stage: III (PU classiﬁcation: not stated)
Age:mean (SD): 69.1 (18.5) years and 69.4 (16.5) years. Duration of ulcer:mean (range)
: 29.2 (4.0-104.0) weeks and 30.2 (6-95.3) weeks. Ulcer size: mean (range): 21.1 (3.5-
1.2) and 19.8 (5.2-60.7) cm²
Wound characteristics at baseline: no wounds infected; slough not reported; no wounds
necrotic; exudate not reported
Comment: after debridement, no infection or necrotic tissue
Interventions Group 1: combination intervention - other: non-adherent + saline gauze + foam (Allevyn)
dressing; n = 16. Grouped intervention category: mixed advanced and basic dressings
Group 2: ineligible intervention - graft + conventional dressing (Dermagraft + interven-
tion 1 dressings); n = 18. Grouped intervention category: ineligible - graft + basic and
advanced
Outcomes Primary outcomes: proportion completely healed at 26 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation adequate - computer-
generated. Allocation concealment unclear
- “sealed envelopes”. Baseline comparabil-
ity adequate - no suggestion of problems.
Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who outcome assessor was
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Payne 2004 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing data: Group 1 - 11/16 (69%) (1
death due to unrelated cause, other with-
drawals related to morbidity). Group 2 -
13/18 (72%) (3 deaths due to unrelated
causes, other withdrawals related to mor-
bidity)
i.e. similar ratemissing in both groups; high
rate - more than control event rate
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (1 ulcer/person) - largest ul-
cer selected
Other bias
additional
Low risk Adequate - no suggestion of problems
ALL-DOMAIN RISK OF BIAS High risk Rating: very high
Reasons: unclear selection bias, high attri-
tion bias
Comments: high levels of missing data
(70%). Says it was single blind, so this could
be the outcome assessor
ALL-DOMAIN RISK OF BIAS 2 High risk
Payne 2009
Methods RCT; participants randomised (> 1 wound per person, largest selected)
Funding: industry funded - funded by Smith & Nephew (manufacturers of PU foam).
Setting: care home and hospital and community
Duration of follow-up 4 weeks
Unit of analysis: person (1 ulcer/person)
Participants 36 participants with pressure ulcers. PU Stage: 2 (PU classiﬁcation: NPUAP)
Age: median 74.0 years and 71.5 years; mean (SD): 72.5 (14.3) years and 73.3 (12.4)
years. Duration of ulcer: median 3.5 weeks and 2.0 weeks. Ulcer size: median 1.8 cm²
and 1.4 cm²
Wound characteristics at baseline: no wounds infected; slough not reported; necrosis not
reported; exudate low-moderate levels
Comment:multicentre (2 hospital inpatient wards, 1 hospital outpatients, 1 community,
1 care home)
Interventions Group 1: foam dressing - Allevyn Thin: no secondary dressing; n = 20. Grouped inter-
vention category: advanced dressing
Group 2: gauze saline dressing - saline soaked (secondary dressing as required); n = 16.
Grouped intervention category: basic dressing
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Payne 2009 (Continued)
Outcomes Primary outcomes: proportion completely healed at 4 weeks; time to complete healing
reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - other. Allo-
cation concealment unclear - no informa-
tion on allocation concealment. Baseline
comparability unclear - baseline difference
but unclear of importance. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear - vague
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing data: Group 1 - 6/20 (30%) (3
died, 1 developed wound infection, 1 de-
veloped an abscess unrelated to the study
wound, 1 ineligible for other reasons).
Group 2 - 3/16 (19%) (2 died, 1 asked to
be discharged)
i.e. differential missing data rates; high dif-
ferential rate - likely to change effect esti-
mate
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (1 ulcer/person) - largest ul-
cer selected
ALL-DOMAIN RISK OF BIAS High risk Rating: high
Reasons: unclear selection bias, attrition
bias
Comments: “randomisation schedule”;
may be a difference in duration of wound
at baseline (3.5 and 2.0 weeks)
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Piatkowski 2012
Methods RCT; participants randomised (> 1 wound per person, largest selected)
Funding: industry funded - educational grant from Lohmann&Rauscher GmbH (man-
ufacturer of both interventions). Author employee. Setting: hospital inpatients
Duration of follow-up 3 weeks (also reported at 2 weeks)
Unit of analysis: person (1 ulcer/person)
Participants 10 participants with pressure ulcers. PU Stage: 3 (PU classiﬁcation: EPUAP)
Age: mean (range): 67.0 (59-71) years and 63.0 (52-68) years. Duration of ulcer: at least
4 weeks . Ulcer size: median (range) diameter: 11.4 (5.2-19.6) cm and 9.3 (4.3-21.0)
cm.
Wound characteristics at baseline: no wounds infected; no wounds sloughy; no wounds
necrotic; exudate not reported
Interventions Group 1: protease-modulating dressing - Suprasorb C: with Suprasorb P as secondary
dressing; n = 5. Grouped intervention category: protease-modulating dressing
Group 2: foam dressing - Suprasorb P (not in BNF); n = 5. Grouped intervention
category: advanced dressing
Outcomes Primary outcomes: proportion completely healed at 3 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation adequate - computer-
generated. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability unclear -
baseline difference but unclear of impor-
tance. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who outcome assessor was
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data: Group 1 - 0. Group 2 - 0 i.e.
no missing data (clearly stated)
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (1 ulcer/person) - largest ul-
cer selected
Other bias
additional
Unclear risk Insufﬁcient information to assess whether
an important risk of bias exists
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Piatkowski 2012 (Continued)
ALL-DOMAIN RISK OF BIAS Unclear risk Rating: unclear
Reasons: unclear selection bias
Comments: differences at baseline proba-
bly unimportant - slightly bigger diameter
for the collagen group
Price 2000
Methods RCT; participants randomised (only 1 wound per person)
Funding: not stated - clear statement of no funding. Setting: hospital and community
Duration of follow-up 6 weeks
Unit of analysis: person (1 ulcer/person)
Participants 58 participants with pressure ulcers. PU Stage: III (92% and 80%) and IV (PU classiﬁ-
cation: not stated)
Age:mean (SD): 69.76 (16.2) years and 75.72 (16.8) years. Duration of ulcer: not stated.
Ulcer size: mean (SD): 9.8 (12.0) cm² and 7.3 (7.0) cm², median 4.18 cm² and 5.10
cm²
Wound characteristics at baseline: no wounds infected; slough not reported; necrosis not
reported; exudate not reported
Comment: range of settings from hospitals to their own homes. Same number of ulcers
as participants in tables 1 and 2
Interventions Group 1: alginate dressing - type not stated (standard care); n = 26 (missing data added)
. Grouped intervention category: advanced dressing
Group 2: ineligible intervention - radiant heat; n = 32 (missing data added). Grouped
intervention category: ineligible - radiant heat
Outcomes Primary outcomes: proportion completely healed at 6 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation adequate - computer-
generated. Allocation concealment ade-
quate - serially-numbered opaque sealed
envelopes. Baseline comparability unclear
- baseline difference but unclear of impor-
tance. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded to interventions (clear description)
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Price 2000 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing data: Group 1 - 1/26 (4%); Group
2 - 7/32 (22%). Reasons for ’missing-
ness’ across both groups: 3 died, 3 experi-
enced general deterioration, 1 experienced
device-related deterioration and 1 asked
to withdraw: i.e. differential missing data
rates; high differential rate - likely to change
effect estimate
Selective reporting (reporting bias) Low risk Adequate - outcomemeasured but not nec-
essarily analysed for a good reason
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (1 ulcer/person)
ALL-DOMAIN RISK OF BIAS High risk Rating: high
Reasons: unclear selection bias (baseline
differences); attrition bias
Comments: time to event recorded for
75%, 50%, 25% healed but not 100% -
probably available, but few events. Differ-
ences at baseline in diabetes, urinary incon-
tinence, neurological disorders, BMI (di-
rection not stated), proportion of stage III
(92% and 80%)
Ramos-Torrecillas 2015
Methods RCT; participants randomised (> 1 wound per person, all followed)
Funding: non-industry funding. Setting: hospital inpatients
Duration of follow-up 5 (36 days) weeks
Unit of analysis: ulcer
Participants 124 ulcers, participants with pressure ulcers. PU Stage: 2 and 3 (control: 96%, group A:
85.3%, group B: 100% and group C: 60%) (PU classiﬁcation: EPUAP)
Age: overall mean (SD): 82.5 (4.7) years, range 64-90 years. Duration of ulcer: mean
(SD): control 6.2 (1.5) months; group A 4.8 (1.1) months, group B 5.0 (1.6) months
and group C 4 (1.1) months. Ulcer size: not stated
Wound characteristics at baseline: no wounds infected; slough not reported; no wounds
necrotic; exudate not reported
Comment: one long-stay hospital and 3 ’geriatric centres’ in Granada, Spain
Interventions Group 1: hydrogel dressing - Intrasite Gel: saline cleansing, hydrogel and PU (secondary)
dressing; n = 25 ulcers. Grouped intervention category: advanced dressing
Group 2: ineligible intervention - growth factor gel (combining 2 GF groups (1 and 2
doses) + hydrogel; % estimated from graph (8% and 32% respectively); n = 59 ulcers.
Grouped intervention category: ineligible - growth factor gel
Group 3: growth factor gel + hyaluronic acid - platelet GF + HA + hydrogel (platelet
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Ramos-Torrecillas 2015 (Continued)
GF + HA + hydrogel; n = 40 ulcers;. Grouped intervention category: ineligible - growth
factor gel + HA
Outcomes Primary outcomes: proportion completely healed at 5 (36 days) weeks; time to complete
healing not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation adequate - computer-
generated. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability unclear -
baseline difference but unclear of impor-
tance. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded (’open label’) and no evidence
that outcome assessor was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing data: Group 1 - 15/115 (13%)
overall (loss to follow-up). Group 2 - 15/
115 (13%) overall (loss to follow-up).
Group 3 - 15/115 (13%) overall (loss to
follow-up).
i.e. overall rate only; high rate - comparable
with control event rate
Selective reporting (reporting bias) Unclear risk Unclear reporting
Other bias
unit of analysis
High risk Unit of randomisation person and unit of
analysis ulcer - multiple PUs per person
treated with the same interventions. 140
ulcers in 100 persons across both groups.
Unit of analysis issue
Other bias
additional
Unclear risk Data extracted from graph
ALL-DOMAIN RISK OF BIAS High risk Rating: very high
Reasons: unclear selection bias, not
blinded, unit of analysis issues, data ex-
tracted from graph
Comments: some baseline differences (e.g.
group C had more Grade II ulcers)
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Ramos-Torrecillas 2015 (Continued)
ALL-DOMAIN RISK OF BIAS 2 High risk
Rees 1999
Methods RCT; participants randomised (> 1 wound per person, likely slowest healing wound
selected)
Funding: industry funded - funded by Johnson & Johnson Inc. Setting: unclear
Duration of follow-up 16 weeks
Unit of analysis: person (1 ulcer/person)
Participants 124 participants with pressure ulcers. PU Stage: 3 and 4 (PU classiﬁcation: NPUAP)
Age: mean (SD) group 1: 50 (13.6) years; group 2: 48 (13.1) years; group 3: 49 (12.
5) years and group 4: 51 (18.3) years. Duration of ulcer: median (IQR) Group 1: 30
(43) weeks; group 2: 22 (32) weeks; group 3: 33 (40) weeks and group 4: 22 (52) weeks.
Ulcer size: ulcer volume median (IQR): group 1: 19.6 (21.9) cm²; group 2: 16.6 (15.1)
cm²; group 3: 17.2 (19.7) cm² and group 4: 17.6 (33.8) cm²
Wound characteristics at baseline: no wounds infected; no wounds sloughy; no wounds
necrotic; exudate not reported
Comment: probably a community-based study; ulcer selected that was likely to be the
slowest healing; debridement to remove necrotic material and ﬁbrin (slough)
Interventions Group 1: hydrogel dressing - carboxymethylcellulose vehicle gel (as placebo) + saline
gauze; n = 31. Grouped intervention category: advanced dressing
Group 2: ineligible intervention - 100 µg / g of growth factor in sodium carboxymethyl-
cellulose vehicle gel + saline gauze
Group 3: ineligible intervention - 300 µg / g of growth factor in vehicle gel + saline gauze
Group 4: ineligible intervention - 100 µg / g of growth factor in vehicle gel, twice daily
+ saline gauze
Results available separately - numbers calculated from % - but results from groups 2-4
were combined ( n = 93). Grouped intervention category: ineligible - growth factor gel
Outcomes Primary outcomes: proportion completely healed at 16 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability unclear -
baseline difference but unclear of impor-
tance. Rating: unclear
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Rees 1999 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who outcome assessor was
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Missing data: Group 1 - unclear but may be
0. Group 2 - unclear but may be 1 (1 par-
ticipant with 100microg bid discontinued)
. i.e. similar rate missing in both groups;
unclear rate
Selective reporting (reporting bias) Unclear risk Unclear reporting
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (1 ulcer/person) - ulcer se-
lected that was likely to be the slowest heal-
ing
Other bias
additional
Unclear risk Results calculated from percentages
ALL-DOMAIN RISK OF BIAS High risk Rating: high
Reasons: unclear selection bias; results cal-
culated from percentages
Comments: number of missing data un-
clear, assumed 0. Slight differences in du-
ration of ulcer
Romanelli 2001
Methods RCT (abstract); participants randomised (unclear if > 1 wound per person)
Funding: not stated. Setting: not stated
Duration of follow-up 8 weeks
Unit of analysis: unclear
Participants 12 participants with pressure ulcers. PU Stage: 2 and 3 (proportions not stated) (PU
classiﬁcation: EPUAP)
Age: not stated. Duration of ulcer: not stated. Ulcer size: not stated
Wound characteristics at baseline: infection not reported; slough not reported; necrosis
not reported; exudate not reported
Interventions Group 1: hydrogel dressing - DuoDERMHydrogel (not in BNF): with OpSite Flexigrid
secondary dressing; n = 6. Grouped intervention category: advanced dressing
Group 2: topical - tripeptide-copper gel + OpSite; n = 6. Grouped intervention category:
tripeptide-copper
Outcomes Primary outcomes: proportion completely healed at 8 weeks; time to complete healing
not reported
112Dressings and topical agents for treating pressure ulcers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fo
r P
re
vie
w 
On
ly
Romanelli 2001 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability unclear - no
information. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who outcome assessor was
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Missing data: Group 1 - 0 (implied). Group
2 - 0 (implied)
i.e. unclear if data missing; unclear rate
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
Unclear risk Unit of randomisation person and unit of
analysis unclear - 1 ulcer per person implied
Other bias
additional
Unclear risk Insufﬁcient information to assess whether
an important risk of bias exists
ALL-DOMAIN RISK OF BIAS Unclear risk Rating: unclear
Reasons: unclear selection bias, unclear at-
trition, unclear blinding (abstract); prelim-
inary results
Comments: abstract - few details
Sebern 1986
Methods RCT; ulcers randomised (> 1 wound per person, all followed)
Funding: mixed industry and non-industry - part supported by Research Grant Award
to the University Nursing dept from Sigma Theta Tau and part funded by 3M Medical
Division. Setting: home care population
Duration of follow-up 8 weeks
Unit of analysis: ulcer
Participants 48 participants with pressure ulcers. PU Stage: II and III (41% and 70% grade III) (PU
classiﬁcation: Shea). All participants had chronic illness (focal cerebral disorders, spinal
chord disorders, neurological disorders, cardiac disease, diabetes)
Age -mean (SD): group 1: 76.3 (SD 17.6) years; group 2: 72.4 (SD17.8) years. Duration
of ulcer: not stated. Ulcer size: group 1: grade II median (range) 1.9 (0.1-32.9) cm²;
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Sebern 1986 (Continued)
grade III 6.1 (0.3-33.0) cm². Group 2: grade II 3.4 (0.6-23.9) cm², grade III 4.5 (0.5-
47.1) cm²
Interventions Group1: vapour-permeable dressing: polyurethane adhesive dressing; vapour-permeable;
n = unclear number randomised, but overall 48 participants in analysed population.
Grouped intervention category: advanced dressing
Group 2: gauze saline dressing - wet-to-dry; n = unclear number randomised, but overall
48 participants in analysed population. Grouped intervention category: basic dressing
Outcomes Primary outcomes: complete healing not reported; time to complete healing not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias High risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- other. Baseline comparability inadequate
- baseline characteristics different between
arms. Rating: high
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear - vague
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Missing data: Group 1 - 13/50 (26%) ul-
cers missing (number participants missing
not reported) (Overall, the “Most frequent
causes of dropout were: death, hospitali-
sation, and inability to comply with pro-
tocol for pressure relief ” - no more in-
formation). Group 2 - 10/50 (20%) ul-
cers missing (number participants missing
not reported) (Overall, the “Most frequent
causes of dropout were: death, hospitalisa-
tion, and inability to comply with protocol
for pressure relief ” - no more information)
i.e. similar rate missing in both groups; un-
clear rate
Selective reporting (reporting bias) High risk Comment: inadequate - reported incom-
pletely (results given only for grade II ulcers
and “not signiﬁcantly different” for grade
III ulcers)
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Sebern 1986 (Continued)
Other bias
unit of analysis
Low risk Unit of randomisation ulcer and unit of
analysis ulcer; > 6 people had 2 or more ul-
cers; 6 people had 2 ulcers assigned to dif-
ferent treatments; 77/48 (1.6) ulcers: peo-
ple in available case analysis
Other bias
additional
Unclear risk Insufﬁcient information to assess whether
an important risk of bias exists
ALL-DOMAIN RISK OF BIAS High risk Rating: very high
Reasons: selection bias (baseline differ-
ences), unit of analysis issues; selective out-
come reporting bias
Comments: sequential list of 100 random
numbers was used to assign the treatment:
unclear where list kept. Outcome assessor
was project director who made weekly vis-
its to assess the wound and review the pro-
tocol for wound care - implies not blinded;
baseline differences: proportion of stage II
different (59% vs 30%) and size of ulcer
differences but numbers only reported for
stage II
ALL-DOMAIN RISK OF BIAS 2 High risk
Seeley 1999
Methods RCT; participants randomised (> 1 wound per person, largest selected)
Funding: not stated. Setting: care home and outpatients
Duration of follow-up 8 weeks
Unit of analysis: person (selected ulcer)
Participants 40 participants with pressure ulcers. PUStage: II (11 and 15%) and III (PU classiﬁcation:
AHCPR)
Age: mean (SD): 76.7 (19.5) years and 75.7 (18.6) years. Duration of ulcer: median: 10
weeks and 9 weeks. Ulcer size: mean(SD): 4.61 (5.56) cm² and 6.84 (8.19) cm²
Wound characteristics at baseline: no wounds infected; some wounds sloughy; necrosis
not reported; exudate not reported
Comment: slough: 4/19 (21%) and 5/20 (25%)
Interventions Group 1: hydrocolloid dressing - DuoDERM CGF (not BNF); n = 20. Grouped inter-
vention category: advanced dressing
Group 2: foam dressing - Allevyn Adhesive; n = 20. Grouped intervention category:
advanced dressing
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Seeley 1999 (Continued)
Outcomes Primary outcomes: proportion completely healed at 8 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation adequate - computer-
generated. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability adequate - no
suggestion of problems. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Other evidence for no blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing data: Group 1 - 6/20 (30%) (2 ad-
verse effects (both due to dressing), 1 death,
2 increased ulcer size, 1 unable to tolerate
dressing). Group 2 - 8/20 (40%) (1 partic-
ipant request, 3 loss to follow-up, 2 adverse
effects (1 related to dressing), 1 death, 1 in-
fection).
i.e. similar ratemissing in both groups; high
rate - comparable with control event rate
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (selected ulcer) - largest ul-
cer selected
Other bias
additional
Low risk Adequate - no suggestion of problems
ALL-DOMAIN RISK OF BIAS High risk Rating: high
Reasons: unclear selection bias, not
blinded, some attrition bias
Comments: stratiﬁed randomisation (by
size); unlikely to be blinded - assessors were
clinical investigators who changed dress-
ings. Attrition bias borderline high (be-
cause of reasons for missingness)
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Serena 2010
Methods RCT (abstract); not stated randomised (unclear if > 1 wound per person)
Funding: not stated. Setting: not stated
Duration of follow-up 12 weeks
Unit of analysis: person (unclear if > 1 ulcer analysed)
Participants 74 participants with pressure ulcers. PU Stage: 3 (PU classiﬁcation: NPUAP)
Age: not stated. Duration of ulcer: mean (SD): 71 (59) weeks and 84 (139) weeks. Ulcer
size: mean (SD): 8.1 (76.1) cm² and 9.8 (12.5) cm²
Wound characteristics at baseline: infection not reported; slough not reported; necrosis
not reported; exudate not reported
Comment: debridement throughout trial
Interventions Group 1: combination intervention - “primary nonadherent silicone dressing and foam
dressing”; n = 44. Grouped intervention category: advanced dressing
Group 2: ineligible intervention - skin substitute (Apligraf (bilayered living cell-based
treatment)); n = 30. Grouped intervention category: ineligible - skin substitute
Outcomes Primary outcomes: proportion completely healed at 12 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability unclear -
baseline difference but unclear of impor-
tance. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who outcome assessor was
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Missingdata:Group1 - none stated.Group
2 - none stated
i.e. unclear if data missing; unclear rate
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
Unclear risk Unit of randomisation not stated and unit
of analysis person (unclear if > 1 ulcer anal-
ysed) - implies 1 per person
Other bias
additional
Unclear risk Unclear if the trial was stopped early be-
cause of the results
117Dressings and topical agents for treating pressure ulcers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fo
r P
re
vie
w 
On
ly
Serena 2010 (Continued)
ALL-DOMAIN RISK OF BIAS High risk Rating: high
Reasons: unclear selection bias, possibly
terminated early, unclear blinding and at-
trition - abstract.
Comments: conclusions say “although this
study was terminated early… trials of
longer duration are required”. It is unclear
if this means the trial was stopped early be-
cause of the results. Baseline difference in
ulcer size and duration (larger for the bi-
layer)
Sipponen 2008
Methods RCT; participants randomised (> 1 wound per person, all followed)
Funding: industry funded - study authors have now founded a company tomanufacturer
intervention 1. Setting: hospital inpatients
Duration of follow-up 26 weeks (6 months)
Unit of analysis: results for both people and ulcers
Participants 37 participants with pressure ulcers. PU Stage: 2 (39% and 45%), 3 (50% and 45%)
and 4 (11% and 9%) (PU classiﬁcation: EPUAP)
Age: per protocol: mean (SD) 80 (10) years and 74 (8) years; range 58-98 years and 60-
88 years. Duration of ulcer: not stated. Ulcer size: width mean(SD): 3.2 (2.4) cm and
4.2 (2.8) cm
Wound characteristics at baseline: some wounds infected; slough not reported; necrosis
not reported; exudate not reported
Comment: 27/21 and 18/16 ulcers per person (18 (86%) and 14 (88%) participants
had only 1 ulcer); number of ulcers infected not stated
Interventions Group 1: resin salve - resin salve: Norway spruce salve mixed with butter between gauze;
n = 21. Grouped intervention category: antimicrobial
Group2: hydrocolloid or hydrocolloid silver dressing -Aquacel +Aquacel Ag (Aquacel Ag
if infected wounds (NS proportion)); n = 16). Grouped intervention category: advanced
- antimicrobial
Outcomes Primary outcomes: proportion completely healed at 26 (6 months) weeks; time to com-
plete healing reported (Kaplan Meier plot included)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - other. Allo-
cation concealment unclear - other. Base-
line comparability unclear - baseline dif-
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Sipponen 2008 (Continued)
ference but unclear of importance. Rating:
unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear - vague
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing data: Group 1 - 8/21 (38%) (3
deaths, 2 admissions to operative treat-
ment, 1 allergic skin reaction, 1misdiagno-
sis, 1 participant-based refusal without any
speciﬁc cause). Group 2 - 7/16 (44%) (4
deaths, 2 participant-based refusal without
any speciﬁc cause, 1 participant-based re-
fusal because of randomisation to control
group)
i.e. similar ratemissing in both groups; high
rate - more than control event rate
Selective reporting (reporting bias) High risk Inadequate - other. Time to event outcome
excluded dropouts
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis results for both people and ulcers -
3/21 (14%) and 2/16 (12.5%) participants
had > 1 ulcer; study analysis seemed to re-
quire that all ulcers in a person should heal;
ulcers:person ratio = 27/21 (1.3) and 18/
16 (1.1)
Other bias
additional
Low risk Adequate - no suggestion of problems
ALL-DOMAIN RISK OF BIAS High risk Rating: high
Reasons: unclear selection bias, attrition
bias, time to event outcome excluded drop
outs, so risk of outcome reporting bias for
that outcome only
Comments: randomisation in permuted
blocks of 4. Randomisation list in closed
envelopes. Independent physicians in each
hospital assessed wound - this is probably
enough for blinding. Time to event out-
come excluded dropouts
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Sopata 2002
Methods RCT; participants randomised (> 1 wound per person, all followed)
Funding: non-industry funding - declaration of interest: none. Setting: hospital inpa-
tients
Duration of follow-up 8 weeks
Unit of analysis: ulcer
Participants 34 participants with pressure ulcers. PU Stage: II (non-blanching erythema and super-
ﬁcial damage - may be closer to NPUAP I; 33% and 30%) and III (PU classiﬁcation:
Torrance)
Age: mean (SD): 58.7 (14.1) years and 58.5 (16.9) years. Range overall: 24-88 years.
Duration of ulcer: mean (SD): 2.45 (1.60) weeks and 2.46 (0.24) weeks. Ulcer size:
mean (SD): 8.28 (13.90) cm² and 11.04 (11.65) cm². Range: 0.41-98.78 and 0.68-51.
05 cm²
Wound characteristics at baseline: some wounds infected; slough not reported; no
wounds necrotic; exudate not reported
Comment: participants were people with advanced cancer in palliative care department;
38/34 ulcers per person; 9/17 (53%) and 10/17 (59%) participants had infected wounds
Interventions Group 1: hydrogel dressing - Aquagel (not in BNF); n = 17. Grouped intervention
category: advanced dressing
Group 2: foam dressing - Lyofoam; n = 17. Grouped intervention category: advanced
dressing
Outcomes Primary outcomes: proportion completely healed at 8 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation adequate - computer-
generated. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability unclear -
baseline difference but unclear of impor-
tance. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who outcome assessor was
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missingdata:Group1 - 3/17 (18%) (3 died
). Group 2 - 2/17 (12%) (2 died)
i.e. similar rate missing in both groups; low
rate - less than control event rate
Selective reporting (reporting bias) Low risk Adequate - full results reported
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Sopata 2002 (Continued)
Other bias
unit of analysis
High risk Unit of randomisation person and unit of
analysis ulcer - ulcer:person ratio = 20/17
(1.2) and 18/17 (1.1)
Other bias
additional
Unclear risk Insufﬁcient information to assess whether
an important risk of bias exists
ALL-DOMAIN RISK OF BIAS High risk Rating: high
Comments: unclear selection bias, unclear
subgroup - grade II Torrance may be closer
toNPUAP stage I, could be subgroup issue.
Slightly larger wounds for foam. Slight unit
of analysis issue
Thomas 1997a
Methods RCT; participants randomised (only 1 wound per person)
Funding: not stated. Setting: community
Duration of follow-up 6 weeks
Unit of analysis: person (1 ulcer/person)
Participants 99 participants stratiﬁed by wound. PU Stage: II and III (61% and 54% grade II) (PU
classiﬁcation: Stirling)
Age: 78.6 (SD 14.3) years, 80.1 (SD 10.2) years. Duration of ulcer: 9 and 8 at < 1
month; 18 and 21 at 1-3 months, 21 and 20 at > 3 months. Ulcer size: not stated
Wound characteristics at baseline: no wounds infected; slough not reported; necrosis not
reported; exudate not reported
Comment: text says “for eachwound type, patients were allocated to 2 treatment groups”
=> implied stratiﬁcation
Interventions Group 1: hydrocolloid dressing - Granuﬂex: cleansed using 0.9% saline as necessary; n
= 49. Grouped intervention category: advanced dressing
Group2: foamdressing -Tielle (cleansed using 0.9%saline as necessary); n =50.Grouped
intervention category: advanced dressing
Outcomes Primary outcomes: proportion completely healed at 6 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- “sealed envelopes”. Baseline comparabil-
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Thomas 1997a (Continued)
ity unclear - baseline difference but unclear
of importance. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded (’open label’) and no evidence
that outcome assessor was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data: Group 1 - 1/49 (2%) and
some may have died (reason not stated;
overall 5 participants died). Group 2 - 2/
50 (4%) and some may have died (reason
not stated; overall 5 participants died)
i.e. similar rate missing in both groups; low
rate - less than control event rate
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (1 ulcer/person)
Other bias
additional
Unclear risk Insufﬁcient information to assess whether
an important risk of bias exists
ALL-DOMAIN RISK OF BIAS High risk Rating: high
Reasons: unclear selection bias, not blinded
Comments: difference in proportion of
grade II ulcers (61% and 54%)
Thomas 1998
Methods RCT; participants randomised (> 1 wound per person, other selection of wound)
Funding: industry funded - grant from Carrington labs Inc (hydrogel manufacturers).
Setting: care home and community
Duration of follow-up 10 weeks
Unit of analysis: person (1 ulcer/person)
Participants 41 participants with pressure ulcers. PU Stage: II (50% and 43%), III (38% and 50%)
and IV (13% and 7%) (PU classiﬁcation: not stated)
Age: mean (SD): 79 (9) years and 72 (13) years. Duration of ulcer: not stated. Ulcer
size: mean (SD): 8.9 (9.3) cm² and 5.9 (6.0) cm²
Wound characteristics at baseline: no wounds infected; slough not reported; necrosis not
reported; exudate not reported
Interventions Group 1: hydrogel dressing - Carrosyn Gel Wound Dressing (contains Acemannan
hydrogel - from aloe vera); n = 22. Grouped intervention category: advanced dressing
Group 2: gauze saline dressing - saline moist; n = 19. Grouped intervention category:
basic dressing
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Thomas 1998 (Continued)
Outcomes Primary outcomes: proportion completely healed at 10 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability unclear -
baseline difference but unclear of impor-
tance. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear - vague
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missingdata:Group1 - 6/22 (27%) (4 died
(not attributed to treatment), 1 showed de-
terioration and was terminated from study,
1 participant hospitalised). Group 2 - 5/
19 (26%) (2 died (not attributed to treat-
ment), 1 showed deterioration and was ter-
minated from study, 1 participant hospi-
talised, 1 protocol violation)
i.e. similar rate missing in both groups; low
rate - less than control event rate
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (1 ulcer/person) - 1 per per-
son; NS how selected
Other bias
additional
Low risk Adequate - no suggestion of problems
ALL-DOMAIN RISK OF BIAS Unclear risk Rating: unclear
Reasons: unclear selection bias; unclear
blinding
Comments: baseline difference in ulcer size
(8.9 cm² and 5.9 cm², but not signiﬁcant)
; unclear if outcome assessors were blinded
- “study nurses who evaluated weekly”
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Thomas 2005
Methods RCT; participants randomised (only 1 wound per person)
Funding: not stated. Setting: care home and outpatients
Duration of follow-up 12 weeks
Unit of analysis: person (1 ulcer/person)
Participants 41 participants with pressure ulcers. PU Stage: III (55% and 52%) or IV (PU classiﬁca-
tion: not stated)
Age: mean (SD): 77.0 (11.5) years and 74.1 (13.8) years. Duration of ulcer: not stated.
Ulcer size: mean (SD): 12.1 (18.2) cm² and 11.0 (9.5) cm²
Wound characteristics at baseline: no wounds infected; slough not reported; necrosis not
reported; exudate not reported
Comment: one ulcer evaluated per person
Interventions Group 1: hydrocolloid with or without alginate - DuoDERM with or without Sorbasan:
calcium alginate ﬁller given as needed if the wound was highly exudative. Dressing
changed every 7 d; n = 20. Grouped intervention category: advanced dressing
Group 2: ineligible intervention - radiant heat (dressing change every 7 d); n = 21.
Grouped intervention category: ineligible - radiant heat
Outcomes Primary outcomes: proportion completely healed at 12 weeks; time to complete healing
reported (Kaplan Meier plot included)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation adequate - computer-
generated. Allocation concealment unclear
- “opaque envelopes”. Baseline comparabil-
ity adequate - no suggestion of problems.
Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded to interventions - deduced
from interventions
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing data: Group 1 - 4/20 (20%) (1
died, 3 hospitalised). Group 2 - 6/21 (29%)
(2 died, 2 hospitalised, 2 dropped out for
non-study-related reasons)
i.e. similar ratemissing in both groups; high
rate - comparable with control event rate
Selective reporting (reporting bias) Low risk Adequate - full results reported
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Thomas 2005 (Continued)
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (1 ulcer/person) - unclear if
selected
Other bias
additional
Unclear risk Insufﬁcient information to assess whether
an important risk of bias exists
ALL-DOMAIN RISK OF BIAS High risk Rating: very high
Reasons: unclear selection bias, not
blinded, attrition bias
Comments: outcome assessed at each visit
after removing dressing - not blinded
ALL-DOMAIN RISK OF BIAS 2 High risk
Van De Looverbosch 2004
Methods RCT (abstract); participants randomised (unclear if > 1 wound per person)
Funding: industry funded - Molnlycke Health Care sponsored the study. Setting: not
stated
Duration of follow-up 8 weeks
Unit of analysis: person (unclear if > 1 ulcer analysed)
Participants 11 participants with pressure ulcers. PU Stage: II only (no subcutaneous involvement)
(PU classiﬁcation: not stated)
Age: mean 87.7 years and 88.2 years; 75 years and over. Duration of ulcer: more than 1
month. Ulcer size: not stated
Wound characteristics at baseline: infection not reported; slough not reported; necrosis
not reported; exudate not reported
Interventions Group 1: topical - enamel matrix protein; n = 6. Grouped intervention category: enamel
matrix protein
Group 2: topical - propylene glycol alginate (vehicle - propylene glycol alginate); n = 5.
Grouped intervention category: propylene glycol alginate
Outcomes Primary outcomes: proportion completely healed at 8 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability unclear -
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Van De Looverbosch 2004 (Continued)
baseline difference but unclear of impor-
tance. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded (“open label”) andno evidence
that outcome assessor was blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Missingdata:Group1 - none stated.Group
2 - none stated
i.e. unclear if data missing; unclear rate
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
Unclear risk Unit of randomisation person and unit of
analysis person (unclear if > 1 ulcer anal-
ysed) - implies 1 per person
Other bias
additional
Unclear risk Insufﬁcient information to assess whether
an important risk of bias exists
ALL-DOMAIN RISK OF BIAS High risk Rating: high
Reasons: unclear selection bias, not blinded
Comments: comparable in age, more
women in control group
Xakellis 1992
Methods RCT; participants randomised (> 1 wound per person, ulcer chosen at random)
Funding: non-industry funding - explicit statement that not industry funded. Supported
by The Family Health Foundation of America. Setting: care home
Duration of follow-up 26 weeks (6 months) protocol
Unit of analysis: person (1 ulcer/person)
Participants 39 participants with pressure ulcers. PU Stage: II (100% and 90%) and III (Shea - must
have a break in the skin for inclusion) (PU classiﬁcation: Shea)
Age: mean (SD): 77.3 (16.9) years and 83.5 (10.6) years. Duration of ulcer: not stated.
Ulcer size: median (range): 0.66 (0.12-13.4) cm² and 0.38 (0.04-24.6) cm²
Wound characteristics at baseline: infection not reported; slough not reported; some
wounds necrotic; exudate mixed levels
Comment: necrotic tissue: 2/18 (11%) and 7/21 (33%) but debridement used before and
throughout, so unclear whether successful. Exudate: level not stated, but 9/18 (50%) and
7/21 (33%) had exudate at baseline. Exudate and necrosis were independent predictors
of healing
Interventions Group 1: hydrocolloid dressing - DuoDERM; n = 18. Grouped intervention category:
advanced dressing
Group 2: gauze saline dressing - saline wet-to-moist; n = 21. Grouped intervention
category: basic dressing
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Xakellis 1992 (Continued)
Outcomes Primary outcomes: proportion completely healed at 26 weeks (6 months); time to com-
plete healing reported (Kaplan Meier plot included)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation unclear - “ran-
domised”. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability adequate - no
suggestion of problems. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded to interventions - clear de-
scription
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data: Group 1 - 2/18 (11%) (1 hos-
pitalised, 1 withdrew consent). Group 2 -
3/21 (14%) (3 died)
i.e. similar rate missing in both groups; low
rate - unlikely to alter the effect estimate
Selective reporting (reporting bias) Low risk Adequate - full results reported
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (1 ulcer/person) - ulcer cho-
sen at random (by coin toss)
Other bias
additional
Low risk Adequate - no suggestion of problems
ALL-DOMAIN RISK OF BIAS High risk Rating: high
Reasons: unclear selection bias, not blinded
Yapucu Güne 2007
Methods RCT; participants randomised (> 1 wound per person, all followed)
Funding: not stated. Setting: hospital inpatients
Duration of follow-up 5 weeks
Unit of analysis: ulcer
Participants 27 participants with pressure ulcers. PU Stage: II and III (96% III in both groups) (PU
classiﬁcation: AHCRQ)
Age:mean (SD): 65.80 (6.30) years and 66.56 (5.53) years. Duration of ulcer: not stated.
Ulcer size: not stated
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Yapucu Güne 2007 (Continued)
Wound characteristics at baseline: unclear infection; slough not reported; necrosis not
reported; exudate not reported
Comment: staging used AHRQ guidelines (probably NPUAP). Infection implied (con-
trol said to be a treatment for infected ulcers). 50+ ulcers (1 participant excluded and
not stated no. of ulcers), 27 participants; all ulcers assessed
Interventions Group 1: honey - unprocessed gauze impregnated (dressing): semi-permeable adhesive
secondary dressing; n = 15. Grouped intervention category: antimicrobial
Group 2: combination dressing - ethoxy-diaminoacridine plus nitrofurazone dressings;
n = 12. Grouped intervention category: antimicrobial
Outcomes Primary outcomes: proportion completely healed at 5 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation adequate - computer-
generated. Allocation concealment unclear
- no information on allocation conceal-
ment. Baseline comparability adequate - no
suggestion of problems. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded to interventions - clear de-
scription
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing data: Group 1 - 0. Group 2 - 1/12
(8%) (1 died)
i.e. similar ratemissing in both groups; high
rate - comparable with control event rate
Selective reporting (reporting bias) Low risk Adequate - reported incompletely as ‘sig-
niﬁcant’ or P value < 0.05
Other bias
unit of analysis
High risk Unit of randomisation person and unit of
analysis ulcer - ulcer:person ratio: 25/15 (1.
7) and 26/12 (2.2)
Other bias
additional
Unclear risk Only available case analysis reported
ALL-DOMAIN RISK OF BIAS High risk Rating: very high
Reasons: unclear selection bias, not
blinded, attrition bias, unit of analysis is-
sues
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Yapucu Güne 2007 (Continued)
ALL-DOMAIN RISK OF BIAS 2 High risk
Zeron 2007
Methods RCT; participants randomised (only 1 wound per person)
Funding: unclear - product supplied by Aspid. Setting: hospital inpatients
Duration of follow-up 3 weeks
Unit of analysis: person (1 ulcer/person)
Participants 24 participants with pressure ulcers. PU Stage: 2 and 3 (PU classiﬁcation: NPUAP)
Age: mean 79.8 years and 78.3 years. Duration of ulcer: not stated. Ulcer size: diameter
mean (SD): 3.4 (1.2) cm and 2.9 (1.3) cm
Wound characteristics at baseline: infection not reported; slough not reported; necrosis
not reported; exudate not reported
Comment: IPD reported
Interventions Group 1: protease-modulating dressing - Fibroquel: collagen plus polyvinylpyrrolidone +
zinc oxide paste cleansing; n = 12. Grouped intervention category: protease-modulating
dressing
Group 2: polyvinylpyrrolidone (PVP + zinc oxide paste cleansing); n = 12. Grouped
intervention category: basic dressing
Outcomes Primary outcomes: proportion completely healed at 3 weeks; time to complete healing
not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Selection bias Unclear risk Sequence generation adequate - random
number tables. Allocation concealment un-
clear - no information on allocation con-
cealment. Baseline comparability unclear -
baseline difference but unclear of impor-
tance. Rating: unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who outcome assessor was
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data: Group 1 - none. Group 2 -
none. i.e. no missing data (clearly stated)
Selective reporting (reporting bias) Unclear risk Unclear reporting
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Zeron 2007 (Continued)
Other bias
unit of analysis
Low risk Unit of randomisation person and unit of
analysis person (1 ulcer/person)
Other bias
additional
Unclear risk Insufﬁcient information to assess whether
an important risk of bias exists
ALL-DOMAIN RISK OF BIAS Unclear risk Rating: unclear
Reasons: unclear selection bias, unclear
who outcome assessor was, unclear report-
ing of numbers healed (but not a problem)
Comments: healing data not reported ex-
plicitly, but deduced from IPDonulcer size
(number with zero size)
AHRQ: US Agency for Healthcare Research and Quality
BNF: British National Formulary
HC: hydrocolloid
IPD: individual participant data
NPWT: negative pressure wound therapy
NS: not stated
RCT: randomized controlled trial
UV: ultraviolet
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abbott 1968 Ineligible outcomes
Agren 1985 Ineligible outcomes
Ahmad 2008 Ineligible intervention
Alvarez 1999 Ineligible outcomes
Alvarez 2000a Ineligible outcomes
Alvarez 2000b Ineligible outcomes
Alvarez 2002 Ineligible outcomes
Alvarez Vázquez 2014 Ineligible patient population
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Aminian 1999 Ineligible type of healing outcome
Amione 2005 Comparison of two interventions in the same class
Anitua 2008 Ineligible patient population
Anonymous 1982 Ineligible study design
Anonymous 2000 Ineligible study design
Anzai 1989 Ineligible patient population
Avanzi 1998a Ineligible outcomes
Avanzi 1998b Ineligible outcomes
Avanzi 2000a Ineligible outcomes
Avanzi 2000b Ineligible outcomes
Avanzi 2000c Ineligible outcomes
Avanzi 2001 Ineligible outcomes
Baade 1965 Ineligible intervention
Baatenburg de Jong 2004 Ineligible patient population
Baker 1981 Ineligible study design
Bale 1997b Ineligible outcomes
Bale 1997c Comparison of two interventions in the same class
Bale 1998a Ineligible patient population
Bale 1998b Ineligible outcomes
Bale 2004 Ineligible outcomes
Banks 1997a Ineligible outcomes
Banks 1997b Ineligible indication
Barnes 1992 Comparison of two interventions in the same class
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(Continued)
Bazzigaluppi 1991 Ineligible study design
Becker 1984 Ineligible type of healing outcome
Beele 2010 Ineligible patient population
Berard 1986 Ineligible study design
Bigolari 1991 Ineligible patient population
Bito 2012 Mixed intervention
Blanco Blanco 2002 Ineligible indication
Blum 1973 Ineligible patient population
Boxer 1969 Ineligible outcomes
Boykin 1989 Ineligible study design
Brady 1987 Ineligible study design
Brem 2000 Ineligible study design
Brett 2003 Ineligible outcomes
Brown-Etris 1999a Ineligible type of healing outcome
Brown-Etris 1999b Mixed intervention
Burgos 2000 Comparison of two interventions in the same class
Burke 1998 Ineligible type of healing outcome
Capillas Pérez 2000 Ineligible patient population
Carusone 2001 Ineligible indication
Casali 1997 Ineligible study design
Chang 1998 Ineligible outcomes
Chen 2004 Ineligible intervention
Cheneworth 1994 Ineligible study design
Chirwa 2010 Ineligible patient population
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Chuangsuwanich 2011a Ineligible type of healing outcome
Chuangsuwanich 2011b Ineligible outcomes
Chuangsuwanich 2013 Ineligible outcomes
Colin 1996a Ineligible type of healing outcome
Colin 1996b Ineligible type of healing outcome
Colonna 2004 Ineligible study design
Cooper 2008 Ineligible patient population
Coutts 2000 Ineligible outcomes
D’Aniello 1998 Ineligible outcomes
Dat 2014 Ineligible study design
Day 1995 Comparison of two interventions in the same class
De Laat 2005 Ineligible outcomes
De Laat 2011 Ineligible type of healing outcome
Dealey 1997 Ineligible outcomes
Dealey 1998 Ineligible study design
Dealey 2008 Editorial
Dierick 2004a Ineligible outcomes
Dierick 2004b Ineligible type of healing outcome
Dobrzanski 1990 Comparison of two interventions in the same class
Durovi 2008 Ineligible type of healing outcome
Dwivedi 2016 Ineligible type of healing outcome
El Zayat 1989 Ineligible study design
Ellis 2002 Ineligible type of healing outcome
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Characteristics of ongoing studies [ordered by study ID]
ChiCTR-TRC-13003959
Trial name or title ChiCTR-TRC-13003959
Methods RCT pilot study;
Duration 3 months
Participants 30 eligible participants with pressure ulcers randomised in a ratio of 1:1
Interventions Treatment group: indirect moxibustion for 30 min before application of a dressing, 1 session daily, 5 sessions
weekly for 4 weeks
Control group will only receive a dressing, applied in the same way as in the treatment group
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ChiCTR-TRC-13003959 (Continued)
Outcomes Primary outcomes: wound surface area (WSA) and proportion of ulcers healed within trial period
Starting date registered 7/12/2013
Contact information
Notes Protocol only
ISRCTN57842461
Trial name or title ISCRCTN57842461 study reported to be registered
Methods RCT; participants randomised
Duration 8 weeks
Participants 820 participants with at least 1 grade II pressure ulcer will be recruited from primary health care
and home care centres
Interventions Polyurethane foam and hydrocolloid dressings
Outcomes Primary outcome: percentage of wounds healed after 8 weeks. Secondary outcomes will include cost-effec-
tiveness, as
evaluated by cost per healed ulcer and cost per treated participant and safety evaluated by adverse events
Starting date Not stated
Contact information
Notes Protocol only; trial not on ClinicalTrials.gov
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Direct evidence: individual interventions, number with complete healing
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Interventions vs saline gauze 10 Risk Ratio (IV, Random, 95% CI) Subtotals only
1.1 Hydrocolloid vs saline
gauze
4 279 Risk Ratio (IV, Random, 95% CI) 1.89 [0.91, 3.93]
1.2 Hydrogel vs saline gauze 3 110 Risk Ratio (IV, Random, 95% CI) 2.44 [0.64, 9.27]
1.3 Foam vs saline gauze 3 93 Risk Ratio (IV, Random, 95% CI) 1.51 [0.78, 2.90]
2 Interventions vs hydrocolloid 13 Risk Ratio (IV, Random, 95% CI) Subtotals only
2.1 Hydrogel vs hydrocolloid 4 322 Risk Ratio (IV, Random, 95% CI) 1.11 [0.74, 1.67]
2.2 Foam vs hydrocolloid 6 292 Risk Ratio (IV, Random, 95% CI) 1.05 [0.81, 1.36]
2.3 Collagenase ointment vs
hydrocolloid
2 61 Risk Ratio (IV, Random, 95% CI) 1.51 [0.93, 2.43]
2.4 Protease-modulating
dressing vs hydrocolloid
1 65 Risk Ratio (IV, Random, 95% CI) 1.03 [0.64, 1.66]
Comparison 2. Direct evidence group intervention, number with complete healing
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Intervention 1 vs intervention 2 18 Risk Ratio (IV, Random, 95% CI) Subtotals only
1.1 Advanced dressing vs basic
dressing
11 532 Risk Ratio (IV, Random, 95% CI) 1.55 [1.10, 2.19]
1.2 Antimicrobial dressing vs
advanced dressing
2 125 Risk Ratio (IV, Random, 95% CI) 0.69 [0.48, 0.99]
1.3 Collagenase ointment vs
advanced dressing
2 61 Risk Ratio (IV, Random, 95% CI) 1.51 [0.93, 2.43]
1.4 Protease-modulating
dressing vs advanced dressing
3 112 Risk Ratio (IV, Random, 95% CI) 1.13 [0.80, 1.60]
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Comparison 3. Direct evidence: individual interventions, time-to-healing data
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time-to-healing (survival
analysis)
7 Hazard Ratio (Fixed, 95% CI) Subtotals only
1.1 Hydrocolloid versus saline
gauze
2 95 Hazard Ratio (Fixed, 95% CI) 1.75 [1.00, 3.05]
1.2 Hydrogel versus
hydrocolloid
1 43 Hazard Ratio (Fixed, 95% CI) 1.30 [0.54, 3.13]
1.3 Protease-modulating
versus hydrocolloid
1 65 Hazard Ratio (Fixed, 95% CI) 1.34 [0.67, 2.65]
1.4 Collagenase ointment
versus hydrocolloid
1 24 Hazard Ratio (Fixed, 95% CI) 2.59 [1.01, 6.62]
1.5 Foam versus saline gauze 1 36 Hazard Ratio (Fixed, 95% CI) 1.13 [0.42, 3.00]
1.6 Hydrocolloid +/- alginate
versus ineligible: radiant heat
1 41 Hazard Ratio (Fixed, 95% CI) 0.64 [0.23, 1.77]
Comparison 4. Direct evidence: group interventions, time-to-healing data
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time-to-healing (survival
analysis)
5 Hazard Ratio (Fixed, 95% CI) Subtotals only
1.1 Advanced dressing versus
basic dressing
3 Hazard Ratio (Fixed, 95% CI) 1.57 [0.97, 2.55]
1.2 Protease-modulating
dressing versus advanced
dressing
1 Hazard Ratio (Fixed, 95% CI) 1.34 [0.67, 2.65]
1.3 Advanced dressings versus
collagenase ointment
1 Hazard Ratio (Fixed, 95% CI) 0.27 [0.11, 0.67]
Comparison 5. Direct evidence - non-network comparisons
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Intervention 1 vs intervention 2 4 Risk Ratio (IV, Random, 95% CI) Totals not selected
1.1 Sugar + povidone iodine
vs lysosyme
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Enamel matrix protein vs
propylene glycol alginate
1 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
145Dressings and topical agents for treating pressure ulcers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fo
r P
re
vie
w 
On
ly
